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ABSTRACT
Particulate carrier systems have been developed to produce hybrid particles that present 
viral proteins in a multivalent form as potential recombinant vaccines. The presentation 
of epitopes from human immunodeficiency virus (HTV) and simian immunodeficiency 
virus (SIV) has been evaluated using two different carrier systems.
The first system exploits the self assembly properties of a protein (pi) encoded by the 
yeast retrotransposon Ty. Expression of pi-fusion proteins in yeast results in the 
formation of hybrid Ty virus-like particles (Ty-VLPs) containing multiple copies of the 
added antigen. The ability of hybrid Ty-VLPs carrying the major neutralizing epitope of 
HTV (the V3 loop) from different virus isolates to elicit production of virus-neutralizing 
antibodies has been investigated. High titre neutralizing antibodies were induced by 
Ty-VLPs carrying the V3 loop from the HXB2 clone of virus isolate MB following 
immunization in either Freund's adjuvant or aluminium hydroxide. Ty-VLPs carrying 
the V3 loop of isolate MN only induced high titre neutralizing antibodies following 
immunization with Freund's adjuvant Hybrid Ty-VLPs containing an equivalent 
region from SIV were also investigated. However, this region was only weakly 
immunogenic and did not elicit high titre neutralizing antibodies, suggesting that the V3 
loop of SIV is not the principal neutralizing determinant of SIV.
The Ty protein pi is functionally analogous to the core proteins encoded by the gag 
gene of retroviruses such as HIV. The second carrier system evaluated therefore 
addressed the use of gag-encoded proteins to present the V3 loop. This system has the 
potential advantage of eliciting both anti-core and anti-envelope responses. Modification 
of the GAG protein was required to produce hybrid GAG: V3 particles in both yeast and 
insect cell expression systems. Immunogenicity studies of hybrid GAG:V3 particles 
demonstrated that although the humoral response to the V3 loop was weak, substantial 
anti-GAG antibodies were induced.
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This project forms part of the vaccine programme at British Bio-technology Limited 
The main aim of this programme is to produce a candidate vaccine against the aetiologic 
agent of Acquired Immunodeficiency Syndrome, the human immunodeficiency virus 
(HTV). The introduction will discuss current vaccine technologies, the development of 
novel antigen presentation systems and the primary targets of this investigation, the 
human immunodeficiency virus and the simian immunodeficiency virus.
1.1 IMMUNE RESPONSES TO VIRAL INFECTION
The immune response to viral infection is extremely complex and the precise 
mechanisms that occur for successful recovery from infection with some viruses and 
not others are not yet fully understood. The function of the immune system is to 
eliminate free virus and to destroy virally infected cells. The immune response is 
mediated by recognition of antigenic sites or epitopes of viral proteins. B cell epitopes 
are recognised by antibody and T cell epitopes are only recognised by the appropriate T 
cell after antigen presentation. This section will provide a brief summary of the cell 
types that are involved in eliciting the immune response.
The immune response involves cooperation between the cell types of the immune 
system, outlined in Figure 1.1. The first cell type is the antigen presenting cell that 
processes the virus into components for recognition by the other cells. Antigen 
presenting cells include macrophages, dendritic cells and B cells. Lymphocyte 
activation is a key reaction in the immune response and both T and B lymphocytes 
respond to the binding of antigen by differentiating into active lymphoblasts and 
dividing into a clonal population, some cells of which provide immunological memory.







Figure 1.1 Schematic representation of the basic mechanisms 
of the immune response
M 0= macrophage; B= B cell; CTL= cytotoxic T cell; TH= T helper cell 
TCR= T cell receptor; Ig= immunoglobulin; Ab= Antibody
cells. T cells can only recognise antigen when presented in conjunction with the major 
histocompatibility (MHC) self antigen. Antigen presentation by MHC is restricted by 
HLA type which results in differential recognition of antigens. The MHC in man 
consist of three loci (HLA-A, B and Q  for class I antigens and three (HLA-DP, DQ 
and DR) for class II. T helper cells recognise antigen in association with class II MHC 
antigens that are present on macrophages and related cells. Recognition is mediated 
through the T cell receptor and CD4 molecules. T helper cells provide help for the 
activation of B cells and the generation of specific cytotoxic T cells. Cytotoxic T cells 
recognise antigen in association with class I MHC antigens that are present on most 
cells and in this way can recognise and destroy virally infected cells. Recognition is 
mediated through the T cell receptor and CD8 molecules. Peak cytotoxic T cell activity 
occurs about a week after viral infection and is therefore an early defence mechanism. 
Memory cytotoxic T cells are thought to exist for life.
B cells are responsible for antibody production. B cells bind antigen that contain 
antigenic determinants complementary to their receptors (antibody) and, after receiving 
the appropriate help from T cells, divide and differentiate into antibody secreting cells. 
Early in the response, in the presence of large amounts of viral antigen, B cells can be 
activated that produce low affinity antibodies due to the poor fit of receptor to antigen. 
Later in infection selection of B cells occurs that secrete high affinity antibodies and 
memory B cells are also generated. There are five different immunoglobulin classes of 
antibody. Multivalent IgM antibodies are produced early in infection and are later 
replaced by the major circulating IgG antibodies. IgA antibodies are important in 
establishing mucosal immunity. IgD antibodies are present on the surface of B cells and 
it is thought that together with IgM act as antigen receptors for lymphocyte activation 
and suppression. IgE antibodies cause an acute inflammatory reaction by recruitment of 
effector cells involved in protecting external mucosal surfaces. Antibodies act on the
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virus via several different mechanisms. Antibodies that bind with high affinity to certain 
epitopes on the viral envelope inhibit infectivity and therefore neutralize the virus.
These epitopes are known as neutralization epitopes. Activity of neutralizing antibodies 
may be enhanced by complement activation. Antibody-complement mechanisms may 
also be involved in the destruction of virally infected cells. Antibody dependent 
cell-mediated cytotoxicity (ADCQ is mediated by the antibody bound to a viral antigen 
on the surface of an infected cell. Effector cells such as killer cells and macrophages 
then target the infected cell
Recovery from viral infection, induction of immunological memory and therefore rapid 
clearance of further infection are due to a combination of the responses outlined above. 
However the exact mechanisms that lead to a successful immune response are not 
known and are likely to vary from virus to virus and host to host
1.2 VIRAL VACCINES
With one exception, successful viral vaccines to date that have been administered to 
humans are viruses themselves, presented either as live (attenuated or closely related 
non-pathogenic) or killed viruses. The majority of live attenuated viruses have been 
produced by passage of the virus in cell culture until an avirulent mutant emerges.
These vaccines have the advantage of presenting the virus in the "natural" form to 
induce protective immunity but also have certain disadvantages which include possible 
reversion to virulence and the presence of contaminants introduced into the vaccine 
preparation from the cell culture. Killed virus vaccines are prepared by inactivating the 
virus using, for example, formalin. Such vaccines are generally considered safe as the 
virus is non-infectious, but have certain disadvantages including the need to be injected 




Variola virus, the causative agent of smallpox, is the only virus that has been eradicated 
from the world's population by vaccination (reviewed by Fenner, 1982). Vaccinia virus 
was used for vaccination against smallpox and was introduced by Jenner (1798). The 
origin of vaccinia virus is unknown, although the first vaccine preparations were 
isolated from infected cows. Subsequently, vaccinia virus was isolated from calves or 
sheep, or grown in chick embyros. The vaccine programme to eradicate smallpox 
began in 1967 and the last case was reported in 1977 (Fenner, 1982).
Poliomyelitis vaccine
The first poliomyelitis vaccine was a formalin killed preparation of the three 
immunological subtypes, grown in cultures of monkey testicular or kidney tissue and 
was shown to induce levels of antibody comparable to the natural infection (Salk 
1953). Sabin (1957) developed the live attenuated oral vaccine which consists of 
attenuated strains of the three subtypes. Originally the vaccine strains were prepared by 
culturing in monkey kidney cells and are now grown in human diploid cell cultures. As 
the vaccine strains infect, multiply and subsequently are excreted from the vaccinee, 
they are spread into the community giving the advantages of infecting and therefore 
protecting non-vaccinated hosts and also of replacing wild-type viruses. However 
extensive genetic changes have been shown to occur on replication in the vaccinee or 
contact host (Kew et al.. 1981; Minor et al.. 1986) and reversion to virulence 
sometimes occurs, particularly in the type 3 virus. Successful vaccination programmes 
have resulted in only rare cases of poliomyletitis being observed in developed countries 
(reviewed by Sabin (1985)).
Other live attenuated vaccines that are routinely administered include vaccines against 
measles, rubella and mumps (reviewed by Melnick (1986)).
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Hepatitis B vaccine
The hepatitis B vaccine is the only currently available sub-unit vaccine. In an infected 
host the hepatitis B surface antigen (HBsAg) occurs as 22nm particles. The first 
vaccine preparations were HBsAg particles purified from the plasma of infected 
individuals and were found to induce protective immunity (Szmuness et al.. 1980). 
HBsAg particles have now been produced as recombinant proteins in yeast (Valenzuela 
et al.. 1982). These particles represent the first recombinant vaccine to be administered 
to humans.
Outlined above are examples of successful vaccine strategies currently in use. Due to 
the mechanisms of HIV infection and the long latency period it is unlikely that a vaccine 
could be developed using a live attenuated strain or killed virus preparation. Avirulence 
of attenuated vaccine strains are confirmed using animal models. No such model exists 
for HIV as although chimpanzees can be infected they do not develop disease 
symptoms. The possibilty of reversion to virulence also makes an attenuated strain 
unfeasible for an HIV vaccine. Killed virus preparations are also unlikely to meet safety 
requirements due to concerns about incomplete inactivation and about the ability of the 
"non-infectious" virus to still retain integration properties. Suitable HTV vaccine 
candidates are therefore likely to be recombinant sub-unit preparations. However, viral 
components that would induce protective immunity in man have yet to be defined. 
Analysis of the immune response in infected individuals progressing towards disease 
has focussed attention on the envelope and core proteins of the virus and presentation 
systems that express these proteins have been developed, which are included in the 
discussion in section 1.3.
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1.3 PRESENTATION SYSTEMS
Several expression systems are now being exploited for the production of potential 
sub-unit vaccines. These include the production of monomeric proteins using a variety 
of expression technologies and systems which utilize viruses to express heterologous 
antigens either as part of a replicating recombinant virus, or as a purified antigen from 
infected cells. Antigen carrier systems have been developed where the antigen of 
interest is presented in a multivalent form as a particulate fusion protein. Examples of 
these expression systems are given below with particular reference to expression of 
HIV proteins.
13.1 Production of monomeric proteins in non-replicating systems 
Recombinant HIV envelope proteins have been expressed in a variety of cell types. 
Envelope proteins produced in yeast elicited production of anti-envelope antibodies 
(Barr et al.. 1987). Recombinant envelope glycoprotein gpl20 produced in mammalian 
cells has been shown to elicit a protective immune response on HIV challenge in 
vaccinated chimpanzees (Berman et al.. 1990).
13.2 Replicating expression systems
Polioviruses have been exploited as antigen carriers. The first poliovirus chimaera was 
made by inserting a defined region of type 3 poliovirus into the type 1 Sabin vaccine 
strain. This chimaera induced the production of type 3 neutralizing antibodies (Burke £1 
al., 1988). Poliovirus/HIV chimaeras have also been produced. Evans et al. (1989) 
showed that a chimaera containing a sequence from the HIV envelope glycoprotein 
gp41 induced the production of broadly cross-neutralizing HIV antibodies. A 
poliovirus chimaera with a sequence inserted from the human papillomavirus type 16 
major capsid protein induced the production of antibodies against the inserted sequence 
(Jenkins et al.. 1991).
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Recombinant vaccinia viruses have been constructed that express proteins from other 
viruses, in particular HIV proteins. Viruses that express the gp 160 envelope 
glycoprotein have been made and have been shown to elicit an anti-gpl60 response 
following infection of experimental animals (Chakrabarti et al.. 1986; Hu et al.. 1986). 
However, vaccinated chimpanzees were not protected when challenged with HIV (Hu 
et al.. 1987). Clinical trials of recombinant viruses that express gpl60 have been 
carried out and vaccinated individuals generated both humoral and cellular anti-gpl60 
responses (Zagury et al.. 1988; Cooney et al.. 1991). Recombinant vaccinia viruses 
have also been produced that express the GAG and GAG-POL precursor proteins of 
HIV. Karacostas et al. (1989) demonstrated that when mammalian cells were infected 
with a recombinant vaccinia virus that encoded the GAG-POL precursor protein, 
virus-like particles were produced that contained reverse transcriptase and processed 
GAG proteins. Particles have also been produced when the GAG precursor alone was 
expressed from a recombinant vaccinia virus carrying the gag gene of HTV (Shioda and 
Shibuta, 1990). Vaccina-GAG recombinant viruses have been shown to elicit 
anti-GAG humoral and cellular responses following infection of experimental animals 
(Hu et al.. 1990). Coinfection of mammalian cells with recombinant viruses carrying 
gag and protease genes and the env gene of HIV resulted in the formation of particles 
containing GAG and envelope proteins (Haffar et al.. 1990).
Recombinant adenoviruses have also been produced that express heterologous viral 
proteins. Infection of mammalian cells with a recombinant adenovirus expressing the 
hepatitis B surface antigen resulted in the formation of 22-nm particles (Davis et al.. 
1985). Protection from hepatitis B challenge has been demonstrated in a chimpanzee 
infected with this recombinant adenovirus (Lubeck et al.. 1989). HIV proteins have 
also been expressed using recombinant adenoviruses. Dewar et al. (1989) demonstrated 
that when human cells were infected with a recombinant adenovirus expressing gpl60,
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this precursor protein was processed to the envelope glycoproteins gpl20 and gp41. 
Animals infected with the recombinant adenovirus generated anti-envelope antibodies. 
Coinfection of cells with recombinant adenoviruses earring the gag and pol genes of 
HTV resulted in the formation of virus-like particles (Vemon et al.. 1991). Macaques 
immunized with a recombinant adenovirus encoding the HIV capsid protein p24 
generated anti-p24 antibodies (Prevec et al.. 1991).
An expression system that exploits the Autographa califomica nuclear polyhedrosis 
virus which infects insects has been developed. This baculovirus system will be 
discussed in detail in chapter 7. Recombinant baculoviruses that express HIV proteins 
have been produced. Gheysen et al. (1989) showed that infection of insect cells with a 
recombinant baculovirus carrying the gag gene of HIV resulted in formation of 
virus-like particles that budded from the cell surface. The envelope glycoprotein gpl60 
has also been expressed using this system (Wells and Compans, 1990).
A further live recombinant vaccine vehicle has been produced that expresses HTV 
proteins. This system utilizes the human tuberculosis vaccine Mycobacterium bovis 
bacillus Calmette-Guerin (BCG). BCG recombinants have been produced that express 
the gag, pol. and guy gene products of HIV. Mice immunized with BCG-HIV GAG 
and BCG-HIV ENV generated low levels of anti-HIV antibodies and cell-mediated 
responses were demonstrated in the mice immunized with BCG-HIV GAG (Aldovini 
and Young, 1991).
1.3.3 Particulate antigen carrier systems
Both hepatitis B core and surface antigens have been used to produce hybrid particles 
carrying foreign proteins. Clarke et al. (1987) demonstrated that a fusion protein 
comprising the hepatitis B core protein and a peptide sequence from the foot and mouth
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disease virus (FMDV), produced by expression using the vaccinia system, elicited 
strong anti-FMDV responses. Hybrid FMDV/hepatitis B core particles have also been 
produced in yeast (Beesley et al.. 1990). Recombinant hepatitis B core particles have 
been constructed that carry gp41 of HIV and gp51 of bovine leukemia virus, although 
the immunogenicity of these hybrid particles was reported to be poor (Borisova et al.. 
1989). Hybrid hepatitis B surface particles containing a poliovirus neutralization 
epitope induced poliovirus neutralizing antibodies (Delpeyroux et al.. 1982) and 
induction of HIV neutralizing antibodies by recombinant hepatitis B surface antigen 
particles carrying a fragment of gpl20 has been demonstrated (Michel et al.. 1988).
The self assembly properties of the tobacco mosiac virus coat protein (TMVCP) has 
also been exploited. A TMVCP fusion has been produced that carries an antigenic 
epitope from poliovirus type 3. The TMVCP-polio 3 fusion protein assembled into 
virus-like rods and induced the production of polio virus neutralizing antibodies when 
injected into animals (Haynes et al.. 1986).
Another approach for the production of sub-unit vaccine candidates has been the 
production of immunostimulating complexes or ISCOMs (reviewed by Morein et al.. 
1987). ISCOMs are produced by the incorporation of the antigen of interest with the 
adjuvant Quil A into cage-like structures. ISCOMs have been shown to elicit protective 
immunity against several animal pathogens, for example, gp85 of feline leukemia virus 
in ISCOMs induces protection in cats (Osterhaus et al.. 1985).
The antigen presentation system developed at British Bio-technology that exploits the 
self-assembly properties of pi, a protein encoded by the yeast retrotransposon Ty, is 
discussed in detail in section 1.4.
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1.4 THE YEAST RETROTRANSPOSON, Ty
The term Ty stands for transposon of yeast. Ty elements were originally described by 
Cameron et al. (1979), and are a family of dispersed, repetitive DNA sequences present 
at about 35 copies per haploid genome of Saccharomvces cerevisiae.
Comparisons with retro-eiements such as mammalian and avian retroviruses and the 
mobile repetitive copia-like elements of Drosophila have revealed notable similarities. 
These similarities include the way these elements move from one genomic location to 
another via an RNA intermediate and a reverse transcriptase reaction (Mellor et al.. 
1985a). As a result of this mode of transposition, mobile DNA elements, including Ty, 
have been termed retrotransposons.
Most Ty elements are approximately 5.9kb in length, which can be sub-divided into a 
unique 5.2kb internal region flanked by 340bp terminal repeats or delta sequences 
(Cameron et al.. 1979). The major Ty RNA is a 5.7kb transcript that initiates in the left 
delta and terminates in the right delta such that the RNA has a 50 nucleotide terminal 
redundancy (Elder et al.. 1983). This RNA is both the major message and the 
intermediate in Ty transposition via a reverse transcriptase reaction (Dobson et al..
1984) (Figure 1.2).
The transcriptional unit of Ty is divided into two overlapping reading frames, TYA and 
TYB. that are analogous to retroviral gag and pol genes, respectively. Overexpression 
of all or part of the transcriptional unit using high-efficiency yeast expression vectors 
has allowed the identification of several Ty-encoded proteins (Mellor et a l. 1985b). 
TYA encodes a 50kD protein, pi, which is produced by simple translation from the 
mRNA. Protein pi is subsequently processed via a Ty-encoded protease to a 45kD 








Figure 1.2 Genome organization of Ty and particle formation 
AP= acid protease; RT= Reverse transcriptase; INT= Integrase
1987a). TYB is expressed from the mRNA as a 190kD TYA:TYB fusion protein, p3. 
This process requires a specific ribosomal frameshifting event in order to avoid the 
termination codon in TYA and shift translation into the +1 reading phase of TYB 
(Wilson et al.. 1986). Protein p3 is also proteolytically processed to release the 
protease, reverse transcriptase and integrase enzymes (Figure 1.2) (Adams et a l . 
1987a).
The replicative transposition cycle of Ty elements involves the packaging of Ty RNA 
into virus-like particles (VLPs) where reverse transcription then generates a double 
stranded DNA copy (Figure 1.3). VLP assembly is thought to be a two stage process. 
First, pi and p3 form an initial complex stabilized by both protein-protein interactions 
and protein-RNA interactions to produce a pre-Ty-VLP. Second, cleavage of pi and p3 
results in a morphological change and increased stability of the particle. Wild-type 
Ty-VLPs are approximately 50nm in diameter and when examined under the electron 
microscope can be seen to have an electron-dense core surrounded by an 
electron-luscent shell (Figure 1.4). The mature VLPs are composed mainly of the 
proteolytic cleavage product p2 but also contain reverse transcriptase, protease, 
integrase and a tRNA primer. It is therefore likely that Ty-VLPs contain all the 
components neccesary for replication of the element and subsequent integration of the 
dsDNA copy into the chromosome at a new site (Figure 1.3) (Mellor et al.. 1985a; 
Adams et al.. 1987a).
1.4.1 Formation of hybrid Ty-VLPs
The production of hybrid Ty-VLPs is based on the observation that the protein pi, the 
primary translation product of the TYA gene, can assemble into Ty-VLPs in the 
absence of proteolytic maturation (Adams et al.. 1987a). This led to the suggestion that 









Figure 1.3 Transposition cycle of Ty
Figure 1.4 Transmission electron micrograph of "wild type" Ty-VLPs 
The particles were stained with uranyl acetate
particle forming properties of pi.
Specialized expression vectors have been designed in order to express Ty fusion 
proteins in yeast (Adams etal., 1987b). Plasmid pMA5620 is an E.coli/veast shuttle 
vector which contains DNA origins of replication that allow replication in both cell 
types, plus an ampicillin gene for selection in E.coli and a LEU2 gene for selection in 
leucine auxotrophic yeast strains. The promoter of the yeast phosphoglycerate kinase 
gene (PGK) (Mellor et al.. 1983) drives expression of the first 381 codons of the TYA 
gene (TYA(d)). At codon 381 is a BamHI restriction enzyme site which allows the 
insertion of antigen coding sequences of interest at the 3'end of the TYA(d) gene. This 
BamHI site is followed by translation termination codons and a transcription terminator 
(Figure 1.5).
Occasionally, constitutive expression of a particular pi-fusion protein from the PGK 
promoter causes the yeast cells to grow very slowly. In order to circumvent this 
problem an inducible system has been developed in which the PGK upstream activation 
sequence (UAS) has been replaced by the UAS of the GAL1-10 promoter to generate 
plasmid pOGS40 (Figure 1.5) (Kingsman et al.. 1991). Yeast cells containing plasmids 
with pi-fusion genes under the control of this PGK-GAL hybrid promoter are grown 
to high cell density on media containing glucose. Expression is then induced by the 
addition of galactose to the media. Galactose inducibility is mediated by an alteration in 
the functional interaction between the yeast GAL4 and GAL80 proteins. However the 
utility of the galactose induction system is limited by the low levels of GAL4 protein 
present in yeast cells. Therefore pOGS40 derivatives are cotransformed into yeast cells 
with plasmid pUG4IS which contains the structural gene for GAM. This plasmid 
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Figure 1.5 VLP expression vectors
Cotransformation of yeast cells in this way ensures that the galactose induction system 
works efficiently.
Expression of pi-fusion proteins in yeast results in the formation of hybrid Ty-VLPs 
(Adams et al.. 1987b; Kingsman & Kingsman, 1988). Purified hybrid particles appear 
quite different to "wild type" particles. Figure 1.6 compares the particles produced 
when the TYA(d) gene alone is expressed with hybrid HIV:Ty particles which are 
discussed in detail in chapter 3.
1.5 HUMAN IMMUNODEFICIENCY VIRUS
The HIV retroviruses belong to the subfamily lentiviruses, so called because of the long 
incubation period between infection and overt disease. The human lentivirus HTV-1 
was discovered in 1983 (Barre-Sinoussi et al.. 1983; Gallo et al.. 1983) and HIV-2 in 
1986 (Clavel et al.. 19861. Other examples of lentiviruses include simian 
immunodeficiency virus (SIV) (Daniel et al.. 1984) and feline immunodeficiency virus 
(FIV) (Pederson et al.. 1987).
HIV-1, HIV-2 and SIV are thought to have evolved from a common ancestral 
retrovirus showing tropism for cells expressing the CD4 receptor. HIV-1 and HIV-2 
show 50-60% similarity in primary DNA sequence. HIV-2 is more closely related to 
SIV, with a sequence homology of about 70%. The molecular diversity of HIV-1 has 
been extensively studied and many molecular clones characterised. Multiple variants are 























Figure 1.6 Construction and formation of Ty-VLPs. Panel (a) shows the plasmid pMA5620 above 
an electron micrograph of particles purified from yeast transformed with pMA5620. Panel (b) 
shows the construction of a TYA(d):HIV fusion gene (pOGS514) above an electron micrograph 
of hybrid HIV V3 loop:Ty-VLPs purified from yeast transformed with pOGS514.
1.5.1 HIV genetic organization
The HIV provirus is about 9.7 kilobases long with LTRs of 634 base pairs (Ratner 
al., 1985) (Figure 1.7). The gag, pol. and env genes code for polyprotein precursors. 
Gag and env code for the structural proteins of the core and envelope proteins and pol 
encodes three enzymes, reverse transcriptase, integrase and protease, essential for viral 
replication. There are also additional open reading frames that code for the regulatory 
proteins (tat, rev, nef. vpr). and virion infectivity factor (vif) and vpu protein (vpu) that 
increase infectivity and facilitate export from the cell (reviewed in Haseltine, 1991) 
(Figure 1.7).
The gafi gene
The gag gene encodes a polyprotein precursor, Pr55, which is cleaved by the viral 
protease into the core proteins p24, pl7 and pl5 (Figure 1.7). pl5 is also cleaved to 
produce proteins p7 and p6. p7 is a nucleic acid binding protein and is thought to be 
responsible for condensing the viral RNA within the core (Delassus & Wain-Hobson, 
1988). p24 is phosphorylated and is found within the core of the virion (Veronese et al. 
1988). The p 17 matrix protein is found just inside the viral envelope (Gelderblom et al.
1987) (Figure 1.8).
The jtol gene
The pol gene is expressed as a GAG:POL fusion polyprotein (Prl60) via a ribosomal 
frame-shifting event in the gag-pol overlap region (Jacks et al.. 1988; Wilson et al..
1988) (Figure 1.7). In mature virions the gag and gag:pol gene products are present in 
a ratio of about 20:1 (Veronese et al.. 1986). The POL precursor is cleaved to produce 
protease, reverse transcriptase (RT) and endonuclease (or integrase) (Figure 1.7) 
(Varmus, 1988). The RT also possesses ribonuclease H activity (Varmus, 1988).
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Figure 1.7 HIV genetic organisation and protein formation
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Figure 1.8 Schematic diagram  of an HIV virion
The £M  gene
The polyprotein encoded by the env gene (gpl60) is heavily glycosylated (Robey et al.. 
1985). gpl60 is cleaved to produce the envelope surface protein gpl20 and the 
transmembrane protein gp41 which remain attached via non-covalent interactions. 
gpl20 and gp41 form spikes on the suface of the virion (Figure 1.8) (Gelderblom £t 
al., 1987). Extensive genetic diversity exists between the envelope proteins of different 
isolates of HIV, particularly within hypervariable regions of the gpl20 protein 
(Modrow et al.. 1987).
1.5.2 HIV viral life cycle
The HIV viral life cycle is shown in Figure 1.9. The virus attaches to T helper 
lymphocytes (Dalgleish et al.. 1984) and other CD4 positive cells, e.g., macrophages 
and dendritic cells, via the CD4 receptor. Entry occurs via fusion of cell and virus 
membranes and is mediated by the envelope transmembrane glycoprotein, gp41 (Stein 
et al.. 1987). After entry into the cell the virus is uncoated in the cytoplasm. The RT 
produces hybrid RNA/DNA molecules followed by double-stranded linear DNA 
molecules which contain two copies of the long terminal repeat This DNA is 
translocated into the nucleus and integrated into the viral genome, catalysed by the viral 
integrase. The HIV provirus may then remain latent for several years. Following 
cellular activation, by as yet unclear mechanisms, viral transactivators and host 
transcription factors lead to HIV gene expression (Nabel et al.. 1987). Full length viral 
RNA directs the synthesis of the GAG and POL polypeptide precursors and the ENV 
precursor is made from singly spliced messenger RNA (Haseltine, 1991). These 
precursors are then assembled into viral particles together with two copies of single 
stranded genomic HIV RNA. The virion matures during budding and release from the 
host cell (Figure 1.9) (Varmus, 1988). Transmission electron microscopy demonstrates 
that the mature virion is approximately lOOnm in diameter and has an elongated core
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Figure 1.9 Infection cycle of HIV
(Figure 1.10; open arrow). Figure 1.10 (closed arrows) also shows virions budding 
from the cell surface; the particle seen on the left is at an early stage of budding and the 
particle on the right is nearer the stage of release.
1.5.3 Functional and immunogenic regions of the envelope 
glycoproteins
The precursor envelope glycoprotein, gpl60, is proteolytically cleaved intracellularly to 
the gpl20 and the gp41 transmembrane proteins (Willey et al.. 1988). McCune et al. 
(1988) have shown that endoproteolytic cleavage is required for the production of 
infectious virions.
A number of functional and immunogenic regions of the envelope glycoproteins have 
been identified, which are outlined below. Computer assisted analysis of gpl60 has 
identified conserved and variable regions (Modrow et al.. 1987).
1.5.3.1 Functional regions
The functional domains include the region responsible for the binding of gpl20 to the 
immunoglobulin-like domain of the CD4 receptor (Lasky et al.. 1987). Using 
monoclonal antibodies that blocked the CD4-gpl20 interaction, the binding region was 
found to be within amino acids 397-439. Further analysis has shown that changing 
amino acid residues, 257, 368, 370 and 457 resulted in a significant reduction of CD4 
binding (Olshevsky et al.. 1990). The CD4 binding region is, therefore, composed of 
several, discontinuous regions of gpl20. Once the envelope glycoprotein is bound to 
CD4, the virus enters the cell by envelope fusion of the cell membrane. A hydrophobic 
amino-terminal domain is thought to provide at least one fusion site necessary for viral 
entry (Gallaher et al.. 1987; Bosch et al.. 1989). Fusion can also occur between vims 
infected cells expressing gpl20 and gp41 and uninfected CD4 positive T cells (Lifson
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Figure 1.10 Transmission electron micrograph of an HIV infected cell
The closed arrow indicates a mature budded virion 
The open arrows indicate budding particles
et al.. 1986; Sodroski et al.. 1986). This results in the formation of synyctia, i.e., 
multinucleated giant cells. This type of fusion can allow HIV to pass directly from cell 
to cell. Studies have shown that other regions of gp 120 are also involved in the events 
following CD4 binding. Freed et al. (1990) demonstrated that the amino terminus of 
gp41 is involved in cell to cell fusion. Furthermore, mutational analysis has shown that 
substitutions of single amino acids 266,267 and 268 led to non-infectious virions 
(Willey et al.. 1988). The V3 loop, which is the principal neutralizing determinant of 
HIV (see section 1.5.3.2 below), is also thought to be an important functional region of 
the virus. The V3 loop has a similar sequence to a protease inhibitor, trypstatin (Hattori 
et al.. 1989) and it has been shown that trypstatin inhibits synyctia formation in HTV-1 
infected cell cultures. From this evidence, it has been speculated that, after CD4 
binding, the V3 loop is proteolytically cleaved and that cleavage is essential for viral 
infection of the cell (Stephens et al.. 1990). Clements et al. (1991) have shown that 
thrombin, tryptase and an endosomal aspartic protease, cathepsin E, cleave the V3 loop 
and further suggest that cleavage of the V3 loop occurs during the cell fusion reaction. 
Freed et al. (1991) have suggested that the V3 loop is a fusion domain.
1.5.3.2 B cell epitopes
B cell epitopes have been identified on both gpl20 and gp41.
Neutralizing epitopes
The major neutralizing epitope of HIV is located in a hypervariable region of the 
envelope glycoprotein gpl20 (the third variable domain, V3) found between amino 
acids 296-331 in HIV-1 isolate ITIB (Goudsmitet al. 1988; Palker et al. 1988; Rusche 
et al. 1988). The V3 region is a loop structure which is defined by two flanking 
cysteine residues linked by a disulphide bond (Leonard et al.. 1990).
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When recombinant gpl60 preparations are used to immunize experimental animals the 
neutralizing antibodies are directed against this loop (Rusche et al. 1988). Antibodies to 
this domain neutralize the virus post-CD4 binding (Skinner et al. 1988a). Using 
synthetic peptides the neutralizing determinant of the V3 loop of HIV isolate IHB has 
been mapped to the 8 amino acids found at the tip of the loop (Javaherian et al.. 1989). 
It has subsequently been shown that neutralizing antibodies can be raised against 
hexamer peptides coding for a GPGRAF sequence at the tip of the loop (Javaherian 
al., 1990). HIV human positive sera have been shown to have antibodies that bind to 
this epitope (Goudsmit et al.. 1988; Goudsmit et al. 1989). Human monoclonal 
neutralizing antibodies to the V3 loop have been generated (Scott et al.. 1990; Gomy £t 
al., 1991), demonstrating that anti-V3 neutralizing antibodies are raised in a natural 
infection of HIV. In addition, studies of in utero transmission of HIV have shown that 
mothers who have high affinity/avidity antibodies to this region are less likely to 
transmit HIV to their children (Devash et al.. 1990a) and decline of anti-V3 antibodies 
has been observed during the development of disease in HIV positive individuals 
(Neurath et a!.. 1990). Berman et al.. 1990 showed that chimpanzees immunized with 
recombinant gpl20 were protected from a challenge with the homologous strain of 
HTV-1. The protection was correlated with the induction of high titre neutralizing 
antibodies against the V3 loop. However, direct evidence that neutralizing antibodies 
raised against the V3 loop confer protection comes from the work of Emini et al. (1992) 
who showed that chimpanzees passively immunized with a human/mouse chimaeric V3 
loop monoclonal antibody were protected from challenge with live HIV.
Neutralizing antibodies to this dominant loop are type-specific, i.e., they only neutralize 
the virus isolate against which they were raised. Therefore interest in designing 
sub-unit vaccines based on this epitope has led to serological grouping of HIV-1 
strains. It has been shown that there is a prevalence of antibodies in infected individuals
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which react with the MN isolate (Devash et al.. 1990b) and antibodies that recognised 
the MN V3 loop have been detected in sera from Africa and the Americas (Carrow e£ 
jil., 1991). Therefore the MN V3 loop epitope should be investigated as a sub-unit of a 
potential vaccine.
Neutralizing antibodies have been raised against other domains of gpl20 including 
amino acids 254-274 (Ho et al.. 1988). However, this region is naturally immunosilent 
on gpl20 and, as this result could not be repeated, this epitope is no longer considered 
to be a neutralization epitope (Ronco et al.. 1991). Kennedy et al. (1986) showed that 
antibodies raised against the region encoded by amino acids 503-532 had neutralizing 
activity. Conformation-dependent gpl20 neutralizing antibodies have been identified in 
human sera, although these antibodies arise later in the course of infection and are of 
low titre. Steimer et al. (1991) demonstrated that conformation dependent neutralizing 
antibodies blocked CD4-gpl20 binding. A broadly reactive human monoclonal 
antibody has also characterized a discontinuous epitope in gpl20 as binding of this 
antibody was affected by changes in amino acids 256,257, 360-370,421 and 470-484 
(Thali et al.. 1991). Berkower et al. (1991) also identified human neutralizing 
antibodies that recognised a conformation-dependent epitope that mapped to residues 
342-511 of gpl20. Ho et al. (1991) generated monoclonal antibodies against gpl20, 
one of which identified another discontinuous epitope and had the ablity to 
cross-neutralize viruses.
Another neutralizing domain is located in a conserved site, within gp41, between amino 
acids 735-752 (Chanh et al.. 1986; Dalgleish et al.. 1988). Evans et al (1989) showed 
that when this region was inserted as a surface component of poliovirus, broad cross 
neutralizing antibodies were elicited. The polio chimaera could also remove neutralizing 
antibodies from human HIV positive sera.
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Human monoclonal antibodies that map to the N-terminal two-thirds of gp41 have 
enhanced the infection of HIV-1 in vitro (Robinson et al.. 1990a). Further studies have 
mapped the regions on gp41 to which these antibodies bind; amino acids 586 to 620 
(Robinson et al.. 1990b) and amino acids 579 to 613 and 644 to 663 (Robinson et al.. 
1991). These studies therefore suggest that selected epitopes and not whole proteins 
should be incorporated into vaccine design.
Antibody mediated cellular cytoxicity (ADCC)
It has been shown that anti-gpl20 antibodies present in human sera can mediate ADCC 
(Shepp et al.. 1988; Lyerly et al.. 1987). Antibodies that mediate ADCC appear to be 
broadly cross reactive between HIV isolates (Lyerly et al.. 1988). It has been 
suggested that ADCC may inhibit HIV-1 infection in vivo (Sawyer et al.. 1990) and 
reductions of ADCC titres correlating with disease progression have been reported 
(Ljunggren et al.. 1987). A monoclonal antibody, raised to the V3 loop has been found 
to mediate ADCC (Broliden et al.. 1990). A human monoclonal antibody has also been 
shown to recognise a conformational ADCC epitope on gpl20 (Koup et al.. 1991).
1.5.33  T cell epitopes 
T helper cell epitopes
Several T helper cell epitopes have been identified on gpl20. The CD4 binding region 
contains a sequence that is recognized in conjunction with MHC Class II antigens by 
CD4 positive T helper cells (Cease et al.. 1987). In the same study a T helper epitope 
was also confirmed between amino acids 112-124. Using synthetic peptides that code 
for the V3 loop as immunogens, Palker et al. (1989) have demonstrated 
lymphoproliferative responses to this region. HIV envelope-specific helper T cell 
responses from infected individuals have also been reported (Schrieret al.. 1989). 
Volunteers immunized with various recombinant gpl60 preparations, for example a
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baculovirus rgpl60 (Tacket et a l. 1990) and a recombinant vaccinia-gpl60 (Berzofsky 
et al.. 1988), have developed HIV-specific lymphoproliferative responses. T cell 
epitopes have also been identified on gp41 (Schrier et al.. 1988; Aheame et al.. 1988). 
However, a region has also been identified on gp41 that is immunosuppressive to T cell 
stimulation (Ruegg et al.. 1989).
Cytotoxic T lymphocytes (CTL)
Several CTL epitopes have been identified on the envelope glycoproteins. Clerici et al. 
(1991) demonstrated that in human HIV positive individuals four of the regions on 
gpl20 recognised by T helper cells were also recognised by class I restricted CTL. 
These regions included the V3 loop. Takahasi et al. (1988) have demonstrated the 
recognition of the V3 loop by CD8 positive class IMHC restricted murine CTL. 
Takahasi et al. (1992) have also shown that a murine CTL line that recognised the MN 
V3 loop showed cross-reactivity between isolates.
1.5.3.4 Epitope mimicry
Molecular mimicry by viruses can stimulate the immune system to recognize self 
proteins as foreign antigens, thereby evoking attack on normal cells (Oldstone 1987). 
Several regions of gpl20 and gp41 have been shown to have homology with proteins 
present on the surface of cells. These include homology to IL2 found in the C-terminus 
of gp41 (Reiher et al.. 1986). Homology to the MHC class II domain HLA-DR within 
gp41 has been reported (Golding et al.. 1988). These studies provide further evidence 
that whole envelope glycoproteins used as immunogens could have harmful effects in 
humans.
A number of B and T cell epitopes have therefore been identified on the envelope 
glycoproteins that could be considered for inclusion in a vaccine candidate. However,
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from reports in the literature to date, the V3 loop represents an attractive candidate for 
inclusion into a potential vaccine as it is a "combined" neutralizing, T helper cell and 
CTL epitope.
1.5.4 Functional and immunogenic regions of the gag encoded proteins
1.5.4.1 Functional regions
The GAG precursor Pr55 of HIV is modified by proteolytic cleavage into the proteins 
pl7, p24 and pl5 (p7/p6) (Wellink and von Kammer, 1988). Cleavage is thought to 
occur post budding of the virus from the cell (Kohl et al.. 1988). A further modification 
of Pr55 is the addition of a myristic acid moiety to the N-terminal glycine residue 
(Henderson et al.. 1988). The targeting of other retroviral gag encoded precursors at 
the cell membrane has been shown to be dependent on myristilation (Schultz and 
Oroszkdn, 1983). Studies on GAG precursor protein expressed using a recombinant 
baculovirus system show that myristilation is also essential for HIV GAG Pr55 to 
associate with the plasma cell membrane (Gheysen et al.. 1989).
1.5.4.2 B-cell epitopes
Studies of the immune response in infected humans have shown that there is a strong B 
cell response to p24, the core protein of HIV (Casey et al.. 1985; Samgadaharan et al.. 
1985). Correlation between the decline of anti-GAG antibodies and the onset of disease 
symptoms has been reported (Schubach et al.. 1985; Lange et al.. 1986; Weber et al.. 
1987). However, immunodominant B cell epitopes have not yet been specifically 
mapped on the gag encoded proteins. Anti-GAG monoclonal antibodies have defined 




Examination of lymphoproliferative responses from HIV infected humans or 
immunized animals has identified several T helper cell epitopes on p24 (reviewed by 
Mills et al.. 1989). In a study of HTV positive humans Schrieret al.(19891 
demonstrated lymphocyte proliferative responses against synthetic peptides 
corresponding to five GAG sequences. These sequences coded for amino acids 22-29, 
228-235,282-301,439-446 and 466-473. Using hybrid p24:Ty-VLPs as immunogens 
Mills et al. (1990) have defined two T helper cell epitopes, corresponding to amino 
acids 235-249 and 265-279. Epitope recognition was found to be MHC class II 
restricted by CD4 positive cells.
Cytotoxic T lymphocytes specific for GAG have been identified in HTV seropositive 
individuals. In all cases the CTL have been MHC class I restricted CD8 positive cells 
(Nixon et al.. 1988; Walker et al.. 1987; Riviere et al.. 1989). Nixon et al.. (1988) 
have demonstrated that HLA-B27 restricted CTL recognise a peptide corresponding to 
amino acids 265-279. Thus this region has been shown to be a combined T helper cell 
and CTL epitope. This region is highly conserved between HIV-1 isolates. CTL 
epitopes on GAG that are restricted by other HLA types have also been identified 
(reviewed in Nixon and McMichael, 1991).
Studies on the immune response to gag encoded proteins therefore suggest that these 
proteins should be investigated for inclusion in a vaccine candidate against HIV.
1.6 SIMIAN IMMUNODEFICIENCY VIRUS (SIV)
Candidate vaccines are normally evaluated in challenge experiments using animal 
models. However the only animals that can be infected by HIV are chimpanzees, 
baboons and gibbon apes and in experiments reported in the literature no disease
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symptoms have been induced in these species following infection. These animals are in 
very limited supply and it is therefore not feasible to use them for screening vaccine 
candidates. However, simian immunodeficiency virus (SIV) has been shown to cause 
disease syndromes in macaques similar to human AIDS (Letvin et al.. 1985). An 
alternative approach may therefore be to develop vaccine candidates against SIV that 
could be used as a model for the design of an HTV vaccine candidate.
SIV was first isolated from rhesus macaques in 1985 (Daniel et al.. 1985). An isolate 
of SIV, SlVmac 142, has been cloned and sequenced (Chakrabarti et al.. 1987) which 
showed that SIV has a genome organization similar to that of HTV-1 and HIV-2. The 
differences include a premature translation termination signal in env resulting in a 
truncated form of the transmembrane protein (Hirsch et al.. 1987). SlVmac has 
morphology, growth properties and tropism for CD4 positive cells similar to those of 
HTV (Kannagi et al.. 1985; Beneviste et al.. 1986). Serologic cross reactivity against 
the gag proteins of HIV and SIV has been demonstrated (Beneviste et al.. 1986), 
whereas cross reactivity of the envelope glycoproteins is weak. Immunodominant 
regions of SIV gag and env proteins have not yet been specifically mapped. In 
particular, the major neutralization epitope remains to be identified. However, 
monoclonal antibodies raised against the SIV envelope have been shown to have 
neutralizing activity and suggest that conformation-dependent epitopes exist on gpl20 
(Kent et al.. 1991a). A monoclonal antibody that recognises amino acids 106 to 110 in 
the transmembrane protein has been shown to have strain-specific neutralizing activity 
(Kodama et al.. 1991). Anti-envelope antibodies have been detected in experimentally 
infected macaques (Shafferman et al.. 1989) and T cell proliferative responses reported 
(McGraw et al.. 1990), although important epitopes have not yet been defined. A GAG 
CTL epitope corresponding to amino acids 171-195 has been identified (Yamamoto ££ 
a l. 1990).
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Using inactivated SIV as an immunogen, protection of macaques against SIV has been 
achieved (Desroisers et al. 1989; Murphev-Corb et al.. 1989; Carlson et al.. 1990). 
However, it is not yet clear which components of the whole virus preparation were 
responsible for the protection. Hu etal. (1992) demonstrated that protection of 
macaques against SIV infection can be achieved using a gpl60 envelope based vaccine 
preparation. The animals were immunized with a recombinant vaccinia virus expressing 
gpl60 and boosted with gpl20 purified from insect cells. Following the boost the 
neutralization titres increased and the animals were protected from a subsequent 
challenge with homologous virus. However the epitopes on gpl20 responsible for 
eliciting this protective response have not yet been mapped. There is therefore 
considerable interest in dissecting the protective response to identify key components 
that can be incorporated into a model to aid in the design of HTV vaccine candidates.
1.7 AIMS
The first phase of this project concentrated on the production of hybrid HIV:Ty-VLPs, 
and in particular VLPs that carry HIV envelope proteins. It has previously been 
reported that hybrid HIV:Ty-VLPs elicit an anti-HIV immune response (Adams et al.. 
1987b). This was shown by the detection of serum antibodies in animals immunized 
with the hybrid HIV:Ty-VLPs. However, it is generally believed that one of the 
requirements of a vaccine is that it should be able to induce the immune system to 
produce neutralizing antibodies. The initial aim of this project therefore was to 
investigate the presentation of the major neutralizing epitope of gpl20, the V3 loop, by 
hybrid HIV:Ty-VLPs.
For a vaccine to induce protective immunity it is likely that both the humoral and 
cellular arms of the immune system need to be primed. The B cell population (the 
humoral arm) needs to contain effector cells that can produce virus neutralizing
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antibodies and antibodies that mediate antibody-dependent cellular cytotoxicty (ADCC). 
A sub-population of memory B cells are also required so that there is rapid recall when 
an infection takes place. Induction of the cellular side of the immune system requires 
priming of T helper cells and cytotoxic T lymphocytes and the generation of memory T 
cells.
Although it has been shown that the V3 loop can stimulate lymphoproliferative 
responses in addition to inducing neutralizing antibodies (Palker etal., 1988; Takahasi 
et al.. 1988), it is unlikely that the immune response against this epitope alone will 
confer protective immunity against HIV-1. As stated previously the V3 loop is 
hypervariable and to date the neutralizing antibodies generated against have been type 
specific. Many different isolates of HIV-1 have been identified and an HIV vaccine 
needs to be effective in generating immunity against all isolates. To generate this broad 
cross reactive response it is likely that in addition to the V3 loop, epitopes from other 
viral proteins need to be incorporated into the vaccine design.
A strong candidate for inclusion in an HTV vaccine are the core proteins of the virus 
encoded by the gag gene. As outlined above, HIV infected individuals generate a strong 
immune response to the core proteins of HIV. Furthermore, cellular immunity against 
other viral core proteins, for example the influenza A vims nucleoprotein, has been 
shown to play an important role in recovery from viral infections (Townsend et al.. 
1984; Yewdell et al.. 1985; McMichael et al.. 1986). It has also been demonstrated that 
in the case of hepatitis B vims, helper T cells specific for the hepatitis core antigens can 
’’help" B cells to produce neutralizing antibodies against the envelope as well as against 
the core antigens (Milich et al.. 1987).Taken together these observations suggest that 
incorporation of the gag encoded proteins of HIV into a combination vaccine may 
therefore be advantageous.
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The major Ty structural protein pi is functionally analogous to the core proteins of 
retroviruses such as HIV (Adams et al.. 1987a). An attractive way forward for further 
development of a vaccine candidate against HTV was therefore to see if gag encoded 
proteins could be exploited as an antigen canier system as an alternative to the Ty 
protein pi. The immune response generated against such a gag hybrid would then be 
directly relevant in terms of evoking immunity against HTV. The second phase of this 
project investigated the production of hybrid GAG:V3 VLPs. This GAG:V3 hybrid 
would combine the neutralizing epitope of gpl20 with the T helper cell and CTL 






All the common reagents used in the methods described below were purchased from 
Sigma or BDH. The enzymes used in the molecular biology methods were purchased 
from Northumbria Biologicals Limited. To facilitate description, methods have been 
presented in a protocol format.
2.1 Escherichia coli STRAIN
HW87 = (araD139, (ara-leuMel7697. QacIPOZY)del74, galU, galK, hsdR. rpsL, £rl, 
recA56).
2 2  YEAST STRAIN
Saccharomvces cerevisiae BJ2168: (MATa. ura3. Ieu2-3.112. trpl. ga!2. pep4-3. 
prc1 -407. orb 1-1122).
2 3  E. coli MEDIUM
2 x YT medium
1.6% (w/v) Tryptone, Difco
1 %(w/v) Yeast extract, Difco
0.25%(w/v) NaCl
2 %(w/v) Agar (solid medium)
Sterilize by autoclaving. Add 50mg/ml carbenicillin as required.
2.4 YEAST MEDIA
Transformed yeast cells are maintained in selective media. The yeast strain BJ2168 is
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auxotrophic for leucine, uracil and tryptophan synthesis. Cells transformed with 
pMA5620 (LEU2) derivatives (described in chapter 1, section 1.4) are grown in the 
presence of uracil and tryptophan. Cells transformed with pUG41S QJRA3) and 
pOGS40 (LEH2) derivatives are grown in the presence of tryptophan.
YEPD
2%(w/v) Peptone, Difco 
1% (w/v) Yeast extract 




1 % (w/v) Yeast extract
1% (w/v) Glucose
0.67% (w/v) Yeast Nitrogen
Base (YNB)
3% (w/v) Agar
Sterilize by autoclaving. Add filter 
sterilized solution of 1% uracil/ 
tryptophan or 1% tryptophan as 




0.67% (w/v) YNB 







Add filter sterilized solution of 1% uracil/tryptophan or 1%  tryptophan as appropriate to 
give a final concentration of 20mg/ml.
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2.5 VECTOR PREPARATION
1) Incubate 10|ig of vector DNA for 2 hours at 37°C with 2|il of appropriate 
enzyme, lOx Universal buffer and H2O to 20j l l 1.
2) Dephosphorylate by incubating DNA with l|il of calf intestinal phosphatase in 
Universal buffer for 1 hour at 37°C.
3) Add an equal volume of a 1:1 phenol/chloroform mix, then vortex and 
microfuge for 5 minutes. Remove the upper layer containing the DNA into a 
new eppendorf tube.
4) Repeat step 3 twice.
5) Ethanol precipitate by adding 2.5 volumes of ethanol and 3M Na acetate to give
a final concentration of 0.3M and then incubate at -70°C for 10 minutes.
6) Microfuge for 5 minutes, then remove the supernatant.
7) Add 200pl of 70% ethanol and vortex.
8) Repeat step 6.
9) Resuspend in 30pl of TE.
l x T E lOx Universal Buffer
lOmM Tris 330mM Tris
ImM EDTA 660mM Potassium acetate
pH to 7.4 with HC1 lOOmM Magnesium acetate
40mM Spermidine
5mM Dithiothreitol
pH to 7.9 with HC1
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2.6 OLIGONUCLEOTIDE CLONING
1) Dry down lOpmol of each strand of complementary DNA from aqueous 
solution.
2) Phosphorylate each strand separately at 37°C for 30 minutes by resuspending 
in 2jil 10 x kinase buffer, ljil 15mM ATP, l|il T4 polynucleotide kinase and
16|ii H2O.
3) Anneal the complementary strands by mixing lOjil of each and cool slowly 
from 90°C to room temperature.
4) Ligate a 3 to 5 fold molar excess of insert to the vector with 2pJ ligase buffer,
ljjJ T4 DNA ligase, H2O to 20|il at 16°C for four hours.
5) Transform lOOjil of competent (calcium chloride treated) E.coli cells by 
incubating with half of the ligation mix on ice for 30 minutes. Heat shock the 
mixture at 42°C for 1 minute and then incubate in 1ml 2xYT broth for 60 
minutes.
6) Pellet the cells by microfuging for 1 minute. Resuspend in lOOpJ 2xYT broth 
and spread onto 2xYT plates containing 50pg/ml carbenicillin. Incubate at 
37°C overnight.











2.7 PREPARATION OF E.coli COMPETENT CELLS
1) Inoculate 5mls 2xYT broth with a single E.coli colony. Grow, with shaking, at 
37°C overnight.
2) Inoculate 50ml 2xYT broth with 0.5ml of the pre-culture and grow as above to 
exponential phase (approximately 1.5 hours). The cells are in exponential
phase when an O-D^oo of 0.4 is reached.
3) Pellet the cells at 3 krpm for 5 minutes (Sorvall RT6000B centrifuge) and 
resuspend in lOmls ice cold lOOmM calcium chloride.
4) Incubate on ice for 10 minutes.
5) Pellet the cells at 3 krpm for 5 minutes (Sorvall RT6000B centrifuge) and 
resuspend in 2ml lOOmM calcium chloride.
6) Leave on ice for up to 24 hours.
2.8 ALKALINE LYSIS MINI-PREPARATION OF DNA
1) Inoculate 5ml 2xYT broth and incubate, with shaking, overnight at 37°C
2) Pellet the cells by microfuging for 1 minute and resuspend in lOOp.1 of 
Solution 1. Incubate at room temperature for 5 minutes.
3) Add 200|il of Solution 2, and incubate as above.
4) Add 150fil of Solution 3. Incubate on ice for 5 minutes.
5) Pellet the cell debris by microfuging for 2 minutes. Remove 400pJ of the 
supernatant.
6) Add 400}il of a 1:1 phenol/chloroform mix. Vortex, then microfuge for 5 
minutes. Remove the upper layer containing the DNA.
7) Add 1ml of ethanol and incubate at -70°C for 5 minutes.
8) Microfuge for 5 minutes, remove the supernatant and resuspend the pellet in 
IOjjJ TE.
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Solution 1 Solution 2 Solution 3
20mM Glucose 200mM NaOH 28%(v/v) Acetic acid
25mM Tris 35mM SDS 2.3M KOH
lOmM EDTA
Lysozyme 2mg/ml
2.9 LARGE-SCALE ALKALINE LYSIS DNA PREPARATION
1) Inoculate 500ml 2xYT broth with the appropriate E.coli colony. Incubate, with 
shaking, overnight at 37°C.
2) Harvest cells by centrifuging for 5 minutes at 6krpm (Sorvall RC5B centrifuge, 
Sorvall GSA rotor) and resuspend in 50ml of Solution 1. Incubate at room 
temperature for 5 minutes.
3) Add 100ml of Solution 2 and incubate as above.
4) Add 75ml of Solution 3 and incubate for 15 minutes on ice.
5) Pellet the cell debris by centrifuging for 5 minutes at 6krpm (Sorvall RC5B
centrifuge, Sorvall GSA rotor) and filter the supernatant through glass wool.
6) Add 0.6 volumes of isopropanol and precipitate for 30 minutes on ice.
7) Pellet the DNA by centrifuging at 6krpm (Sorvall RC5B centrifuge, Sorvall
GSA rotor) and resuspend in 5ml TE.
8) Add lg/ml of caesium chloride (BRL) and 200}il oflOmg/ml ethidium bromide.
9) Stand on ice for 15 minutes, then pellet debris by centrifuging at 9kipm 
(Sorvall SA600 rotor).
10) Fill "quick-seal" tubes (Beckman) with the DNA/CsCl/EtBr solution and seal.
11) Spin the gradients at 54Krpm overnight or 65Krpm for 4 hours (Beckman 
L8-70M ultracentrifuge, Beckman VTI65 rotor).
12) Withdraw the plasmid DNA band by first removing the top of the tube and then 
inserting a 21 g needle attached to a 2ml syringe underneath the band. The
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plasmid DNA band is the lower of the 2 bands in the tube.
13) Extract the ethidium bromide by adding 3 volumes of water-saturated 
butanol, vortex gently, and remove the upper butanol layer.
Repeat undl there is no colour remaining in the DNA solution.
14) Ethanol precipitate the DNA by adding 2 volumes of H2O and 2.5 volumes of
ethanol, and incubate at -70°C for 30 minutes.
15) Pellet the DNA by centifiiging at 9 kipm for 20 minutes (Sorvall SA600 rotor).
16) Remove the supernatant, and add 10ml 70% ethanol. Vortex, and repeat step 
15.
13) Resuspend in 200|il of TE.
14) Determine the DNA concentration by adding 5p.l of the DNA solution to 1ml 
H2O and then reading the OD26O of this solution. The ODxlO^ = |ig/ml.
15) Adjust the DNA concentration to 1 mg/ml.
2.10 PLASMID SEQUENCING
Plasmid sequencing is carried out as described by Biggin et al.. (1983). The procedure 
is described briefly below:
1) Denature the DNA by incubating at room temperature for 5 minutes with 1M 
NaOH/lmM EDTA.
2) Centrifuge the DNA through a Sephacryl S3000 dialysis column at 3 krpm for 
4 minutes (Sorvall RT6000B centrifuge).
3) Anneal the DNA to the primer, at 70°C for 2 minutes, followed by 37°C for 30 
minutes.
4) For each sample carry out 4 reactions as outlined below in a microtitre plate:
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A G C T
DNA 4jil 4pl 4|il 4pl
dNTPs lMl lpl lpl lpl
ddATP lfU - - -
ddGTP - lpl - -
ddCTP - - lMl -
ddTTP - - - lpl
Klenow
enzyme
lpl m lpl lpl
35s-dATP
(lOmCi/nl)
0.5jxl 0.5pl 0.5pl 0.5pl
Incubate at 42°C for 15 minutes.
The dNTPs (Pharmacia) are used at 0.5mM diluted in TE, and the ddNTPs 
(Pharmacia) are used at lOmM, made up in 50mM Tris, ImM EDTA, pH7.5.
5) Incubate with chase solution (0.5mM all 4 dNTPs) at 42°C for 5 minutes.
6) Add formamide containing running dyes and denature at 80°C for 15 minutes.
7) Before loading pre-run the polyacrylamide gel at 45W for 15 minutes. Load 
1.5pl of each sample and electrophorese at 45W for 1.5 hours.
8) Fix the gel in 10%methanol/10%acetic acid for 15 minutes, then remove the gel 
from the glass plate onto 2 sheets of Whatman 3MM paper. Cover the gel with 
cling film.
9) Vacuum dry, then remove the cling film and the bottom sheet of 3MM paper.





0.1 g Xylene Cy anol FF
O.lg Bromophenol blue
2ml 0.5mM ETDA
The sequencing gel is poured using the following solutions. Take 50ml of the top gel 
solution and add 75pl of 25% ammonium persulphate and 75pl of TEMED. To 7ml of 
the bottom gel solution add 1 l|il of 25% ammonium persulphate and 1 lpl of TEMED. 
Six ml of the bottom gel is then poured between the gel plates, followed by 30ml of the 
top gel.
Top gel Bottom gel
147g Urea 20.7g Urea
48ml 40% (w/v) Acrylamide 6.75ml 40% (w/v) Acrylamide
16ml IOxTBE 22.5ml IOxTBE
H20  to 320ml 4.5g Sucrose
0.15ml 1% (w/v) Bromophenol blue
IOxTBE
108g(w/v) Tris 
55g (w/v) Boric acid 
7.44g(w/v) EDTA
H2O to 11
Stock acrylamide: 38% (w/v) acrylamide plus 2% (w/v) bis-acrylamide. 
Gel solutions are stored at 4°C.
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2.11 PURIFICATION OF DNA FRAGMENTS
1) Digest lOjig of plasmid DNA with appropriate enzymes in Universal buffer 
for 2 hours at 37°C.
2) Electrophorese the fragments through the appropriate percentage low melting 
point agarose gel at 100V for 40 minutes.
3) Excise the fragment of interest
4) Melt the gel slice in TE plus 5|ig of tRNA.
5) Add 300|il of TE, vortex and then add 500fil of a 1:1 phenol/chloroform mix. 
Vortex and microfuge for 5 minutes.
6) Transfer the upper layer containing the DNA to a new tube and add 500|il of 
the phenol/chloroform mix. Vortex and microfuge for 5 minutes.
7) Repeat step 6.
8) Ethanol precipitate the DNA by adding 2.5 volumes of ethanol and 3M Na 
acetate to give a final concentration of 0.3M and incubate at -70°C for 10 
minutes.
9) Pellet the DNA by microfuging for 5 minutes and then vortex in 500^1 of 
70% ethanol.
10) Pellet the DNA by microfuging for 5 minutes and resuspend in 20jil of TE.
Purified fragments are inserted into the vector DNA as described in section 2.6 (from
step 4).
2.12 TRANSFORMATION OF S.cerevisiae BJ2168
1) Inoculate 100ml YEPD medium with 1 colony of the yeast strain BJ2168. 
Grow overnight, with shaking, at 30°C.
2) Harvest the cells at 1.5 x lO^cells/ml. The cell count is determined using a 
haemocytometer.
39
3) Wash in 10ml of 1M sorbitol.
4) Sphaeroplast in 10ml 1M sorbitol plus 2% (v/v) glusulase (DuPont) at 30°C 
for 2 hours.
5) Wash the cells twice in 10ml of 1M sorbitol/1 OmM calcium chloride/lOmM 
Tris (STC).
6) Resuspend the cells in 1ml of STC.
7) Add 2pg DNA to lOOjil of competent yeast cells, and incubate at room 
temperature for 10 minutes.
8) Add 10 volumes of PEG 4000 and stand at room temperature for 10 minutes.
9) Microfuge the mixture for 40 seconds, remove the supernatant and resuspend 
the cells in 1ml of 1M sorbitol.
10) Add the transformed cells to 18ml regeneration agar (49°C) with the 
appropriate amino acids added (see section 2.4). Pour the agar into a petri dish.
11) Incubate the petri dishes at 30°C for 2-3 days.
12) When the colonies are sufficiendy large, pick using a sterile inoculating loop 
and streak onto the appropriate selection plates (see section 2.4).
2.13 PURIFICATION OF Ty-VLPs
Unless otherwise stated all manipulations are carried out at 4°C
1) Inoculate 50ml of SC-glu media containing the appropriate amino acids with a 
single colony yeast transformant. Grow, with shaking, overnight at 30°C.
2) Transfer to 11 of SC-glu media plus amino acids and incubate as above.
3) Transfer 125ml of this pre-culture to 2 x 11 of SC-glu medium plus amino 
acids and incubate as above.
4) Transfer 125ml of the culture in (3) to 16 x 11 of SC-glu medium if expression 
is driven from the PGK promoter or 161 SC-glu/gal medium if expression is 
driven from the PGK-GAL promoter, plus amino acids. Incubate overnight at
40
30°C with shaking.
Harvest the cells at >2x 10? cells/ml.
Wash the cells twice in H2O and twice in TEN buffer. The cells are washed by
resuspending in 200 mis and then centrifuging at 3krpm for 5 minutes (Sorvall 
RT6000B centrifuge). After the final wash resuspend the cells in 200mls of 
TEN buffer.
Homogenise the cells by bead beating with 6oz of glass beads (40 
mesh) in the presence of protease inhibitors aprotonin, antipain, chymostatin, 
leupeptin and pepstatin each at 1.25pg/ml and phenylmethylsulfonyl flouride at 
50|ig/ml. The cells are homogenized using a bead beater (Biospec products) 
for 30 seconds on, alternating with 30 seconds off for a total of 10 minutes. 
The apparatus is then left to cool for 15 minutes, and the 10 minute 
homogenization procedure is repeated.
Pellet the cell debris at 3 krpm for 5 minutes (Sorvall RT6000B centrifuge). 
Remove the supernatant and centrifuge at 9 krpm for 20 minutes (Sorvall 
RC5B centrifuge, Sorvall SA600 rotor).
Remove the supernatant and pipette 30 mis into each of 6 Ultra clear centrifuge 
tubes (Beckman, 25x89mm). Place 2mls of 60% sucrose/TEN solution into 
the bottom of each tube using a sterile pasteur pipette. Centrifuge the tubes at 
28 krpm for 90 minutes (Beckman L8-70M ultracentrifuge, SW28 rotor). 
Pipette off the supernatant and pool the sucrose cushions. Dialyse the sucrose 
cushion overnight against 11 of pre-cooled TEN buffer.
Centrifuge the dialysate at 9 krpm for 20 minutes (Sorvall SA600 rotor).
Load the supernatant onto a 5-20% (w/v) sucrose/TEN gradient with a 2ml 
60% (w/v) sucrose cushion. The gradients are made in SW28 tubes by 
freezing 30ml 12.5% sucrose/TEN at -70°C, then thawing overnight at 4°C. 
The 60% sucrose/TEN cushions are added prior to the sample using a pasteur
pipette. Centrifuge the gradients for 6 hours at 25 krpm (SW28 rotor).
14) Repeat step 11.
15) Centrifuge the dialysate at 9 krpm for 20 minutes (Sorvall SA600 rotor).
16) Filter supernatant through a 3.5pm membrane (Millipore) and then through a 
0.45pm membrane.
17) Concentrate the sample to 16mls using a Millipore CX-30 ultrafiltration unit 
attached to a Millipore CX Agitator.
18) Load the sample onto a 5 x 100cm Sephacryl S-1000 (Pharmacia) column that 
has previously been equilibrated in TEN buffer. Collect 30 minute fractions at 
a flow rate of 16ml/hr in TEN buffer (8ml per fraction).
19) Determine peak fractions by SDS-polyacrylamide gel (SDS-PAGE) analysis 
(see section 2.14). Pool the peak fractions and concentrate to 1 mg/ml as 
described in step 17. Protein concentrations are determined by a Bradford 
dye-binding (BIORAD) assay according to the manufacturers instructions.
20) The particle preparation is then exchanged from TEN buffer to phosphate 
buffered saline (PBS) by dialysing overnight against 11 of pre-cooled PBS.
1 x TEN buffer
lOmM Tris-HCl (pH7.4) 
2mM EDTA 
140mM NaCl
1 x PBS buffer
0.8% (w/v) NaCl 
0.02% (w/v) KC1 
0.115% (w/v) Disodium hydrogen 
phosphate 




The protease inhibitors antipain, chymostatin, leupeptin, and pepstatin are made up to
1.25|ig/ml in dimethylsulphoxide and aprotinin is made up to 1.25|ig/ml in H2O.
Aliquots (50pJ) are stored at -20°C and 1 aliquot per VLP preparation is used. 
Phenylmethylsulfonyl fluoride is made up fresh to 50|ig/ml in ethanol and lml per 
preparation is used. All the protease inhibitors are purchased from Sigma.
2.14 SDS-PAGE
A 0.25x volume of 5x denaturing buffer is added to the sample and the mixture is 
boiled for 2 minutes. SDS-PAGE gels are made using the following solutions. For 2 
gels take 10ml of resolving gel and add lOOjil of 10% Ammonium persulphate and 
15|il TEMED. Pour this solution between the gel plates leaving approximately 3cm for 
the stacking gel. Take 5ml of stacking gel and add 50jxl of 10% Ammonium 
persulphate and 15pl TEMED. The stacking gel is poured after the resolving gel has 
set.
Resolving gel (10%)
10ml 30% (w/v) Acrylamide
8ml 1% (w/v) Bis-acrylamide
11.2ml 1M Tris-HCl pH8.7
150|il 20% (w/v) SDS
400p.l H2O
Stacking gel (5%)
1.67ml 30% (w/v) Acrylamide
1.3 ml 1% (w/v) Bis-acrylamide
1.25ml 1M Tris-HCl pH6.8
50jil 20% (w/v) SDS
5.7ml H2O
Gel solutions are stored at 4°C.
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Running buffer Denaturing buffer x 5
190mM Glycine 3.85% (w/v) Dithiothreitol
lOOmM Tris 5% (w/v) SDS
3mM SDS 80mM Tris-HCl pH6.8
25% (v/v) Glycerol
0.3% (w/v) Bromophenol blue
The denatured samples are loaded onto the gel and electrophoresed at 200V for 45
minutes using a BIORAD mini-gel apparatus.
2.15 WESTERN BLOTTING
1) Electrophorese the samples through a 10% SDS/PAGE gel at 200V for 45 
minutes.
2) The proteins are transferred to nitrocellulose (0.45pm, Anderman) using a 
Biorad Mini Trans-Blot Electrophoretic Transfer Cell. The transfer apparatus 
is assembled as a "sandwich" as follows: sponge-2pieces of 3MM paper 
(Whatman)-gel-nitrocellulose-2x3MM paper-sponge. The proteins are 
transferred at 100V for 1 hour.
3) Remove the nitrocellulose filter from the transfer apparatus and incubate in 
blocking buffer for 1 hour at room temperature.
4) Incubate the filter in the primary antibody (diluted 1/100-1/1000 in 
blocking buffer) for 30 minutes, at room temperature with agitation.
5) Wash the filter 3 times (2 minutes per wash) in blocking buffer.
6) Incubate the filter in horseradish peroxidase conjugated anti-species antibody 
(Sigma), dilutedl/1000 in blocking buffer, as above.
7) Wash the filter 3 times (2 minutes per wash) in blocking buffer.
8) Develop the filter by immersing in 25ml of developing solution for 1 minute.
9) Wash the filter in H2O to stop the reaction.
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Transfer Buffer Blocking buffer
190mM Glycine 0.5% (w/v) Casein
25mM Tris 150mM NaQ
20 %(v/v) Methanol 0.05% (v/v) Triton-X-100









25ml 50mM phosphate buffer pH 7.4
400pl 2.5% (w/v) 3'3 Diaminobenzidine tetrahydrochloride in PBS
lml 1 % (w/v) Cobalt chloride
50pl Hydrogen peroxide
IMMUNOGOLD ELECTRON MICROSCOPY
Load lOpl of sample (at 0.2mg/ml) onto a formavar-coated election 
microscope grid.
Leave for 30 seconds and then draw off liquid with filter paper. If the sample 
is not to be immunogold labelled, it can be stained at this point with water 
saturated uranyl acetate (UA).
To block the grid load lOpl of 5% normal goat serum (in TBS/BSA) and 
incubate for 1 hour at room temperature.
Remove the blocking buffer. Load lOpl of primary antibody (diluted 1/100 in 
blocking buffer) onto the grid and incubate at room temperature for 2 hours. 
Wash the grid 5x with 10|il 1% normal goat serum (in TBS/BSA).
Load lOjil of secondary antibody (anti-species gold-labelled IgG (Sigma); 
diluted 1/160 in bocking buffer) onto the grid and incubate for 1 hour at room
lml 1% (w/v) Ammonium nickel sulphate
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temperature.
7) Wash the grid 5x with 10(il of H2O. Dry the grid by removing the excess 
liquid with filter paper, then leaving to air dry for 5 minutes.
8) Stain with lOjil saturated UA for 30 seconds, dry the grid as above and 




0.1 %(w/v) Bovine serum albumin
20mM Sodium azide
2.17 FIXED CELL IMMUNOFLUORESCENCE
1) Wash the cell suspension 3x using PBS.
2) Resuspend the cells at a concentration of 1 to 1.5 xlO^ cells/ml in PBS.
3) To each well of a 12 well teflon coated slide add lOjil of cell suspension, 
ensuring complete coverage of the well and leave to air dry.
4) Place the slides in 1:1 (v/v) acetone/methanol and leave at room temperature for 
20 minutes, then air dry.
5) Add 15fil of each antibody dilution (diluted in PBS) to the appropriate well.
6) Place the slides in a sandwich box containing a moist tissue and incubate at 
37°C for 30 minutes.
7) Wash the slides twice in PBS and once in distilled H2O.
8) Add 15̂ 1 per well of FITC conjugate (Sigma) diluted in PBS containing 2
drops 0.25% Evans blue per 2ml volume.
9) Repeat step 6.
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10) Wash the slides twice in PBS then twice in distilled H2O.
11) Mount using 1 drop per well of mounting fluid, overlay with a cover slip and 
seal the edges of the coverslip with nail varnish.
12) Examine the slides using a Nikon Labophot microscope fitted with a UV light 







2.18 ELISA (see Figure 2.1)
1) Sensitise plates (NUNC Immunoplate II) with antigen at a pre-deteimined 
concentration (usually 5pg/ml) by incubating overnight at 4°C with 50|il/well, 
in 50mM sodium carbonate buffer, pH 9.5.
2) Wash the wells twice with PBS and block at 4°C with 100}il PBS-casein (2%) 
for 1 hour.
3) Wash the wells twice with PBS-Tween (1%).
4) Dilute primary antibody in PBS-casein (0.5 %)-Tween (0.1%) and add 50pl to
each well.
5) Incubate at 4°C for 2 hours.
6) Wash wells 3x with PBS-Tween.
7) Add 50|il/well horseradish peroxidase labelled secondary antibody (Sigma) at 
1/1000 in PBS-casein (0.5%)-Tween (0.1%).















Figure 2.1 Schematic diagram of an ELISA assay
9) Wash the wells 5x with PBS-Tween.
10) Add 50^1/well enzyme substrate, 0.01% 3,3,,5,5,-tetramethylbenzidine plus
0.03% hydrogen peroxide in Na acetate, pH6.0
11) After 5 minutes stop the reaction with 25|il/well 2.5M H2SO4.
12) Read the O.D. at 450 nm.
The methods described in sections 2.19 to 2.22 are carried out in a Category HI 
containment facility and all manipulations are carried out in the appropriate 
microbiological safety cabinet. Due to the extensive training required to work on live 
HIV, the preparation of HIV virus stocks and some of the HIV neutralization assays 
were carried out by Dr. Eleanor Berrie and Mrs Linda Holdsworth.
2.19 MAMMALIAN CELL CULTURE
The cells maintained in culture for HIV virus preparation and infection inhibition assays 
are H9 cells and C8166 cells. H9 cells were cloned from a T cell line derived from an 
adult with lymphoid leukaemia that were selected for their high growth rate and virus 
production (Popovic et al.. 1984). These cells are used for the production of virus 
stocks. The C8166 T cell line was cloned from a line derived by fusion of cord blood 
cells with an HTLV-I producing line from an adult T-cell leukemia-lymphoma patient 
(Salahuddin et al.. 1983). These cells are used in infection inhibition assays as a rapid 
cytopathic effect is seen following infection with HTV. The cells are cultured in RPMI 
1640 medium (Sigma) supplemented with 10%(v/v) foetal calf serum (FCS), 
penicillin/streptomycin 100 IU/ml, 2mM glutamine (growth medium).
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2.19.1 Storage of mammalian cells
Stocks of cells are stored under the gaseous phase of liquid nitrogen (-100°Q and are 
frozen using the following procedure:
1) Prepare a cell suspension of 1x10^ cells/ml in ice cold growth medium.
2) Place the vial containing the cell suspension in melting ice and add dropwise an 
equal volume of ice cold medium containing 20% FCS/20% 
dimethylsulphoxide (DMSO).
3) Dispense lml volumes into pre-cooled cryotubes and freeze overnight in the 
top tray of the liquid nitrogen storage vessel.
4) Store the cryotubes in the gaseous phase of the nitrogen.
2.19.2 Cell culture propagation
The cells are revived using the following procedure:
1) Thaw the cells quickly by immersion of the vial in pre-warmed water (37°C).
2) Slowly add a small volume of pre-warmed medium (37°Q to the cells. 
Transfer the cells dropwise to a tube containing 10ml pre-warmed growth 
medium and centrifuge at lkrpm for 10 minutes (Beckman GPKR centrifuge).
3) Discard the supernatant. Resuspend the cell pellet in 1 ml of growth medium. 
Remove an aliquot and count the cells using a haemocytometer.
4) Transfer the cells to 25 cm^ tissue culture flask and add growth medium to
give a cell concentration of 3 to 5 xlO^ cells/ml. The cells are cultured in a CO2 
incubator at 37°C with a 5 to 8% CO2 /95% air mixture.
2.19.3 Culturing of cells
All cells are routinely cultured in 80cm^ plastic tissue culture flasks. The cells are 
maintained at 3-5x10^ cells/ml and are diluted with fresh medium twice a week as 
follows:
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1) Leave the tissue culture flasks standing in the microbiological safety cabinet for 
5 to 10 minutes to allow the cells to settle.
2) Remove the spent tissue culture fluid using a pipette, leaving behind 5 to 8 mis 
of concentrated cell suspension.
3) Add l/4th or l/5th of the cell suspension to fresh tissue culture flasks (as many 
as are required).
4) Add fresh growth medium to give a final volume equivalent to the original 
starting volume.
2.20 HIV VIRUS PREPARATION BY CO-CULTURE
1) Mix 1 part of infected cells with 3 parts of uninfected H9 cells. Transfer the 
cells to a 80cm2 tissue culture flask.
2) Add growth medium to give a final cell concentration of lx 10  ̂cells/ml.
Incubate in a 37°C CO2 incubator for 4 days.
3) Clarify the supernatant by centrifuging at 2krpm for 10 minutes at 4°C
(Beckman GPKR centrifuge).
4) Filter the supernatant on ice using a 0.45jim disposable filter.
5) Dispense in cryotubes and store in the gaseous phase of a nitrogen freezer.
6) Resuspend the cells in the original volume of medium and add an equal 
quantity of uninfected cells. Repeat steps 2 to 5.
2.21 TITRATION OF VIRUS STOCK
HIV virus titrations are carried out using C8166 cells:
1) Prepare a cell suspension containing 7x10^ cells/ml.
2) Dispense 150p.l of the cell suspension to each well of a 96 well microtitre plate.
3) Make dilutions of the virus stock in cold growth medium. Keep the virus 
dilutions on ice.
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4) Inoculate 50p.l of the appropriate virus dilution to a minimum of 5 replicate 
wells.
5) Place the plate in a sandwich box with a moist tissue and incubate at 37°C in a 
CO2 incubator.
6) After 48 hours examine the cells daily and score for cytopathic effects.
7) Terminate the experiment after 7 days.
8) Estimate the titre (TCID50) of the virus stock using the method of Karber 
(described in Clinical Virology Manual, Specter and Lancz).
2.22 HIV INFECTION INHIBITION ASSAY (see Figure 2.2)
Virus-neutralizing antibody titres are measured using a syncytial inhibition assay based
on a method described by Kinney-Thomas et al. (1988).
1) Heat-inactivate serum samples for 30 minutes at 56°C.
2) Make doubling dilutions of the sera in "V" bottomed microtitre plates, using 
growth medium as the diluent
3) Add 50pl of virus containing 1000 TCID50 to each well containing the 
appropriate serum dilution.
4) Prepare "virus controls” by diluting the virus stock to give dilutions with 1000,
100 or 10 TC ID 5q/50|i1. Make replicates of each virus control.
5) Incubate the plates at 37°C in a CO2 incubator for 60 minutes.
6) During the last 30 minutes of the incubation prepare the cells. Harvest C8166 
cells and resuspend in fresh growth medium to give a final cell concentration of 
7x10^ cells/ml.
7) Seed 150jjJ of the cell suspension into microtitre wells.














Figure 2.2 HIV infection inhibition assay
9) Place the plates in a sandwich box containing a moist tissue and incubate at 
37°C in a CO2 incubator for 48 hours.
10) Record the degree of cytopathic effect (i.e. syncytium formation) seen in each 
well.
11) Determine the 90% neutralization titre which is defined as the reciprocal of the 
serum dilution at which there is the same cytopathic effect seen as for the 100
TCED50 "virus controls".
2.23 INSECT CELL CULTURE
The Lepidopteran insect cell line used is Spodoptera frugiperda IPLB-sf-9AE (Sf9). 
These cells are a cloned version of the cell line SF21 originally derived from insect 
pupal ovaries (Vaughn et al.. 1977). The cells can be grown as a monolayer, or 
suspension culture when a larger number of cells are required. The cells have a 
doubling time of 18 to 24 hours.
The cell culture medium is TCI00 (Flow laboratories) containing 10% (v/v) FCS plus 
50 IU/ml penicillin, 50 mg/ml streptomycin.
2.23.1 Maintenance of insect cells
Low passage number cells are stored in liquid nitrogen using the following procedure:
1) Harvest the cells in the exponential phase of growth at a cell density between
1-1.5x106 cells/ml.
2) Add DMSO to a give a final concentration of 10%.
3) Fill cryotubes with lml of cell suspension and chill on ice.
4) Place the tubes in the gaseous phase of liquid nitrogen for 2 hours.
5) Store the tubes in the liquid phase of the nitrogen.
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To revive the cells the following procedure is used:
1) Thaw a vial at room temperature for 1 to 2 minutes.
2) Transfer the cells to a 25cm  ̂tissue culture flask containing 8ml culture 
medium.
3) Leave the cells to settle at 27°C for 3 to 4 hours, then discard the medium and 
replace with fresh medium.
4) Leave the cells at 27°C for 2 to 3 days, until confluent Discard the medium, 
add 3ml of fresh medium and scrape off the cells with a sterile scraper. 
Transfer the cells to a 50ml glass culture flask containing 20 ml of medium and 
incubate on a stirring platform at 27°C for 2 to 3 days.
2.23.2 Passaging of insect cells
1) Count the cells using a haemocytometer and calculate the concentration per ml.
2) Seed new cultures in medium as follows:
1x10^ cells/ml if required in 72 hours.
2x 10^ cells/ml if required in 48 hours.
4x10^ cells/ml if required in 24 hours.
3) Incubate the cell culture on a stirring platform at 27°C
2.24 PREPARATION OF INFECTIOUS AUTOGRAPHA
CALIFORNICA NUCLEAR POLYHEDROSIS VIRAL (AcNPV) DNA
1) Infect a 500ml culture of Sf9 cells at 1.5 xlO^ cells/ml at a multiplicity of 
infection (moi) of 0.1 plaque forming units (pfu) per cell. Incubate at 27°C on 
a stirring platform for 3 days.
2) Clarify the supernatant by centrifuging at 3krpm for 5 minutes (Sorvall 
RT6000B centrifuge).
3) Centrifuge the culture medium at 24krpm for 1 hour to pellet the virus particles
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(SW28 rotor, Beckman L8-70M ultracentrifuge).
4) Resuspend the pellets overnight in 1ml of TE.
5) Layer the virus onto 10 to 50% (w/v) sucrose gradients (in TE). Centrifuge the 
gradients at 24krpm for 1 hour at 4°C (SW28 rotor).
6) Withdraw the virus band, then pellet at 24krpm for 1 hour at 4°C (SW28 
rotor).
7) Resuspend the pellet overnight in 2ml of TE.
8) Add 200|il TE and lOOpl sarkosyl solution to 200pl of virus suspension. 
Incubate at 60°C for 30 minutes.
9) Layer onto a 5ml cushion of 54% (w/v) caesium chloride/TE containing 
25|ig/ml of ethidium bromide. Centrifuge at 35krpm overnight at 20°C (VTI65 
rotor, Beckman L8-70M ultracentrifuge).
10) Harvest the DNA band and extract the ethidium bromide 3 times with an equal
volume of water saturated butanol.
11) Dialyse the DNA overnight against 11 of TE at 4°C.






2.25 CO-TRANSFECTION OF INSECT CELLS TO GENERATE
RECOMBINANT VIRUS
1) Seed 3 35mm dishes with 1.3x10^ cells each.
2) Prepare a 100ng/|il solution of plasmid DNA in sterile H2O.
3) Dilute 24pl of lipofectin (BRL) with 12|il H2O (in a bijou tube).
4) Add lOOng viral DNA (See 2.24) to Ong, 200ng (2|il) or 500ng (5pl) of 
plasmid DNA. Make the solutions up to 12}il with sterile H2O (in bijoux 
tubes).
5) Add 12|il of lipofectin mix to each of the DNA solutions, mix gently and leave 
at room temperature for 15 minutes.
6) Remove the medium from the cells, wash 3 times with FCS-free TC100. Add 
lml FCS-free TC100.
7) Pipette the lipofectin/DNA mixtures dropwise onto the cells and leave at 27°C 
for 4 to 5 hours. Add lml TC100 medium containing 10% FCS and 
antibiotics. Incubate at 27°C for 48 hours.
8) Remove the supernatant from the dishes. Microfuge for 30 seconds, decant 
and store at 4°C.
9) Screen for recombinant virus formation in a Brown-Faulkner plaque assay (see 
below).
2.26 TITRATION OF VIRUS IN A PLAQUE ASSAY
The plaque assay is based on the method of Brown and Faulkner (1977).
1) Prepare 3% (w/v) low-gelling temperature (LGT) agarose in H2O. Sterilize by
autoclaving. Maintain at 45°C.
2) Seed 35mm dishes with 1.4 to 1.5x10^ cells.
3) Remove the medium from the dish and pipette lOOp.1 virus (diluted as
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appropriate in medium) onto the centre of the dish. Leave at room temperature 
for 1 hour, gently agitating the dish occasionally.
4) Remove the virus inocula and add 2ml of agarose/medium (50% LGT/50% 
medium) overlay. Stand at room temperature for 15 minutes to solidify.
5) Add lml of medium. Place the dishes in a sandwich box containing a moist 
tissue and incubate at 27°C for 3 days.
6) Discard the medium and then add lml 6% neutral red stain solution in PBS. 
Leave for 1 hour and then discard the stain solution. Leave dishes overnight at
V
room temperature for the plaques to clear.
7) Calculate the titre of the virus by counting the number of plaques at each virus 
dilution, then multiply this by the virus dilution. Take the average over the 
range of dilutions to give the virus titre, expressed as plaque forming units 
(pfu)/ml.
2.27 PREPARATION OF RECOMBINANT BACULOVIRUS STOCKS
After plaque purification the titre and volume of the recombinant baculovirus is 
increased to provide a working virus stock. This is achieved by a 3 stage infection 
procedure.
1) Seed 35mm dish with 1.2x10^ cells. Discard the medium and infect with 
150|il of a plaque which has been picked and vortexed in 500pl medium. 
Incubate for 1 hour at room temperature.
2) Add 2 ml of medium and incubate at 27°C for 5 to 6 days.
3) Clarify the supernatant by centrifuging at 3krpm for 5 minutes (Sorvall 
RT6000B centrifuge). Store the virus (now at passage number 3)
at 40C.
4) Seed an 80cm3 tissue culture flask with 8x 10^ cells. Discard the medium and 
infect with 250jil of passage 3 virus for 1 hour at room temperature. Add 25ml
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medium and incubate at 27°C for 5 to 6 days.
5) Clarify supernatant by centrifuging at 3krpm for 5 minutes (as above). Store 
the virus (passage 4) at 4°C.
6) litre the passage 4 virus stock using the Brown-Faulkner plaque assay 
described in section 2.26.
When the virus titre has been determined prepare a high titre virus working stock as
follows:
7) Seed a 500ml vessel with 250ml of cells at a density of 2.5x10^ cells/ml. 
Incubate on a stirring platform at 27°C for 24 hours.
8) Infect with passage 4 virus at a multiplicity of infection (moi) of 0.1 plaque 
forming units (pfu) per cell. Incubate on a stirring platform at 27°C for 5 
days. Clarify the supernatant by centrifuging at 3kpm for 5 minutes (as 
above) and store the virus at 4°C
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CHAPTER 3




As stated in chapter one, a major aim of this project was to investigate the presentation 
of the major neutralizing epitope of the envelope glycoprotein gpl20 (the V3 loop) 
using the hybrid Ty-VLP system, and to determine whether hybrid HIV V3:Ty-VLPs 
could induce HIV neutralizing antibodies. As the V3 loop region is hypervariable 
between different isolates of HIV, initial studies of hybrid VLPs carrying the V3 loop 
were made using the IIIB isolate that has been the most extensively sudied to date. The 
main advantages of choosing this isolate were the availability of reagents required for 
assaying the presentation of the V3 loop sequence by the hybrid Ty-VLPs and the 
ability to make a direct comparison with other systems reported in the literature. The 
original IIIB isolate was derived from H9 cells co-cultured with a pool of T cells from 
several American AIDS patients (Popovic et al.. 1984) and is therefore a mixed virus 
population. Several clones from this isolate have been sequenced and it was decided to 
produce hybrid VLPs that carried the V3 loop sequence from two of these HIB clones. 
The V3 loop sequences from the BH10 clone (Ratner et a!.. 1985) and the HXB2 clone 
(Fisher et al.. 1985) are shown below. The two sequences differ by only one amino 
acid, which is underlined:
SNCTRPNNNTRKSIRIQRGPGRAFVTIGKIGNMRQAHCNISG BH10 
SNCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISG HXB2
The hybrid V3:Ty-VLPs were analysed by Western blot and immunogold electron 
microscopy. The immunogenicity of the VLPs, including the ability to induce 
neutralizing antibodies, was studied following immunization of rabbits using different 
adjuvants.
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3.1 CONSTRUCTION OF HIV:Ty-VLPs CONTAINING THE BH10 
AND HXB2 V3 LOOPS
In order to construct TYA:HIV V3 loop fusion genes, synthetic oligomers encoding the 
loop sequences were first cloned into plasmid pSP46 and sequenced. pSP46 is a 
derivative of plasmid pSP64 (Melton et al.. 1984) in which the Hindin  site within the 
polylinker sequence has been replaced with a Bgin site. pSP46 therefore contains both 
BamHI and Belli sites within the polylinker. All of the oligomers synthesized 
containing the V3 loop sequences had a Bgin site at the 5’ end of the annealed pair of 
oligomers and a BamHI site at the 3' end. Cloning of the annealed oligomer pairs into 
BelH-BamHI digested pSP46 therefore generated a plasmid from which the V3 loop 
fragment could be easily excised after verification of the sequence (Figure 3.1). If the 
annealed oligomer pairs were cloned directly into the BamHI site of the VLP expression 
vectors pMA5620 or pOGS40 (described in chapter 1, section 1.4) the fragment could 
not be excised again as a BgHI-BamHI fragment The strategy of cloning the oligomers 
into pSP46 became more important in later constructions where V3 loop fragments 
from different isolates were linked together in one vector (see chapter 5).
After verification by sequencing, the Bgin-BamHI V3 loop fragment was excised from 
the pSP46 derivative and cloned into the BamHI site of the VLP expression vector 
pMA5620 (Figure 1.4).






















Figure 3.1 Cloning strategy for synthetic oligomers 
coding for V3 loops
Hybrid Ty-VLPs purified from yeast cells transformed with the VLP expression 
vectors were given the same name as the plasmid but without the "p" prefix. For 
example, VLPs purified from pOGS514 transformed cells were OGS514 VLPs.
3 2  PURIFICATION OF HYBRID HIV:Ty-VLPs
The purification of VLPs was facilitated by the fact that they are considerably larger in 
size than most cellular proteins. Furthermore, as the basic physical properties of each 
hybrid particle are conferred by the carrier, particle-forming protein, pi, the same 
purification procedures could be used for each construction.
The protocol used for purifying VLPs has been described in section 2.13. For each 
preparation, 161 of cells were grown to a density of greater than 2 x 10^ cells/ml. The 
cells were grown under selective conditions in order to maintain the presence of the 
plasmids. The yeast strain used for the production of VLPs was auxotrophic for 
leucine, uracil and tryptophan synthesis. Cells transformed with a single plasmid 
containing the LEU 2 gene (pMA5620 derivatives) were therefore grown in the 
presence of uracil and tryptophan.
Figures 3.2 and 3.3 illustrate the purification steps involved in the production of VLPs 
from yeast cells transformed with pOGS514 (isolate HXB2). In figure 3.2, the 
SDS-PAGE gel shows the particle protein and other yeast proteins at various stages of 
the purification. The denatured monomeric fusion protein had an estimated molecular 
weight of 60kD by comparison with the molecular weight markers. However the 
calculated molecular weight of the truncated pi protein is 43kD and that of the added 
HIV protein is approximately 4kD. The fusion protein should therefore have a 
molecular weight of 47kD. The discrepancy in size is due to the anomalous migration 












M Molecular weight markers
Figure 3.2 Purification stages of OGS514 VLPs















M Molecular weight markers
Figure 3.3 SDS-PAGE analysis of aliquots of fractions 
following size exclusion chromatography of OGS514 VLPs
As shown in track 1 of Figure 3.2 it was difficult to distinguish the VLP protein from 
cellular proteins in the crude cell homogenate. However, the VLP protein became 
clearly visible after the sucrose gradient step (track 3). The final purification step was to 
pass the material over a size exclusion chromatography column. Figure 3.3 shows an 
SDS-PAGE gel of column fractions containing the OGS514 particles. The final stage of 
the preparation was to concentrate the particles to approximately one mg/ml. The 
OGS514 purification illustrated here yielded 26 mg of VLPs, i.e., 1.6 mg/L 
Preparations of other HIV V3 loop:Ty-VLPs yielded between 10 and 50mg from 161 
cultures.
33  PRELIMINARY CHARACTERISATION OF HYBRID Ty-VLPs
33,1 Western blot analysis
The hybrid VLPs OGS513 (BH10) and OGS514 (HXB2) were analysed by Western 
blotting. The blot shown in Figure 3.4 (a) was probed with a monoclonal antibody 
raised against MA5620 control Ty particles. The blot showed the expected increase in 
size of approximately 4kD for the monomeric proteins of OGS513 and OGS514 as 
compared to the MA5620 control Ty particles. The blot in Figure 3.4 (b) was probed 
with a gp 120-specific monoclonal antibody 9284 (Du Pont). Monoclonal antibody 
(Mab) 9284 was raised against isolate IIIB and maps to the left hand side of the V3 
loop (Skinner etaL, 1988b). Both OGS513 (BH10) and OGS514 (HXB2) VLP 
proteins reacted positively with Mab 9284, indicating that the V3 loop was present in 
the fusion proteins comprising these hybrid V3:Ty-VLPs. As mentioned above, the V3 
loop sequences from these two clones of the HIB isolate differ by only one amino acid 
which is found on the left hand side of the loop. It is therefore interesting to note that 




















Figure 3.4 Western blot analysis of HIV V3:Ty-VLPs 
OGS513 (BH10) and OGS514 (HXB2).
Blot (a) was probed with a monoclonal antibody raised 
against MA5620 control Ty particles. Blot (b) was probed 
with a gpl20 specific monoclonal antibody.
3.3.2 Electron microscopic analysis of OGS 514 (HXB2) Ty-VLPs 
Electron micrographs of purified MA5620 (Ty control) and OGS514 VLPs are shown 
in Figure 1.5. Various conditions were investigated in order to gold-label the OGS514 
VLPs (isolate HXB2) with the gp 120-specific MAb. The optimal conditions that were 
determined are summarized in Section 2.16. Using these conditions the OGS514 VLPs 
were specifically labelled with MAb 9284 (Figure 3.5). As the interior of the particles 
is unlikely to be accessible to the gold/antibody complexes, these data indicate that at 
least some of the V3 loop region was exposed on the surface of the particles.
3.4 IMMUNE RESPONSES GENERATED AGAINST THE 
V3:Ty-VLPs
The major analysis of antigen presentation was by immunization of rabbits with the 
HTV IIIB V3 loop:Ty-VLPs. The immunizations were carried out at Serotec, 
Kidlington, Oxfordshire. All of the experiments utilized the same immunization 
protocol. The dose was 500pg of VLPs which represents approximately 50pg of the 
V3 loop antigen. Each dose was administered via two intramuscular sites. After a 
priming immunization, the rabbits received a boost every two weeks for a total of eight 
boosts. Test bleeds were taken every week in order to allow for close monitoring of the 
antibody levels. After the eighth boost, rabbits were bled every two weeks so that the 
longevity of the response could be investigated.
Initially, the immunizations were earned out using Freund's adjuvant This is a very 
powerful adjuvant because the antigens are presented as an oil emulsion which acts as a 
depot, releasing the antigen slowly. However, Freund's adjuvant can cause adverse 
side effects and is therefore only useful in a primary screen to identify effective antigens 
in experimental animals. These experiments were then followed by an analysis of the 
immunogenicity of HFV:Ty-VLPs carrying the V3 loop from isolate HXB2 (OGS514)
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50nm
Figure 3.5 Immunogold electron microscopy of OGS514 VLPs
VLPs were probed with the monoclonal antibody 9284. Bound antibody 
was detected using a gold labelled (5nm) anti-mouse antibody.
in conjunction with aluminium hydroxide. Aluminium hydroxide is cuirendy the only 
adjuvant approved for use in humans and these experiments were therefore the most 
relevant in terms of candidate vaccine design.
3.4.1 Serum antibody titres of animals immunized with the 
V3:Ty-VLPs in conjunction with Freund's adjuvant
Initial immunizations compared the immunogenicity of OGS513 (BH10) and OGS514 
(HXB2) V3:Ty-VLPs following administration in conjunction with Freund's adjuvant. 
The three rabbits which received the OGS513 (BH10) VLPs were designated 513/1/1, 
513/1/2 and 513/1/3 and the three rabbits that received the OGS514 (HXB2) VLPS 
were designated 514/1/1,514/1/2 and 514/1/3.
The serum antibody titres were determined using an ELISA assay (outlined in Figure 
2.1.) First, wells of a microtitre plate were coated with an appropriate antigen. The 
antigen used in these assays to measure the anti-HIV response was recombinant gpl20 
(rgpl20; isolate HIB), which was obtained from the Medical Research Council AIDS 
Directed Programme. To measure the response against the Ty component of the hybrid 
particle, MA5620 (control Ty) particles were used as the antigen. Secondly, the rabbit 
antisera raised against the HIV V3 loop:Ty-VLPs were titrated against the antigen, 
usually beginning at a 1:100 dilution followed by trebling dilutions to 1:72900. After 
the appropriate washing and detection steps (see figure 2.1), the optical densities 
(O.D.) recorded were converted to mid-point titres. These were calculated as the 
dilution which gave rise to half of the maximum O.D. achieved by the lowest dilutions. 
Mid-point titres were used as they are more comparable between assays than end-point 
titres.
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Sera from the animals immunized with the OGS513 and OGS514 VLPs in conjunction 
with Freund's adjuvant were assayed against rgpl20. Figure 3.6 shows the antibody 
titres of the bleeds obtained after each boost In the 513/1 group, animal 513/1/1 
showed an anti-gpl20 response after the first boost which increased gradually up to 
post-boost five, declined post-boosts six and seven and then increased again post-boost 
eight. Animals 513/1/2 and 513/1/3 had relatively low anti-gpl20 titres throughout the 
immunization regime. In the 514/1 group, all three animals showed a strong response 
against rgpl20. The titres of animal 514/1/1 peaked post-boost five at 1:13000 and the 
titres of animals 514/1/2 and 514/1/3 peaked post-boost four at 1:9000 and 1:12500 
respectively. The titres declined after subsequent boosts, which may have been due to 
anti-V3 loop antibodies present at the time of the boost complexing with the additional 
V3 antigen presented by the V3:Ty-VLPs. It is possible that this would have had the 
effect of decreasing the antibody population and/or increasing the rate of clearance of 
the antigen. As Figure 3.6 demonstrates, the animals in group 514/1 showed a much 
greater anti-gpl20 response as compared to the animals in group 513/1. These data 
therefore suggested that OGS514 hybrid VLPs were more effective at eliciting an 
anti-HIV response.
Figure 3.7 shows the antibody titres obtained against the Ty component of hybrid 
VLPs in the animals in groups 513/1 and 514/1. All the animals in both groups had 
high anti-Ty titres, although the response was highly variable throughout the 
immunization schedule. The titres of animals 513/1/1 and 513/1/3 peaked at 1:1000000 
post-boosts eight and seven respectively, whereas the maximum response in animal 
513/1/2 occurred after the second boost with a titre of 1:650000. In the 514/1 group, 
the anti-Ty titres of animal 514/1/1 peaked after the third boost at 1:200000 and then 
declined gradually following subsequent boosts. The peak titre of animal 514/1/2 of 
1:600000 occurred after the fifth boost and animal 514/1/3 had maximum titres of
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Figure 3.6 ELISA mid-point titres of groups 
513/1 and 514/1 assayed against rgp!20. The 
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Figure 3.7 Anti-Ty mid-point titres of groups 
513/1 and 514/1. The sera were assayed against 
control Ty particles.
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1:1000000 post-boosts five, seven and eight.
Comparison of the anti-gpl20 responses with the anti-Ty responses showed that higher 
titres were generated against Ty. This observation may correspond to the fact that in the 
hybrid particles the majority of the protein was Ty, and the V3 loop represented only 
10% of the particulate protein. There appeared to be little correlation between the 
responses generated against the two components of the particle, either when comparing 
the responses in individual animals or comparing the responses between the two 
different groups.
3.4.2 Induction of anti-HIV neutralizing antibodies following 
immunizations with V3:Ty-VLPs in conjunction with Freund’s adjuvant
Antisera from the animals in groups 513/1 and 514/1 described above in section 3.4.1 
were assayed for their ability to neutralize HIV-1 isolate HIB in vitro. The assay has 
been described in section 2.22 and is shown diagrammatically in figure 2.2. Virus 
neutralizing antibody titres were expressed as the reciprocal of the dilution that gave rise 
to a 90% inhibition of infectivity.
Figure 3.8 compares the neutralization titres of the animals in group 513/1 with the 
animals in group 514/1. After the first boost, all the animals in group 514/1 had 
neutralizing antibodies and, in particular, animal 514/1/3 had a substantial titre of 
1/128. In contrast, none of the animals in group 513/1 had neutralizing antibodies 
following the first boost In general, titres increased in most animals up to post-boost 
four or five, and titres in group 514/1 were higher than those in group 513/1. The 
neutralization titres therefore provided further evidence to suggest that a stronger 
immune response was generated against the HXB2 V3 loop carried by the OGS514 
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Figure 3.8 Neutralization titres of sera from 
groups 513/1 and 514/1 assayed against HIVIIIB.
3.4.3 Longevity of the antibody response in animals immunized with 
V3:Ty-VLPs in conjunction with Freund's adjuvant
The longevity of the antibody response in the animals in groups 513/1 and 514/1 was 
assessed by measuring the anti-gpl20 titres of the sera taken at monthly intervals for 
six months. Table 3/1 shows that all the animals in both groups still had anti-gpl20 
antibodies after six months and in some animals the titres increased during this period. 
This maintenance of antibody levels was probably due to the depot effect of the 
Freund's adjuvant at the site of injection, slowing releasing antigen for some time after 
the eighth boost.
3.4.4 Recall of the immune response of animals immunized with 
V3:Ty-VLPs in conjunction with Freund's adjuvant
In order to determine whether a memory response had been generated against the V3 
loops carried by the OGS513 (BH10) and OGS514 (HXB2) VLPs the animals in 
groups 513/1 and 514/1 were given a further boost seven months after the eighth boost 
Table 3/2 gives the HTV neutralization titres before and after the ninth boost. 
Neutralizing antibodies were still present at the time of boosting and did not 
significantly increase in titre after the boost Due to the sustained response in all of the 
animals prior to boost nine this experiment could not demonstrate whether or not a 
memory response had been induced.
3.4.5 Serum antibody titres of animals immunized with OGS514 
(HXB2) VLPs in conjunction with aluminium hydroxide
As stated above, immunizations carried out in conjunction with Freund's adjuvant can 
be useful as a primary screen to investigate the immunogenicity of novel antigens.
The initial immunizations carried out with OGS513 (BH10) VLPs and OGS514 
(HXB2) VLPs administered in conjunction with Freund's adjuvant suggested that
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TABLE 3/1. LONGEVITY OF THE ANTI-GP120 RESPONSE IN ANIMALS 
IN GROUPS 513/1 AND 514/1
Anti-gpl20 titres were expressed as the reciprocal of the dilution of the mid-point titre.
Animal
513/1/1 513/1/2 513/1/3 514/1/1 514/1/2 514/1/3
Weeks after
boost 8
4 1800 600 350 1100 5000 4400
8 550 1400 1200 700 3000 5000
12 650 750 850 1700 1000 2100
16 850 650 600 500 1800 2400
20 950 1500 1500 350 1800 2700
24 350 700 950 350 1800 1500
TABLE 3/2. NEUTRALIZATION TITRES OF ANIMALS IN GROUPS 513/1 
AND 514/1PRE AND POST THE NINTH BOOST
Neutralization titres were expressed as the reciprocal of dilution that gave rise to 90% inihibtion 
of syncytium formation.
Animal
513/1/1 513/1/2 513/1/3 514/1/1 514/1/2 514/1/3
pre boost 8 16 8 16 64 128
post boost 32 8 8 32 128 128
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Figure 3.9 ELISA mid-point titres of group 514/2 
assayed against rgpl20. The sera were assayed 
seven days post boost.
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Figure 3.10 ELISA mid-point titres of sera from 
animal 514/2/2. The sera were assayed against rgpl20.
Figure 3.11 shows the Ty responses from the animals in group 514/2. Animals 514/2/1 
and 514/2/3 had the highest anti-Ty responses. However these animals also had the 
lowest anti-gpl20 response, which indicated that animals 514/2/1 and 514/2/3 
preferentially responded to Ty. In general, in the four animals that had strong 
anti-gpl20 responses, a similar trend in their anti-Ty responses was observed to that of 
the anti-gpl20 responses (Figure 3.9), with peak titres occurring post-boost four or 
five. These data further indicated that antibodies already present may be complexing 
with the antigen in subsequent boosts. This therefore suggested that the boosting 
regime for the experiments, although chosen on the basis of experiments described in 
the literature, was too frequent The maximum anti-Ty titres were approximately three 
to ten fold higher than the titres against gpl20. In addition, the anti-Ty titres in the 
animals immunized with OGS514 VLPs in conjunction with aluminium hydroxide were 
approximately ten fold lower than the animals immunized with the OGS514 VLPs in 
Freund’s adjuvant.
The sera from animal 514/2/2 were assayed against the control Ty particles before and 
after each boost. Figure 3.12 shows that although the titres against Ty were higher than 
the serum antibody titres against gp 120 the pattern of response was similar. The 
decreases in titre between boosts were not as great as those seen with the gpl20 
antibody titres indicating that the anti-Ty antibodies had a longer half-life than the 
anti-gpl20 antibodies.
3.4.6 Neutralizing antibody titres of animals immunized with OGS 514 
(HXB2) VLPs in conjunction with aluminium hydroxide
Sera from the animals in group 514/2 were tested for the presence of HTV neutralizing 
antibodies in a syncytium inhibition assay. Figure 3.13 shows the neutralization titres 
obtained. The neutralization titres reflected the anti-gp!20 responses with four of the
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Figure 3.11 Anti-Ty mid-point titres of group 
514/2. The sera were assayed against control Ty 
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Figure 3.12 Anti-Ty mid-point titres of animal 514/2/2. 
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Figure 3.13 Neutralization titres of sera from 
group 514/2 assayed against HIVIIIB. Titres of 
1/512 are actually equal to or greater than 1/512.
animals having high levels of neutralizing antibodies. The pattern of the responses was 
also similar with peak titres occuring after the fourth or fifth boosts. The neutralization 
titres of the animals in group 514/2 were comparable with the titres in group 514/1, 
demonstrating again that similar anti-HIV responses were elicited whether the 
immunizations were carried out in conjunction with aluminium hydroxide or Freund's 
adjuvant
The neutralizing antibody titres from animal 514/2/2 were determined before and after 
each boost Figure 3.14 shows that the trend seen in the neutralization titres was similar 
to that of the anti-gpl20 antibody titres shown in Figure 3.10. This suggested that a 
significant proportion of the antibodies induced against the HXB2 V3 loop presented 
on OGS514 VLPs were virus neutralizing antibodies. The high titres of neutralizing 
antibodies observed with a maximum of 1:2048 (animal 514/2/2, post-boost five), 
demonstrated the efficacy of the OGS514 VLPs following administration in a clinically 
relevant formulation.
3.4.7 Longevity of the antibody response in animals 514/2/2 and 
514/2/6
The longevity of the response in all six animals in group 514/2 could not be monitored 
due to the loss of four of the animals as a result of an infection contracted in the animal 
house.
Table 3/3 shows the serum gpl20 and neutralizing antibody titres obtained up to 10 
weeks after the last boost in animals 514/2/2 and 514/2/6. The neutralizing antibody 
titres of animal 514/2/2 remained constant at 1/512 for eight weeks following the final 
boost and then dropped to 1/64, whereas the ability of sera from animal 514/2/6 to 
neutralize declined gradually throughout the 10 week period. However, in both
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Figure 3.14 Neutralization titres of sera from 
animal 514/2/2. Sera were assayed against HIVIIIB.
TABLE 3/3. LONGEVITY OF THE ANTIBODY RESPONSE OF ANIMALS 
514/2/2 AND 514/2/6
Weeks following the final boost 
Animal 2 4 6 8 10
i) Reciprocal gpl20 antibody mid-point titre
514/2/2 1000 4000 800 1100 300
514/2/6 200 300 400 200 300
ii) Reciprocal HTV neutralizing antibody titre
514/2/2 512 512 512 512 64
514/2/6 64 64 32 16 16
animals, significant levels of gpl20 and neutralizing antibodies were still present 10 
weeks following boost eight. Sera from animal 514/2/6 still had detectable anti-gpl20 
titres up to 20 weeks after the eighth boost (data not shown).
3.4.8 Recall of the response in animal 514/2/6
In order to determine whether antigen-specific memory cells had been induced by the 
OGS514 VLPs, animal 514/2/6 received a further boost after a 6 month rest period. At 
the time of the boost no gpl20 or neutralizing antibodies were detected. However, sera 
taken 7,14 and 21 days after the ninth boost had neutralizing antibody titres of 1/16, 
1/32 and 1/128 respectively. In the initial immunization regime, neutralizing antibodies 
were not detected after the first boost and the maximum titre of 1/128 was only 
achieved after the third boost. Boosting after a six month rest period therefore induced a 
rapid recall of the response to the HXB2 V3 loop presented on OGS514 VLPs, with 
the maximum neutralization titre being achieved in three weeks.
3.5 DISCUSSION
Hybrid Ty-VLPs have been constructed that cany the major neutralizing epitope of HIV 
clones BH10 and HXB2. The VLPs reacted positively by Western blot analysis with a 
V3 loop monoclonal antibody, confirming the presence of the V3 loop sequence on the 
hybrid V3:Ty-VLPs. Immunogold labelling experiments with VLPs carrying the HXB2 
V3 loop indicated that at least some of the V3 loop sequence was exposed on the 
surface of the VLPs. However, although the labelling by the anti-gpl20 antibody was 
specific, the antibody did not label the entire surface of the VLPs. One possible 
explanation was that only a limited amount of antibodies were able to bind due to steric 
hindrance. Alternatively, as the reactions were not carried out in solution, it is possible 
that some disruption of the VLP structure occurred as the particles were loaded onto the 
grid, thereby exposing previously hidden epitopes.
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Immunizations of experimental animals have been carried out to test the efficacy of the 
hybrid V3:Ty-VLPs. Initial immunizations compared the immunogenicity of OGS513 
(BH10) and OGS514 (HXB2) VLPs in conjunction with Freund's adjuvant. The data 
demonstrated that although both the OGS513 (BH10) and OGS514 (HXB2) particles 
elicited anti-gpl20 and virus neutralizing antibodies, a greater response was seen 
following immunization with OGS514 VLPs. In contrast, similar anti-Ty responses 
were induced in both groups of animals, indicating that both particle preparations were 
similarly immunogenic. Three possible explanations for the differences seen in the 
anti-HIV responses elicited by the OGS513 and OGS514 VLPs are outlined below.
First, higher anti-HIV responses elicited by OGS514 VLPs may be due to the variation 
in the V3 loop sequences. The V3 loop sequences differ by only one amino acid, with a 
serine residue in BH10 being substituted by an arginine residue in HXB2. This is not a 
conservative change; although both residues are polar, serine is uncharged whereas the 
side chain of arginine is basic. This charge difference may in itself affect antigenicity.
In addition, the bulky side chain of the arginine residue may influence the overall 
structure of the V3 loop, thereby altering the antigenic properties of the sequence.
Secondly, the differences observed in neutralization titres may reflect the relative 
proportions of the HXB2 and the BH10 clones within the mixed MB population used 
in the assays. If anti-HXB2 and anti-BHIO antibodies can only neutralize HXB2-like 
and BH 10-like clones respectively, differences in titres may simply indicate that the 
BIB population contains more HXB2-like than BH 10-like viruses. However, there was 
a good correlation between the anti-gpl20 titres and the HIV neutralizing titres 
suggesting that a significant proportion of the antibodies raised against the V3 loops 
were virus-neutralizing antibodies. As the recombinant gpl20 used in the ELISA assay
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had the BH10 V3 loop sequence, it is therefore unlikely that the differences observed 
were due to the reagents used in the assays.
Thirdly, the observed variation in response may be because only relative small numbers 
of animals were used in the experiments. As the animals were outbred and therefore 
likely to have different MHC haplotypes, it is possible that the animals in group 514/1 
were fortuitously better responders to the V3 loop sequence.
A second series of immunizations were carried out using the OGS514 VLPs in 
conjunction with aluminium hydroxide. High-titre anti-gpl20 and virus neutralizing 
antibodies were again generated and these data demonstrated that OGS514 VLPs are 
efficacious in a clinically relevant formulation. Overall, the titres induced by OGS514 
VLPs were similar whether the immunizations were administered in conjunction with 
aluminium hydroxide or with Freund's adjuvant. These results indicate that the 
OGS514 VLPs effectively present the V3 loop sequence to the immune system and that 
this presentation is not dependent on the use of a powerful enhancer of 
immunogenicity. Differences were observed in the number of animals in the two 
adjuvant groups that induced strong anti-HIV responses. The animals in the Freund's 
group all showed similar high titre responses whereas only four out of the six animals 
in the group that had received OGS514 VLPs in conjunction with aluminium hydroxide 
had substantial titres. These differences were probably due to the different adjuvants 
used but could also be attributed to the variations inherent when using small groups of 
animals. The variations could be addressed by comparing the relative responses 
induced by OGS514 VLPs following immunization in conjunction with Freund’s 
adjuvant or aluminium hydroxide, using larger groups in which the animals have been 
MHC haplotyped. A difference was also observed in the longevity of the response 
induced in the two OGS514 experiments. The more sustained response in the Freund's
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group was probably due to the depot effect of this adjuvant.
The results presented in this chapter demonstrate that hybrid Ty-VLPs carrying the 
HXB2 V3 loop elicit high-titre HIV neutralizing antibodies when administered in a 
clinically relevant formulation. Immunization also generates a memory response. The 
OGS514 V3:Ty-VLPs therefore induce responses that are likely to be required of a 
potential HIV vaccine candidate.
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CHAPTER 4
IMMUNE RESPONSES INDUCED BY HYBRID Ty-VLPs 
CONTAINING THE V3 LOOP FROM THE MN ISOLATE
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4.0 INTRODUCTION
In recent years many isolates of HIV from the USA and Europe have been sequenced 
and this analysis has shown that the isolate IIIB is not prevalent Isolates from infected 
individuals have been found to be more similar to the isolate MN that was originally 
sequenced by Gurgo et al.(19881. Serological studies of HIV infected patients showed 
that 18% (Devash et al.. 1990b) and 14% (LaRosa et al.. 1990) had antibodies that 
recognised the V3 loop from the RIB isolate. In contrast these studies and a further 
study by Zwart etal.(1991) demonstrated that a high percentage of patient sera reacted 
with the V3 loop from the MN isolate. These data suggest that a potential vaccine 
candidate should include a component that would elicit a neutralizing response against 
the MN isolate. Hybrid Ty-VLPs were therefore constructed carrying the MN V3 loop 
whose sequence is shown below:
SNCTRPNYNKRKRIHIGPGRAFYTTKNIIGTIRQAHCNISG
4.1 CONSTRUCTION AND PURIFICATION OF MN V3:Ty-VLPs
A TYA:MN V3 loop fusion gene was constructed by first cloning synthetic oligomers 
encoding the MN V3 loop sequence into pSP46 in the same way as described in chapter 
3, section 3.1. The resulting plasmid was designated pOGS524. The MN V3 loop gene 
was then cloned into the yeast expression vector pMA5620 to generate pOGS525. 
However yeast cells that were transformed with pOGS525 grew very slowly and gave 
a poor yield of hybrid VLPs. This indicated that the pl:MN V3 loop fusion protein in 
some way had a toxic effect on the yeast cells. The MN V3 loop gene was therefore 
cloned into the expression vector pOGS40 to generate pOGS530 which expressed the 
fusion protein from the galactose inducible promoter described in chapter 1, section 
1.4.1. Yeast cells were transformed with pOGS530 and then OGS530 (MN) hybrid 
V3:Ty-VLPs were purified using the method described in chapter 2, section 2.3.
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4.2 PRELIMINARY CHARACTERIZATION OF OGS530 (MN)
V3:Ty-VLPs
Preliminary characterization of OGS530 (MN) VLPs was carried out by Western blot 
analysis. The blot in Figure 4.1a was probed with a polyclonal antiserum raised against 
MA5620 control Ty particles and showed an increase in size of the pl:MN V3 
monomeric protein as compared to pi. The blot in Figure 4.1b was probed with a 
polyclonal antiserum raised against an MN V3 loop peptide and the positive reaction 
indicated the presence of the MN V3 loop in the OGS530 VLP fusion protein.
Figure 4.1c shows two Western blot filters in which a panel of hybrid Ty-VLPs 
carrying the V3 loops from a diverse range of isolates were probed with two separate 
pools of ten HTV-1 positive sera. These included the OGS513 (BH10) and OGS514 
(HXB2) VLPs carrying the V3 loops from the IIIB isolate (chapter 3) and also 
OGS515 VLPs that cany the V3 loop from the Haitian isolate RF. OGS516 (MAL) and 
OGS519 (ELI) contain the V3 loops from two African isolates. These hybrid 
V3:Ty-VLPs are discussed in chapter 5. It is interesting to note that both pools of sera 
gave the same pattern of reactivity. A weak response was observed with OGS513 
(BH10) and OGS514 (HXB2) VLPs, a stronger response was seen with OGS516 
(MAL) VLPs and a very strong response was seen with the OGS530 (MN) VLPs. 
These results support the observations outlined in the introduction that MN-like isolates 
are more common than any others examined to date.
43  IMMUNE RESPONSES GENERATED AGAINST THE MN 
V3:Ty-VLPs
To test the immunogenicity of OGS530 (MN) VLPs, five rabbits were immunized in 
conjunction with aluminium hydroxide (designated group 530/1). The immunization 













































Figure 4.1 Western blot analysis of OGS530 (MN) VLPs
Blot (a) was probed with a monoclonal antibody raised against 
MA5620 control Ty particles. Blot (b) was probed with a 
polyclonal serum raised against a MN V3 peptide. Each blot 
in (c) was probed with a separate pool of HIV-1 positive sera.
priming immunization and a total of eight boosts of 500}ig of OGS530 VLPs at 
two-weekly intervals. Sera from the immunized animals were tested for their ability to 
neutralize the HTV isolate MN. Only two animals had low levels of neutralizing 
antibodies against MN. Serum antibody levels measured against a peptide coding for 
the MN V3 loop were also low. The anti-Ty titres were measured and were found to be 
approximately ten fold lower as compared to the titres obtained in group 514/2 (chapter 
3, section 3.4.5). This indicated that for some unknown reason, the animals in group 
530/1 had induced a very poor response against the OGS530 VLPs.
To examine the anti-OGS530 response further, an additional series of immunizations 
were therefore carried out. One group of five rabbits were immunized with the OGS530 
VLPs in conjunction with aluminum hydroxide (designated group 530/2) and another 
five rabbits were immunized in conjunction with Freund's adjuvant (group 530/3). 
Antisera from the ten animals up to post-boost five were assayed by ELISA against Ty 
and the MN peptide. Again a poor response was observed in all ten animals, with 
similar titres obtained in each group. When the anti-Ty response of animals immunized 
with OGS514 VLPs had been compared previously, either in conjunction with 
Freund's adjuvant or aluminium hydroxide, it was found that the titres in the Freund's 
group were approximately ten fold higher. This enhancement of the anti-Ty response 
was not observed in the animals that received the OGS530 (MN) VLPs with Freund's 
adjuvant The results obtained for the three groups of rabbits immunized with the 
OGS530 VLPs therefore indicated that a poor immune response was generated against 
these particles. As the same preparation of OGS530 VLPs was used for the 
immunizations one possible explanation of the poor responses was that some impurity 
in this batch had a deleterious effect on the immune system of the rabbits. Another 
possibility was that the MN V3 loop sequence was in some way immunosuppressive. 
However, this seemed unlikely as there is significant homology between the MN
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sequence and the HXB2 sequence which had already been shown to be a very effective 
antigen when presented on the OGS514 VLPs (chapter 3).
To address the possibility of bateh-bateh variation of the VLPs a further round of 
immunizations was carried out using a new preparation of OGS530 VLPs. Group 
530/4 received the OGS530 VLPs in conjunction with aluminium hydroxide and group 
530/5 received the immunizations in conjunction with Freunds adjuvant. There were 
five animals in each group and each rabbit received a priming immunization and a total 
of five boosts of 500|ig of OGS530 VLPs at two-weekly intervals. The animals were 
bled at weekly intervals up to the fifth boost and were then bled at two-weekly intervals 
so that the longevity of the response against the OGS530 VLPs could be measured. The 
results obtained for these two groups of rabbits are presented below.
4.3.1 Serum antibody titres of animals immunized with OGS530 VLPs 
in conjunction with aluminium hydroxide or Freund's adjuvant
The serum antibody titres of the animals that received OGS530 VLPs in conjunction 
with aluminium hydroxide (group 530/4) or Freund’s adjuvant (group 530/5) were 
determined using the ELISA assay described in section 2.18. The anti-MN responses 
were assayed against a 40 amino acid peptide coding for the MN V3 loop. The anti-Ty 
responses were measured against the MA5620 (Ty control) particles.
Figure 4.2 compares the anti-MN responses of groups 530/4 (aluminium hydroxide) 
and 530/5 (Freund’s) up to post-boost five. No response was observed in either group 
of animals after the first boost. Following the second boost animal 530/4/1 and three 
animals in group 530/5 had generated a response. After the third boost, two animals in 
group 530/4 had a measurable anti-MN response whereas all five animals in group 
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Figure 4.2 ELISA mid-point titres of groups 530/4 
and 530/5 assayed against the MN V3 peptide. The 




group were variable with maximum responses occurring after boosts three, four or 
five. Animal 530/4/1 showed a peak response of 1:250 post-boost three, animal 
530/4/2 did not respond until after boost five (but showed a significant response of 
1:400), animal 530/4/3 failed to respond to the MN V3 loop, animal 530/4/4 showed a 
peak response of 1:280 post-boost four and animal 530/4/5 only responded after the 
fourth boost. In contrast, in group 530/5, apart from animal 530/5/3, a general trend in 
the increase of the response throughout the immunization regime was observed, with 
peak titres that ranged from 1:300 to 1:1200. It can be seen that higher titres were 
generated in the group that received the immunizations in conjunction with Freund's 
adjuvant These results indicated that to generate a significant response against the MN 
V3 loop presented on the OGS530 VLPs a potent enhancer of the immune response 
was required.
The anti-Ty responses of groups 530/4 and 530/5 up to post-boost five are shown in 
Figure 4.3. In both groups all the animals generated significant anti-Ty responses and it 
can be seen that higher titres were obtained in group 530/5 where Freund's was used as 
the adjuvant. In group 530/4 animals 530/4/1,530/4/3 and 530/4/4 showed peak 
responses post-boost four of 1:20000,1:35000 and 1:50000 respectively. The titres of 
animal 530/4/2 peaked after the third boost at 1:50000 and animal 530/4/5 maintained a 
relatively low response throughout the immunization schedule. A similar pattern of 
responses, but with higher titres, was generated in the 530/5 (Freund's) group with 
peak titres of 1:100000 in three animals occuring after boosts three, four or five. In 
animal 530/4/4 the peak titre of 1:100000 occurred after the second boost and this titre 
was maintained up to post-boost five.
In comparing the anti-MN responses with the anti-Ty responses a general trend was 
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Figure 4.3 Anti-Ty mid-point titres of groups 
530/4 and 530/5. The sera were assayed against Ty 
control particles.
However in individual animals there was little correlation between the maximum 
responses generated against the V3 loop and the Ty portion of the particle. The peak 
titres only corresponded in animals 530/4/4 and animal 530/5/5.
43 .2  Neutralization titres of animals immunized with OGS530 VLPs 
in conjunction with Freund's adjuvant or aluminium hydroxide
Antisera obtained from the animals in groups 530/4 and 530/5 following boosts four 
and five were tested in an HIV neutralization assay against the MN isolate. The results 
are shown in Table 4/1. It can be seen that in the 530/4 group which received the 
OGS530 VLPs in conjunction with aluminium hydroxide, three of the animals 
generated low titre neutralizing antibodies. In the 530/5 group which received the 
immunizations in Freund’s adjuvant all five animals generated neutralizing antibodies. 
Sera from animals 530/5/1 and 530/5/5 had high neutralization titres post-boost five of 
1:128. The maximum response of 1:256 elicited by animal 530/5/4 occurred after the 
fourth boost These data provided further evidence that a significant response against 
the MN V3 loop carried by the OGS530 VLPs was only generated in the presence of a 
powerful enhancer of the immune response, i.e., Freund's adjuvant.
43 .3  Longevity of the immune response generated against the OGS530 
VLPs
The longevity of the immune response generated against the OGS530 VLPs in groups 
530/4 and 530/5 was measured using the anti-MN peptide ELISA. Sera taken at 
monthly intervals after the fifth boost were assayed. In the 530/4 group, anti-MN 
antibodies were detected in four of the animals four weeks after the final boost Sera 
taken up to 24 weeks post-boost five were also assayed, but no antibodies were 
detected. This indicated that the anti-MN response elicited by the OGS530 VLPs when 
immunized in conjunction with aluminium hydroxide was not only weak but also
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TABLE 4/1. NEUTRALIZATION TITRES OF GROUPS 530/4 AND
530/5 POST BOOSTS 4 AND 5
Animal
530/4/1 530/4/2 530/4/3 530/4/4 530/4/5
Post boost
4 -ve -ve -ve -ve 8
5 16 8 -ve -ve -ve
Animal
530/5/1 530/5/2 530/5/3 530/5/4 530/5/5
Post boost
4 32 32 16 256 32
5 128 64 32 128 128
The neutralization titres were expressed as the reciprocal of dilution that gave rise to 
90% inhibition of syncytium formation, -ve indicates a neutralization titre of less than 
or equal to 1:4.
relatively short lived. Table 4/2 gives the anti-MN titres of group 530/5 up to 24 weeks 
after the fifth boost. In four out of the five animals the anti-peptide response increased 
up to eight weeks following the fifth boost. This was probably due to the depot effect 
of the Freund's adjuvant. After 24 weeks, four of the animals had maintained their 
anti-MN titres which demonstrated that a sustained response against the MN V3 loop 
was elicited by the OGS530 VLPs when immunizations were carried out in conjunction 
with Freund's adjuvant.
4.3.4 Recall of the immune response
To test whether a memory response had been induced by the OGS530 VLPs the 
animals in group 530/4 (aluminium hydroxide) were given a further boost 
immunization 26 weeks after the fifth boost. At this time only four animals remained in 
group 530/4. Animal 530/4/2 had died as a result of an accident in the animal house. 
The remaining animals received 500pg of OGS530 VLPs in conjunction with 
aluminium hydroxide and were bled weekly for six weeks in order to monitor the 
response closely. Serum antibody levels were measured against the MN peptide and 
Ty. A significant increase in the anti-Ty titres was observed. No anti-MN antibodies 
were detected following the boost which indicated that MN V3 specific-memory cells 
had not been induced by the OGS530 VLPs. However sera taken three weeks after the 
sixth boost were tested for the presence of neutralizing antibodies and animal 530/4/1 
had a neutralization titre of 1:8. Sera taken after the first boost in the indal regime had 
not been tested for neutralizing antibodies and it was not therefore possible to determine 
whether memory B cells had been primed in this animal. However, as only a low titre 
neutralizing response was detected in just one of the animals post-boost six, this result 
was not regarded as significant.
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TABLE4/2. LONGEVITY OF THE ANTI-MN RESPONSE IN GROUP 
530/5

















In order to determine whether a Ty-independent MN-specific memory response had 
been generated against the V3 loop carried by the OGS530 VLPs, the animals in group 
530/5 (Freund's adjuvant) were boosted with a 40 amino acid MN peptide coding for 
the V3 loop. Each animal received 125|ig of the peptide in conjunction with Freund's 
incomplete adjuvant 26 weeks after the fifth boost with OGS530 VLPs. Sera taken for 
six weeks following the peptide boost were assayed for the presence of anti-MN and 
anti-Ty antibodies. Table 4/3 shows the titres obtained pre-boost, one week following 
the boost and three weeks after the boost when the maximum anti-MN response was 
observed. As expected, the anti-Ty titres had not increased. Prior to the boost only 
animal 530/5/4 had a measurable anti-MN response. In four of the animals serum 
antibodies against the MN peptide were detected one week following the boost and the 
titres increased up to three weeks after the boost. Sera taken at the time of the peptide 
boost and three weeks afterwards were tested for the presence of MN neutralizing 
antibodies. Three of the animals still had neutralizing antibodies present at the time of 
the boost. However, it can be seen that in four animals a significant increase in the 
neutralization titres occured following the peptide boost. These results indicated that the 
immune system had been primed following immunization with OGS530 VLPs in 
conjunction with Freund's adjuvant and that this anti-MN response was not dependent 
on the presence of anti-Ty memory cells.
4.4 DISCUSSION
Hybrid Ty-VLPs have been produced that carry the V3 loop from the MN isolate. 
These OGS530 VLPs were shown to react postitively with a MN V3 specific 
polyclonal serum and also reacted very strongly with two pools of human HIV positive 
sera. As mentioned above, this observation supports several reports in the literature that 
MN-like isolates are the most common sequences identified to date in the population.
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TABLE 4/3. ANTIBODY TITRES OF GROUP 530/5 PRE AND POST BOOST SIX
Anti-Ty and anti-MN titres were expressed as the reciprocal of the dilution of the mid-point titre. 
Neutralization titres were expressed as the reciprocal of dilution that gave rise to 90% inhibition of 
syncytium formation:
Animal 530/5/1 530/5/2 530/5/3 530/5/4 530/5/5
Anti-Ty titres
pre boost 30000 40000 100000 100000 10000
1 week 20000 60000 100000 100000 8000
post boost
3 weeks 13000 50000 100000 100000 4500
post boost
Anti-MN titres
Pre boost 0 0 0 100 0
1 week 300 1100 200 600 0
post boost
3 weeks 1900 1900 600 3000 0
post boost
Neutralization titres
Pre boost 0 16 0 64 4
3 weeks 256 512 32 512 8
post boost
To analyse the immunogenicity of the OGS530 VLPs rabbits have been immunized 
with the VLPs either in conjunction with aluminium hydroxide or Freund's adjuvant. In 
contrast to the results obtained with the OGS514 (HXB2) VLPs (chapter 3), where a 
similar response was generated irrespective of the adjuvant used, different responses 
were seen in the two groups of rabbits that received the OGS530 VLPs. A comparison 
of the responses induced by the OGS514 and the OGS530 VLPs is made in chapter 8.
Anti-MN serum and virus neutralizing antibody titres have also been measured. In 
comparing the levels of anti-MN antibodies between groups 530/4 and 530/5, higher 
maximum titres were observed in the 530/5 group although several animals in each 
group had similar titres. However, when the antisera were tested for the presence of 
neutralizing antibodies a significant difference in the response was observed. All five 
animals in group 530/5 generated neutralizing antibodies, with high titre neutralizing 
antibodies present in three of the animals. In contrast, only three of the animals in 
group 530/4 had neutralizing antibodies and these were of low titre. Comparison of the 
serum and neutralization titres indicated that there was some discrepancy and suggested 
that the ELISA assay was not detecting all of the antibodies present. A possible 
explanation could be that when the MN peptide was coated onto the ELISA plate it was 
not presented in the correct way to be recognized by the some of the anti-V3 loop 
antibodies, and in particular the antibody population that neutralized the virus. When 
antisera raised against the OGS514 (HXB2) VLPs were tested in an ELISA against 
either a HXB2 V3 peptide or IIIB rgpl20 as the coating antigen, much lower titres 
were recorded against the peptide (data not shown). Taken together, these data indicate 
that peptides are not particularly effective for detecting V3 loop antibodies. This may 
well account for the differences observed between the relative serum and neutralizing 
titres in groups 530/4 and 530/5.
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Anaylsis of the longevity of the response in groups 530/4 and 530/5 also showed 
significant differences between the groups. When the OGS530 VLPs were immunized 
in conjunction with aluminium hydroxide (group 530/4), the response following the 
last boost was relatively short lived. In contrast, a sustained response was observed 
when the OGS530 VLPs were immunized in Freund’s adjuvant This effect was 
probably due to the depot effect of this adjuvant.
When group 530/4 were tested for a recall response to the OGS530 VLPs it was found 
that memory B cells had not been primed. This may be because the MN V3 loop on the 
VLPs is only weakly immunogenic when immunizations are carried out with aluminium 
hydroxide.
A Ty-independent memory response was observed when the animals in group 530/5 
received a boost with MN V3 peptide. Neutralization titres increased significantly 
which suggested that the immune system had been primed to generate neutralizing 
antibodies following immunizations with the OGS530 VLPs in conjunction with 
Freund's adjuvant. However, this result could indicate that the MN peptide itself is 
strongly immunogenic. This seems unlikely as Javerhian et al. (1989) reported an 
anti-MN peptide neutralization titie of 1:20. To investigate whether the high neutralizing 
titres seen following the peptide boost in group 530/5 were entirely due to priming of 
the immune system by the OGS530 VLPs it would be neccesary to cany out an 
experiment using the MN V3 peptide as both the priming and boosting immunogen.
The results presented in this chapter indicate that a substantial anti-MN response was 
only elicited by OGS530 VLPs in the presence of an immune response potentiator. 
Although the MN V3 loop may be correctly presented on the OGS530 VLPs it is 
possible that the sequence itself is not intrinsically immunogenic, thereby resulting in
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weak responses following immunization with aluminium hydroxide. Ideally, an HIV 
vaccine candidate should contain a component that elicits the production of anti-MN 
neutralizing antibodies and it may therefore be necessary to explore alternative methods 
in order to increase the immunogenicity of the MN V3 loop sequence.
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CHAPTER 5 
PRESENTATION OF MULTIPLE V3 LOOPS
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5.0 INTRODUCTION
The V3 loop is a hypervariable sequence and neutralizing antibodies raised against this 
region are type-specific. However, an HIV vaccine candidate needs to be able to elicit 
the production of antibodies that will neutralize a broad range of HIV isolates. A 
possible way of achieving this would be to present V3 loop sequences from different 
isolates. The hybrid Ty-VLP system provides several routes for presenting multiple V3 
loops to the immune system. One approach would be to produce hybrid Ty-VLPs 
carrying single V3 loop sequences from different isolates and then make a "cocktail” of 
the different V3:Ty-VLPs to be used as the immunogen. An alternative would be to 
produce a hybrid Ty-VLP that carries multiple V3 loop sequences. These two 
approaches have been investigated and the results are presented below.
5.1 IMMUNE RESPONSES GENERATED AGAINST A COCKTAIL 
OF V3:Ty-VLPs
Hybrid Ty-VLPs were produced that carried V3 loop sequences from divergent HTV 
isolates. The isolates used and their origins are:
Isolate Country Reference
of origin
BH10 USA Ratner et al.. 1985
HXB2 USA Fisher et al.. 1985
RF HAITI Starcich et al.. 1986
MAL ZAIRE Alizon et al.. 1986
ELI ZAIRE Alizon et al.. 1986
The amino acid sequences of the different V3 loops are shown in Table 5/1.
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TABLE 5/1. V3 LOOP AMINO ACID SEQUENCES
SNCTRPNNNTRKSIRIQRGPGRAFVTIGKIGNMRQAHCNISG
SNCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISG
S N CTRPGNNTRRGIHFGPGQALYTTGIVDEIRRA YCNISG 
S N CTRPGNNTRRGIHFGPGQAL YTTGIVDIRRA YCTING










Synthetic oligomers coding for the different V3 loops were cloned into pSP46 and then 
into the VLP expression vectors as described in chapter 3, section 3.1. The expression 








Particle preparations were carried out for the five different VLPs using the method 
described in chapter 2, section 2.13. When pOGS517 (ELI) was transformed into yeast 
the cells grew very slowly and the yield of hybrid VLPs purified from the cells was 
extremely low. Therefore the pl:V3 (ELI) fusion gene was cloned into the VLP 
expression vector pOGS40 containing the PGK:GAL inducible promoter (chapter 1, 
section 1.4) and the resulting plasmid was designated pOGS519. Hybrid VLPs 
containing the V3 loop from the ELI isolate were therefore purified from cells 
transformed with pOGS519.
The sequence information from which the RF, MAL and ELI V3 loop oligomers were 
originally designed was subsequently found to be incorrect This finding only came to 
light after the OGS515, OGS516 and OGS519 VLPs had been made and the 
immunizations completed. For comparison, the correct sequences are also given in 
Table 5/1.
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OGS515 (RF) VLPs were shown to react positively with an antiserum raised against a 
RF V3 loop peptide (a gift from Dr. Dani Bolognesi, Duke University). Antisera 
reactive with the V3 loops from the MAL and ELI isolates was not available to test the 
OGS516 and the OGS519 VLPs.
Initially the various V3:Ty-VLPs were used to immunize groups of three rabbits as 
single immunogens in conjunction with Freund's adjuvant. The immunization schedule 
was as described in chapter 3, section 3.4. Each rabbit received a priming immunization 
and a total of eight boosts of 500}ig of VLPs at two weekly intervals. The immune 
responses generated by hybrid Ty-VLPs OGS513 and OGS514 carrying the V3 loops 
from the BH10 and HXB2 clones of the isolate IBB were described previously in 
chapter 3. Both VLPs generated IHB-specific neutralizing antibodies with the highest 
titres elicited by OGS514 VLPs. Antisera raised against OGS515 (RF) VLPs were 
tested for the presence of antibodies that neutralized the RF isolate. Neutralizing 
antibodies were generated against OGS515 VLPs and peak titres of 1/64 in two animals 
occurred after the fifth boost The relatively low levels of RF neutralizing antibodies 
generated by the OGS515 VLPs may be due to differences in V3 sequences between 
the immunizing antigen and the test virus. Antisera raised against OGS516 (MAL) and 
OGS519 (ELI) VLPs could not be tested for neutralizing antibodies as the virus isolates 
were not available. However, the three animals that received OGS516 and OGS519 
VLPs had induced antibodies that reacted with MAL and ELI V3 peptides respectively.
The immunizations carried out seperately with the five hybrid V3:Ty-VLPs 
demonstrated that each VLP elicited a type-specific response. A further group of three 
rabbits was then immunized with a "cocktail" of OGS513, OGS514, OGS515, 
OGS516 and OGS519 VLPs, in conjunction with Freund's adjuvant The 
immunization schedule was the same as for the immunizations when the VLPs were
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used as single immunogens and each rabbit received 500|ig of each VLP per dose. 
Therefore a total of 2.5mg of VLPs was administered in each immunization. The group 
was designated MIX5 and the serum and neutralizing antibodies induced are described 
below.
5.1.1 Serum antibody titres of animals immunized with the cocktail of 
V3:Ty-VLPs
Serum antibody titres were determined against rgpl20 (HIB isolate) using the ELISA 
assay described in chapter 2, section 2.18. Figure 5.1a shows the titres after each 
boost It can be seen that anti-gpl20 antibodies were not detected in any of the animals 
until the third boost had been administered. Animals MIX5/2 and MIX5/3 only 
produced substantial titres after the fifth boost. Animal MIX5/1 also generated peak 
titres post-boost five, although only relatively low levels of antibodies were detected in 
this animal. Sera from the animals in group MIX5 were also assayed against peptides 
containing V3 loop sequences of isolates RF, MAL and ELI (a gift from Dr. Dani 
Bolognesi). Animal MIX5/2 had low levels of antibodies against RF and animal 
MIX5/1 had generated antibodies against ELI. None of the animals had detectable 
anti-MAL antibodies.
Figure 5.1b shows the anti-Ty titres of group MIX5. The sera were assayed against 
MA5620 (control Ty) particles. All of the animals generated high levels of anti-Ty 
antibodies, although the response in animal MIX5/1 was generally lower than in 
animals MIX5/2 and MIX5/3. This indicated that the intrinsic ability of animal MIX5/1 
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Figure 5.1 ELISA mid-point titres of group MIX5.
5.1.2 Neutralization titres of animals immunized with the cocktail of 
V3:Ty-VLPs
As mentioned previously neutralization of MAL and ELI could not be tested as the 
isolates were not available. Antisera raised against the cocktail of hybrid V3:Ty-VLPs 
in group MIX5 were tested for the presence of neutralizing antibodies against isolate 
LUB. The neutralization titres are shown in Table 5/2. Neutralizing antibodies were not 
detected until after boost four, with substantial responses observed after the fifth boost 
in animals MIX5/2 and MIX5/3. Animal MIX5/2 maintained high titres of neutralizing 
antibodies up to post-boost seven. Animal MIX5/1 generated relatively low levels of 
neutralizing antibodies after the fifth and seventh boosts. Sera taken following boost 
five were also tested for anti-RF neutralizing antibodies. Animals MDC5/2 and MIX5/3 
had neutralization titres of 1/16 against RF.
A general correlation was observed between anti-rgpl20 (IIIB) antibody and anti-IlIB 
neutralization titres, with substantial responses detected only after the fifth boost was 
administered. In contrast, animals immunized with OGS514 (HXB2) VLPs alone had 
both anti-gpl20 and neutralizing antibodies after a single boost (see chapter 3). This 
result indicated that a frequent immunization regime using a mixture of hybrid 
V3:Ty-VLPs did not result in the rapid induction of V3-specific antibodies, with at least 
four boosts being required to stimulate a response. In this respect a single VLP 
immunogen would be a better vaccine candidate where responses need to be elicited 
after a minimum number of immunizations.
5.2 CONSTRUCTION AND PRODUCTION OF HYBRID 
HIV:Ty-VLPs CARRYING MULTIPLE V3 LOOPS
In an attempt to generate a combined early and cross-reactive response against hybrid 
HIV V3:Ty-VLPs, particles were constructed that cany V3 loop sequences from
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TABLE 5/2. NEUTRALIZATION TITRES OF ANIMALS IN GROUP 
MIX5
Animal MIX5/1 MIX5/2 MIX5/3
Post
Boost
1 -ve -ve -ve
2 -ve -ve -ve
3 -ve -ve -ve
4 16 16 8
5 32 256 128
6 16 512 128
7 32 512 64
8 4 64 32
The neutralization titres against the HTV isolate IIIB were determined and expressed as 
the reciprocal of dilution that gave rise to 90% inhibition of syncytium formation, -ve 
indicates a neutralization titre of less than or equal to 1:4.
isolates HXB2, MN and RF in tandem. The construction of these VLPs is shown 
schematically in Figure 5.2. Oligomers encoding the V3 loop sequences were first 
cloned into pSP46 so that the Bglll-BamHI fragments could be then be excised for 
linking together into one vector. The genes encoding the V3 loops were cloned into the 
VLP expression vector pOGS40 that contains the PGK:GAL inducible promoter 
(chapter 1, section 1.4) because the MN sequence was toxic to the yeast cells when 
expressed from the constitutive PGK promoter (chapter 4, section 4.1).
The gene coding for the HXB2 V3 loop was cloned into the BamHI site of pOGS40 
and the resulting plasmid designated pOGS531.
The gene encoding the MN V3 loop was inserted into the BamHI site of pOGS531 to 
generate plasmid pOGS560. pOGS560 therefore contained sequences that coded for the 
HXB2 and MN V3 loops.
As the original oligomers containing the V3 loop sequence were incorrect new 
oligomers encoding the correct RF V3 loop sequence were synthesized and cloned into 
pSP46 to generate plasmid pOGS547. The RF V3 loop fragment from pOGS547 was 
then inserted into the BamHI site of pOGS560. The resulting plasmid, pOGS561, 
therefore contained the HXB2:MN:RF V3 loop sequences in a tandem array at the 
C-terminus of pi.
When particle preparations were carried out using the standard VLP production method 
described in chapter 2, section 2.13, the yield of OGS561 VLPs was extremely low. 
Analysis of samples taken throughout the preparation showed that substantial losses of 
the VLPs occurred at the chromatography stage. A modified purification strategy that 
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Figure 5.2 Construction of expression vectors for VLPs 
containing combinations of V3 loop sequences
Yeast cells were broken using a hand bead-beating method. Packed cells (5ml) were 
resuspended in 10ml of TEN buffer and 5g of glass beads added. The cells were 
broken by vortexing vigorously for ten minutes, with periods of thirty seconds of 
vortexing interspersed with thirty seconds on ice. The supernatant was then collected 
following removal of cell debris by centrifugation at 3krpm (Sorvall RT6000B 
centrifuge) for five minutes. The procedure was repeated twice more and the resulting 
supernatants pooled. The supernatant was centrifuged at 9krpm (Sorvall RC5B 
centrifuge, Sorvall SA600 rotor) for twenty minutes and then centrifuged at 41krpm 
(Beckman L8-70M ultracentrifuge, SW41 rotor) for one and a half hours onto a 60% 
sucrose/TEN cushion. The cushion was removed and dialysed overnight against TEN 
buffer. The dialysate was centrifuged at 9krpm (Sorvall RC5B centifuge, Sorvall 
S A600 rotor) for twenty minutes and the supernatant was loaded onto a 5-20% sucrose 
gradient containing a 60% sucrose cushion at the bottom. The gradient was centrifuged 
at 41krpm (Beckman L8-70M ultracentrifiige, SW41 rotor) for two and a half hours 
and then fractionated into 1ml fractions. An SDS-PAGE gel of the sucrose gradient 
fractions is shown in Figure 5.3. The gel shows that the majority of the contaminating 
yeast proteins remained in the gradient whereas the OGS561 particles were found in the 
cushion. The cushion was collected and dialysed against PBS buffer overnight, 
followed by centrifugation of the dialysate at 9krpm (Sorvall RC5B centifuge, Sorvall 
SA600 rotor) for twenty minutes to remove debris. Figure 5.3 also shows the final 
material produced from this preparation from which 21 mg of OGS561 VLPs were 
purified from 20ml of packed cells.
When purified OGS561 VLPs were examined by transmission electron microscopy, 
many of the VLPs appeared to have aggregated into chains (Figure 5.4). This 
aggregation effect was not observed with VLPs that carried a single V3 loop and 
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Figure 5.3 SDS-PAGE analysis of an OGS561 particle preparation
a) Sucrose gradient fractions. The gradient was fractionated into 
lm l fractions.
b) Purified OGS561 particles. 10(ig of OGS561 VLPs were loaded.
50nm
Figure 5.4 Electron micrograph of OGS561 VLPs 
The VLPs were stained with uranyl acetate
S3  WESTERN BLOT ANALYSIS OF OGS561 VLPs 
Preliminary characterization of the multiple V3 loop VLPs was carried out by Western 
blot analysis (Figure 5.5). The OGS560 (HXB2:MN) and OGS561 (HXB2:MN:RF) 
proteins reacted positively with MAb 9284 (Fig 5.5 (a)), indicating that the HXB2 V3 
loop on the multiple loop VLPs was recognised by the IHB-specific antibody. This 
Western blot also shows the increase in size of the monomeric proteins of OGS560 and 
OGS561 as compared to OGS514. When the VLPs were probed with a pool of human 
HIV positive sera (Fig 5.5 (b)) a strong reaction was observed against both OGS560 
and OGS561 proteins. This reactivity was probably due to the presence of the MN V3 
loop as previous analyses with human sera had only shown a strong response to 
OGS530 (MN) VLPs and not to VLPs carrying the HXB2 or RF V3 loops. The 
OGS561 protein also reacted positively when probed with an antiserum raised against 
an RF V3 loop peptide (data not shown).
The Western blot analysis therefore indicated that OGS561 VLPs contained regions that 
were reactive against antisera to the V3 loop sequences HXB2, MN and RF.
5.4 IMMUNE RESPONSES GENERATED BY OGS561 VLPs
A group of five rabbits was immunized in order to determine whether OGS561 VLPs 
could elicit neutralizing antibodies against the three virus isolates IBB, MN and RF. 
The immunizations were administered in conjunction with the clinically relevant 
adjuvant, aluminium hydroxide. Each rabbit received a priming immunization and eight 
boosts of 500|ig of OGS561 VLPs at two-weekly intervals. The group was designated 
561/1, containing animals one to five.
5.4.1 Serum antibody titres of animals immunized with OGS561 VLPs 
Serum antibody levels against the three V3 loops carried by OGS561 VLPs were
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Figure 5.5 Western blot analysis of V3 multiples
OGS514 carried the HXB2 V3 loop, OGS560 carried 
the HXB2 and the MN V3 loops, and OGS561 carried 
the HXB2, MN and RF V3 loops
Blot (a) was probed with monoclonal antibody 9284 






s i z e
(kDa)
measured in an ELISA assay using peptides containing either IIIB, MN or RF V3 
loops. Figure 5.6 shows that the five animals generated serum antibodies against all 
three of the V3 loops. High titres were obtained against the HXB2 and MN peptides, 
and a lower response was observed against RF. In general, although the antibody 
levels to each V3 loop differed in individual animals there was a correlation between the 
pattern of response against each V3 loop throughout the immunization schedule. 
Responses were not observed in all animals until after the fourth boost was 
administered, although two animals responded after a single boost immunization.
The responses induced against Ty were also measured using MA5620 (control Ty) 
particles (Figure 5.7). The responses generated in animal 561/1/1 increased gradually 
after each boost However, in other animals the anti-Ty titres were variable throughout 
the immunization schedule. The anti-Ty titres in group 561/1 were comparable to those 
seen in group 514/2 which received OGS514 (HXB2) VLPs in conjunction with 
aluminium hydroxide (chapter 3). There appeared to be little correlation between the 
anti-Ty titres and the anti-V3 titres induced after each boost.
5.4.2 Neutralization titres of animals immunized with OGS561 VLPs 
Serum samples taken after boosts three, four, six, seven and eight were tested for 
neutralizing antibodies against the virus isolates IIIB, MN and RF. Virus neutralizing 
antibodies were not detected in animal 516/1/1, and animal 561/1/3 only had low levels 
of neutralizing antibodies against isolate RF following boosts seven and eight The 
neutralization titres of animals 561/1/2,561/1/4 and 561/1/5 are shown in Table 5/3. 
Only animal 561/1/2 had neutralizing antibodies against all three virus isolates, with a 
maximum titre of 1/64 against IIIB and MN and low levels of anti-RF antibodies. 
Animal 561/1/4 generated anti-MN neutralizing antibodies after boost four, although the 
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TABLE 5/3. NEUTRALIZATION TITRES OF ANIMALS 561/1/2,
561/1/4 AND 561/1/5
The neutralization titres against the virus isolates IHB, MN and RF were determined 
and the titres expressed as the reciprocal of dilution that gave rise to 90% inhibition of 



































516/1/5 3 -ve -ve -ve
4 -ve 20 -ve
6 -ve 32 -ve
7 -ve 64 -ve
8 -ve 32 8
neutralization titre after the seventh boost and low levels of anti-RF neutralizing 
antibodies after boost eight
No correlation was seen between the anti-V3 antibody titres and neutralization activity. 
All of the animals had significant anti-HXB2 V3 antibodies whereas only animal 
561/1/2 had anti-EIB neutralizing antibodies. The animals also had high anti-MN serum 
antibody levels, but only animals 561/1/2 and 561/1/5 had substantial anti-MN 
neutralization titres. Four animals had anti-RF serum antibodies whereas no animals 
generated significant levels of anti-RF neutralizing antibodies.
These results demonstrated that antibodies were raised against the V3 loops presented 
on OGS561 VLPs, but that the majority of the antibodies were not virus-neutralizing 
antibodies.
5.4.3 Longevity of the immune response
Serum samples taken at four-weekly intervals after the eighth boost were assayed for 
anti-V3 antibodies. Anti-RF antibodies were only detected in three animals up to four 
weeks after boost eight In animal 561/1/1 anti-HXB2 and anti-MN antibodies were 
detected up to twenty-four and sixteen weeks after the last boost respectively. Animal 
561/1/2 had anti-HXB2 and anti-MN antibodies up to eight and sixteen weeks 
post-boost eight respectively. The responses observed in animal 561/1/3 were similar to 
those seen in 561/1/2. Animal 516/1/4 had no detectable anti-V3 loop antibodies four 
weeks after boost eight. Animal 561/1/5 had anti-HXB2 and anti-MN antibodies until 
four weeks and eight weeks post-boost eight respectively.
In general, responses were detected longer in the animals that had initially generated the 
highest anti-V3 titres.
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5.4.4 Recall of the immune response
To determine whether antigen specific memory cells had been generated following 
immunizations with OGS561 VLPs in conjunction with aluminium hydroxide, the 
animals in group 561/1 received a further boost of 500}ig of OGS561 VLPs thirty-two 
weeks after the eighth boost
Serum samples taken at two-weekly intervals after the ninth boost were assayed for 
anti-Ty and anti-V3 antibodies. For each animal, similar titres were observed four 
weeks after boost nine as the maximum response induced during the intial 
immunization regime. This result therefore indicated that a memory response had been 
generated against both the Ty and HIV components of OGS561 VLPs.
Sera taken four weeks post-boost nine were also tested for the presence of neutralizing 
antibodies against virus isolates IIIB, MN and RF. Only two animals showed 
neutralizing activity. Animal 561/1/2 had a substantial anti-MN neutralization titre and 
low titres against both IIIB and RF. Animal 561/1/5 had a moderate anti-MN response 
post-boost nine.
These data therefore provided further evidence that although responses, including a 
memory response, were generated against the V3 loops on the OGS561 VLPs the 
sequences were not presented in the optimum configuration to elicit the production of 
high titre cross-neutralizing antibodies.
5.5 DISCUSSION
Experiments have been carried out to determine whether the presentation of multiple V3 
loops using the hybrid Ty-VLP system could induce cross-isolate neutralizing 
antibodies. Two different approaches were investigated, i.e., presenting different V3
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loop sequences as a cocktail of hybrid V3:Ty-VLPs, or presenting three V3 loops on a 
single hybrid particle.
A cocktail of five different V3:Ty-VLPs was used to immunize rabbits, in conjunction 
with Freund's adjuvant. After the immunizations had been carried out it became 
apparent that the amino acid sequence of three of the V3 loops used were incorrect. It 
was not therefore possible to determine whether this immunization strategy would 
induce a broad range of cioss-isolate neutralizing antibodies. The correct V3 sequences 
carried by OGS513 and OGS514 VLPs were from clones of the IIIB isolate, therefore 
analysis was concentrated on the antibody response to this virus. OGS513 (BH10) and 
OGS514 (HXB2) VLPs had both elicited the production of isolate BIB neutralizing 
antibodies when used as single immunogens (see chapter 3). In particular, OGS514 
VLPs had induced the production of high titre neutralizing antibodies with reactivity 
being detected in the OGS514-immunized animals after only one boost However when 
OGS514 VLPs were used as part of the cocktail, anti-lLIB neutralizing antibodies were 
not detected until after the fourth boost There are several potential explanations for this 
delayed response. One possibility is that the animals in group MDC5 received five times 
more Ty immunogen per immunization than the animals that had received OGS514 
VLPs alone. The Ty component of the hybrid VLPs is a very effective immunogen (see 
chapters 3 and 4) which elicits high titre anti-Ty antibodies. It is therefore possible that 
the 2.5mg total dose of VLPs resulted in the immune system seeing mainly Ty 
epitopes, thereby reducing the effective dose of V3 antigen. However, the anti-Ty 
titres in the group which received the VLP cocktail were comparable with the anti-Ty 
titres of the group that received the OGS514 VLPs alone. This suggests that a 
maximum Ty response was elicited by a 500}ig dose and that the difference observed in 
the V3 responses was not due to an overload of Ty immunogen.
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An alternative explanation is that the V3 loop sequence carried by one of the non-IHB 
hybrid VLPs is immunodominant and that antibodies were preferentially raised to this 
sequence. This hypothesis could not be investigated because the V3 loop sequences 
carried by the other VLPs were incorrect, therefore reagents were not available to assay 
the responses against these sequences.
Although the VLP cocktail experiment did not show whether significant 
cross-neutralizing antibodies could be induced, the results indicated that this would not 
be the optimum way to present multiple sequences. This is because, where tested, 
multiple boosts were required to elicit the production of neutralizing antibodies. One 
requirement of a potential vaccine candidate is that a substantial response needs to be 
generated after administration of a minimum number of boosts. Therefore, even if 
cross-isolate antibodies had been induced using this immunization strategy, this 
requirement would not have been fulfilled.
An alternative strategy for inducing cross-neutralizing responses has been investigated 
by presenting multiple V3 loop sequences on a single hybrid Ty-VLP. OGS561 VLPs 
were produced which carried the V3 loop sequences from the HXB2, MN and RF 
isolates. Western blot analysis of OGS561 VLPs showed that immunoreactive 
sequences to the three virus isolates were present on the VLPs. Rabbits were then 
immunized with OGS561 VLPs in conjunction with aluminium hydroxide. The results 
showed that although antibodies were raised against the three different V3 loop 
sequences presented on OGS561 VLPs, the V3 loops were not presented in an effective 
configuration that induced high titre cross-neutralizing antibodies.
The V3 loop sequences were presented in tandem as a C-terminal fusion with the 
particle-forming protein pi. Electron microscopic analysis of the OGS561 VLPs
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indicated that the presence of the three V3 loop sequences in some way caused the 
VLPs to form chain-like structures. The presence of partly-aggregated material, in 
which the V3 loop presentation may have been sub-optimal, could be responsible for 
the poor immune responses. It is not known whether the VLPs remained in this 
aggregated foim following adsorption onto aluminium hydroxide. This could be 
addressed by electron microscopic analysis of a negatively stained mixture of VLP and 
aluminium hydroxide.
Neutralization titres against the MN isolate were generated in two of the animals and 
although multiple boosts were required to elicit this response, the titres were higher 
than those obtained against the MN V3 loop when it was presented alone as OGS530 
VLPs. In contrast, high titre anti-IHB neutralizing antibodies were generated in the 
majority of the animals immunized with OGS514 (HXB2) VLPs, whereas only one 
animal immunized with OGS561 VLPs generated neutralizing antibodies against this 
isolate. These results may indicate that when the three V3 loop sequences, 
HXB2-MN-RF, were expressed together, the MN loop was optimally presented 
relative to the HXB2 and RF loops.
Analysis of the immune response elicited by presenting multiple V3 loop sequences 
using the hybrid Ty-VLP system in two different ways has shown that neither 
produced high titre cross-neutralizing antibodies after a minimum number of boosts. 
Alternative methods will therefore need to be explored to induce the broad response that 
is required of an HIV vaccine.
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CHAPTER 6
PRODUCTION AND ANALYSIS OF HYBRID SIV:Ty-VLPs
102
6.0 INTRODUCTION
Although non-human primates such as chimpanzees and baboons can be infected with 
HIV, they do not develop disease symptoms. Therefore, challenge experiments with 
non-human primates, which are expensive and difficult to perform, can only 
demonstrate protection against infection. In the absence of a suitable disease model for 
carrying out challenge experiments of potential vaccine candidates against HIV 
alternative approaches have to be taken. One such approach may be to develop vaccine 
candidates against simian immunodeficiency virus (SIV) that could be used as the basis 
for the design of HTV vaccine candidates. For example, the ability of a hybrid 
SIV:Ty-VLP earring the major neutralizing epitope of SIV to prevent either infection or 
disease could be tested in a challenge experiment. If successful, this would lend 
support to the idea of using an analogous HIV construction in humans.
Considerably less is known about the functional and immunogenic regions of the SIV 
envelope glycoprotein than is known for HIV and, as yet, the principle neutralization 
determinant has not been conclusively mapped. Sequence alignment of SIV and HTV-1 
sequences does not clearly identify an SIV region with strong homology to the V3 
loop. However, by aligning conserved cysteine residues within the gpl20 envelope 
proteins it was possible to identify the most likely SIV "V3" sequence. Unlike HIV 
sequences, there is no conserved GPGR sequence within the SIV V3 loop, and the SIV 
V3 sequence is not particularly variable between the SIV envelopes that have been 
characterized by sequence analysis. The putative SIV V3 sequence is found between 
amino acids 313 and 347 of the envelope glycoprotein gp 120. Hybrid SIV:Ty-VLPs 
werej>roduced that carried this region of isolate SIV mac251. The hybrid SIV:Ty-VLPs 
have been analysed by Western blot and by immunogenicity studies carried out in 
rabbits.
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Development of SIV neutralization assays is also somewhat behind the development of 
assays to determine neutralization of HTV. SIV does not cause a rapid cytopathic effect 
in cell culture. Therefore an assay which monitors the inhibition of syncytium 
formation, as described for HIV (section 2.15), is not feasible for testing sera for the 
presence of anti-SIV neutralizing antibodies. An alternative method is to test for SIV 
antigen levels in infected cell cultures. A decrease in antigen level following 
pre-incubation of virus with test sera would show that the virus had been neutralized. 
An assay to test for SIV neutralization by monitoring the levels of the SIV core protein 
p27 has been developed in conjunction with Dr. Eleanor Berrie.
6.1 CONSTRUCTION AND PRODUCTION OF HYBRID 
SIV:Ty-VLPs
The construction of hybrid SIV:Ty-VLPs was similar to the construction of 
HTV:Ty-VLPs as described previously (chapter 3, section 3.1). The amino acid 
sequence of the SIV envelope region encoded by the synthetic oligomers is shown 
below:
CRRPGNKTVLPVTIMSGLVFHSQPLTDRPKQAWC SIVmac251
The synthetic oligomers were first cloned into pSP46 and then into the yeast expression 
vector pMA5620 (see chapter 1, section 1.4). The plasmids were designated pOGS532 
and pOGS533 respectively. When pOGS533 was transformed into yeast, only very 
low yields of VLPs were obtained, indicating that the SIV sequence was toxic to cells. 
The gene coding for the SIV V3 sequence was therefore cloned into the expression 
vector pOGS40 containing the inducible PGK:GAL promoter (chapter 1, section 1.4). 
The resulting plasmid was designated pOGS534. Hybrid SIV:Ty-VLPs were purified 
as described in chapter 3, section 3.2.
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The SIVmac251 V3 sequence contained in the OGS534 VLPs was obtained from the 
1988 Los Alamos Data Base. However, in subsequent editions of the data base the 
sequence given for this region was different. This was only discovered after the 
immunizations had been carried out The differences in the amino acid sequences are 
underlined below:
CRRPGNKTVLPVTIMSGLVFHSQPLTDRPKQAWC SIVmac251 1988 
CRRPGNKTVLPVTIMSGLVFHSQPIHDRPKQAWC SIVmac251 1991
The peptide used to analyse the reactivity of anti-SIV sera (obtained from the MRC 
AIDS Directed Progamme) had the sequence from the 1991 Los Alamos database (see 
section 6.3.1 below). It is not certain which sequences were present in the infectious 
virus used for neutralization assays because viruses had not been molecularly cloned.
6.2 PRELIMINARY CHARACTERIZATION OF HYBRID 
SIViTy-VLPs
The immunoreactivity of purified hybrid SIV:Ty-VLPs (OGS534) was analysed by 
Western blot Figure 6.1 shows the reactivity of VLPs following incubation with HTV 
and SIV positive sera. VLPs purified from yeast cells transformed with pMA5620 
(control Ty) were included as a negative control. The positive control for the blot 
probed with HIV-1 sera was a VLP construction containing an immunoreactive region 
of HIV-1 gp41. Similarly, a VLP construction containing an immunoreactive region of 
HTV-2 gp36 known to react with both HIV-2 or SIV positive sera was used in the blots 
probed with either HIV-2 and SIV positive sera. OGS534 VLPs gave little reaction 
when probed with human HIV-1 positive sera (blot (a)). However it can be seen that 
OGS534 VLPs reacted strongly when probed with either HIV-2 or SIVmac251 positive 























a) HIV-1 pool b) HIV-2 pool c) Anti-SIVmac251
Figure 6.1 Western blot analysis of hybrid SIV:Ty-VLPs (OGS534)
SIV:Ty-VLPs, control Ty-VLPs and HIV-1 gp41 VLPs or HIV-2 gp36 
VLPs were probed with a) a pool of 10 HIV-1 positive sera, b) a pool 
of 6 HIV-2 positive sera or c) serum from a monkey infected with 
SIVmac251.
OGS534 VLPs is immunogenic. The cross-reactivity observed with human HIV-2 sera 
is supported by the significant homology seen between SIV and HIV-2 envelope 
sequences in this region and indicates that this HIV-2 envelope region could also be 
immunogenic.
6 3  ANALYSIS OF THE IMMUNE RESPONSE GENERATED 
AGAINST HYBRID SIV:Ty-VLPs
63,1  Serum antibody levels of rabbits immunized with OGS534 VLPs
Initially, five rabbits were immunized with OGS534 VLPs in conjunction with 
aluminium hydroxide. The group was designated group 534/1. The immunization 
schedule was the same as that used for immunizations with HTV V3:Ty-VLPs. The 
animals received 500|ig of OGS534 VLPs per dose. Boost immunizations were 
administered every two weeks until eight boosts had been given. Serum samples were 
taken every week so that antibody levels could be closely monitored.
The sera taken before and after each boost for each animal in group 534/1 were assayed 
by ELISA against a 20 amino acid peptide coding for the central region of the SIV V3 
sequence. The majority of the samples gave very little reaction against this peptide.
A further ten rabbits were immunized with OGS534 VLPs, five in conjunction with 
aluminium hydroxide and five in conjunction with Freund's adjuvant. The groups were 
designated 534/2 and 534/3 respectively. The immunization schedule was the same as 
for group 534/1. Sera taken from the animals up to the fifth boost were assayed for 
anti-peptide and anti-Ty responses. The V3 peptide used was the 20 amino acid peptide 
described above and the Ty responses were measured against control Ty particles, 
MA5620. The anti-Ty responses were similar to the responses seen against the HIV 
V3:Ty-VLPs described in chapters 3 and 4, with maximum titres of 1:60000 in group
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534/2 and 1:100000 in group 534/3. However, as observed for group 534/1, very little 
response was detected against the SIV peptide. It was possible that this peptide was not 
an effective antigen for detecting anti-SIV V3 antibodies. This explanation is suggested 
by the previous observation that a peptide coding for the central region of the HTV V3 
loop (HXB2) did not detect anti-V3 antibodies in anti-OGS514 antisera that had high 
titre serum antibodies when assayed against rgpl20 (data not shown).
Due to concerns about the 20-mer V3 peptide an alternative SIV antigen was 
investigated in order to detect anti-SIV antibodies in the anti-OGS534 samples. A lysate 
of cells that had been infected with SIV was obtained from Dr. Karen Kent (NIBSQ. 
A limited amount of this antigen was available, therefore only sera taken after boosts 
one, five and eight from the three groups of animals immunized with OGS534 VLPs 
were assayed. Low levels of anti-SIV antibodies were detected and sera giving a 
positive reaction are shown in Table 6. As the SIV infected cell lysate was known to be 
effective at detecting anti-gpl20 antibodies (Dr. Karen Kent, personal communication), 
these results suggested that only weak responses had been elicited by OGS534 VLPs.
63.2 Development of an SIV neutralization assay 
In order to test anti-OGS534 sera for neutralizing antibodies against SIV, and to 
determine whether the SIV envelope sequence carried by OGS534 VLPs was a 
neutralization epitope, attempts were made to develop an SIV neutralization assay. 
During culture of HIV or SIV-infected cells, virus and therefore viral antigens, are 
released into the culture medium. In particular, core antigens p24 (HIV) and p27 (SIV) 
are readily detected. The assay was therefore divided into two stages. The first stage 
was to culture the virus following incubation with anti-OGS534 antisera and the second 
stage was to assess the levels of SIV core protein p27 present in the cell culture 
medium. A reduction in p27 levels would indicate that the virus had been neutralized by
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TABLE 6. REACTIVITY OF OGS534 ANTISERA AGAINST AN SIV 
INFECTED CELL LYSATE IN AN ELISA ASSAY





534/1/5 + + +
534/2 534/2/1 _ +
534/2/2 + +
534/2/3 + + _
534/2/4 +
534/2/5 +
534/3 534/3/1 + +
534/3/2 __
534/3/3 + + +
534/3/4 __
534/3/5 +
Groups 534/1 and 534/2 recieved the immunizations in conjunction with aluminium 
hydroxide and group 534/3 received the immunizations in conjunction with Freund's 
adjuvant + and - indicates an O.D. above or equal to the background O.D. of 
pre-immune serum respectively.
antibodies in the antisera. The assay is shown diagrammatically in Figure 6.2.
The first stage of the assay was optimised by Dr. Berne with analysis of various 
parameters being carried out. For example, different cell lines were examined to 
determine a cell line to support optimum growth of SIV, and H9 cells were selected for 
use in the assay. To provide a base line for the assay, the time course of infection was 
investigated by measuring p27 levels over time. Levels of p27 were measured using the 
p27 antigen capture assay described below. In general, cells were cultured for 27 days 
after infection, with viral antigen first being detected between days 16 and 18.
The first step towards developing a sandwich capture p27 ELISA was to identify 
antibodies that could capture and detect p27 from the cell supernatant fluid of SIV 
infected cells. Two potential sources of anti-p27 antibodies were available for testing in 
the ELISA. One source was antisera obtained from a macaque experimentally infected 
with SIV (a gift from Dr. Kingston Mills, NIBSC). The second source was to raise 
antisera against VLPs developed by other members of the group which carried the p27 
core protein of SIV (OGS249 VLPs). The OGS249 VLPs were constructed as part of 
another project at British Bio-technology. Five rabbits were immunized with OGS249 
VLPs in conjunction with aluminium hydroxide. The immunization schedule was as 
described above for OGS534 VLPs. Antisera obtained after boost five from each 
animal was used to probe an SIV infected cell lysate by Western blot. The antisera from 
all five animals identified a protein band of 27 kD, which indicated that the antisera 
contained antibodies reactive with p27.
Initially, a rabbit anti-OGS249 antiserum was used to coat ELISA plates to provide 
capture antibody and the macaque anti-SIV antiserum obtained from NIBSC was used 
as the detecting antibody. The plates were coated overnight at 4°C with anti-OGS249
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Figure 6.2 Schematic diagram of the SIV neutralization assay
antiserum in a series of dilutions. Plates were also coated with pre-immune sera as a 
control. All further incubations were carried out for two hours at 4°C and the plates 
were washed three times in PBS-0.5%Tween between incubations. Following coating, 
the plates were blocked using PBS-2% casein to prevent non-specific binding. After 
washing, Triton-X-100-treated supernatant fluid from SIV infected cells was added to 
the plates. Samples of supernatant fluid from uninfected cells were also included as 
negative control. After 2 hrs incubation at 4°C the anti-SIV antiserum was added to the 
plates, again in a series of dilutions. Following incubation of the anti-SIV antiserum 
and washing, anti-monkey horseradish peroxidase labelled antibodies were added at a 
single dilution. The plates were developed using hydrogen peroxide in the presence of 
TMB and the reaction stopped with 2.5M sulphuric acid. The OJD. of the plates were 
then read at a wavelength of 450nm.
Using this configuration (rabbit anti-OGS249 to capture; macaque anti-SIV to detect) 
no significant difference was observed between the test (infected cell supernatant) and 
control (uninfected cell supernatant) samples.
The antigen assay was then carried out in the opposite orientation, using macaque 
anti-SIV antiserum for capture and rabbit anti-OGS249 antiserum for detection. Figure
6.3 shows the results obtained in this assay. All of the samples were tested in triplicate. 
The graph shows that differences in optical density (O.D.) readings were observed 
between test and control samples, although the O.D.s recorded were generally low. 
Background levels were observed when pre-immune sera was used in the detecting step 
or when uninfected cell supernatant was used instead of infected cell supernatant 
Titration of the detecting antibody (anti-OGS249) against the infected cell supernatant 
indicated that the reaction was specific. Similar O.D. values were obtained for each of 
the triplicate samples at each dilution of detecting antibody. Several parameters were
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Figure 6.3 p27 antigen capture assay. p27 was 
captured by the macaque anti-SIV antiserum at 
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investigated in order to improve the sensitivity of the assay. These included varying the 
length and temperature of the incubation times for each of the different stages. 
However, only incubating the infected cell supernatant at room temperature instead of 
4°C resulted in a slight increase in the O.D.s recorded.
Although the assay described above resulted in low O.D.s, the reaction observed was 
specific and reproducibility was demonstrated between replicates. This assay was 
therefore used to test serum samples from animals immunized with OGS534 VLPs for 
the ability to prevent or delay the appearance of p27 antigen in infected cell cultures (see 
section 6.3.3).
Further studies were conducted to address the sensitvity of the capture assay. The most 
likely explanation for the low O.D.S recorded was that one or both of the antibodies 
used was limiting. This would result in either inefficient capture of p27 or inefficient 
detection of bound p27. Other sources of antibody (HIV-1 human positive sera, mouse 
anti-OGS249) were also tested but failed to generate higher O.D.S. The next step was 
to assess a panel of monoclonal antibodies raised against p27 by the Immunology 
group at British Bio-technology.
The monoclonal antibodies were tested for their ability to capture p27. An example of a 
test assay to compare two anti-p27 monoclonal antibodies is shown in Figure 6.4. The 
concentration of each antibody was adjusted so that a 1:10 dilution was equivalent to 
50jig/ml. Plates were coated with antibody at doubling dilutions up to a dilution of 
1:1280. SlV-infected cell supernatants were tested in duplicate at undiluted, 1:2 and 1:4 
concentrations. The rabbit anti-OGS249 antiserum was used as the detecting antibody. 
The results were expressed as the average of each duplicate supernatant sample. As the 















100 200 300 400 500 600 700 900 1000 1100 1200 1300
reciprocal of dilution-antibody coating
— o— MAb lOf 2 uninfected S/N
—  1— MAb 10F2 infected S/N
-- 2-- MAb 10F2 infected S/N 1: 2
--4-- MAb 10F2 infected S/N 1: 4
.. A.. MAb 12G6 uninfected S/N
---- 1----- MAb 12G6 infected S/N
-- 2-- MAb 12G6 infected S/N 1: 2
— 4— MAb 12G6 infected S/N 1: 4
Figure 6.4 An example of a p27 MAb test assay.
antibody 10F2. Antibody 12G6 was found to be the most effective capturing antibody 
of six monoclonal antibodies tested and this antibody was therefore chosen as the 
capture antibody for further studies.
Figure 6.5 shows the results obtained with 12G6 as the capture antibody when either 
the macaque anti-SIV antiserum or the rabbit anti-OGS249 antiserum were used to 
detect the captured p27. The assay was carried out as described previously. Two 
different samples of infected cell supernatant fluids were tested in the assay. The results 
showed that antibodies present in the macaque anti-SIV antiserum were slightly more 
effective at detecting captured p27 than those in the anti-OGS249 serum. In order to 
determine the sensitivity of the assay a titration of recombinant p27 (a gift from Dr. 
Mark Page, NIBSC) was included. The sensitivity of the assay was approximately 
50ng/ml and 125ng/ml when the macaque anti-SIV antiserum and rabbit anti-OGS249 
antiserum were used as the detecting antibody, respectively.
6 J.3 Induction of SIV neutralizing antibodies by OGS534 VLPs
The cell culture involved in the neutralization assay described in section 6.3.2 has to be
carried out under Category m  containment conditions and takes 27 days to complete,
with samples being taken every two days. Due to the labour intensive nature of this
assay, and the limited amount of macaque anti-SIV serum available, only sera from
experiment 534/1 (aluminium hydroxide) were tested for the presence of neutralizing
antibodies.
First, antisera taken after the fifth boost of animals in group 543/1 were tested. The 
antisera were diluted 1:10 and then incubated with the virus stock, diluted 1:4, for one 
hour at 37°C. The virus-antibody mixture was then added to H9 cells. Following a 
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Figure 6.5 SIV antigen capture by MAb12G6 Cell 
supernatants were titrated in doubling dilutions 
from neat. Recombinant p27 was titrated in 
doubling dilutions from lug/ml. Anti-0GS249 
detecting antibody was used at a dilution of 
1: 100. Anti-SIV detecting antibody was used at a 
dilution of 1:1000.
cultures maintained for 27 days. Samples were taken every two days and frozen at 
-20°C until they could be assayed in the sandwich capture ELISA for p27 levels. The 
assay used macaque anti-SIV antiserum as the capture antibody and rabbit anti-OGS249 
as the detecting antibody (Figure 6.6a). The virus control (no antibody) samples 
showed that significant p27 levels were not detected until day 17 and that they peaked 
around day 25. It can be seen that the time course of infection for virus incubated with 
the anti-OGS534 sera from four of the animals was similar to that of the virus control 
curve. This indicated that the virus had not been neutralized by sera from animals 
543/1/2,3,4 or 5. However, antigen levels in the culture medium of cells infected with 
virus that had been incubated with the serum from animal 534/1/1 remained at basal 
levels until day 25. This result suggested that neutralizing antibodies against SIV were 
present.
During the course of these studies a p27 capture ELISA became commercially available 
from Coulter. The samples tested in the assay described above were therefore also 
tested in the Coulter assay (Figure 6.6b). Although the O.D.S obtained with this assay 
were greater than those in the '’in-house" assay, the results were generally similar. 
Pre-immune sera or sera from animals from animals 534/1/2,3,4 and 5 did not delay 
the appearance of p27 in the culture medium, and in some cases antigen was detected 
before the appearance of p27 in the virus control. However, samples taken after 
pre-incubation with antiserum from animal 534/1/1 again only showed detectable p27 
on day 25.
A second experiment was carried out in which antiserum taken from rabbit 534/1/1 after 
the fifth boost was diluted 1:10 or 1:40 prior to incubation with the vims. Analysis of 
the p27 antigen levels through a 27 day period demonstrated a nine day and ten day 
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Figure 6.6 p27 antigen levels from an SIV 
neutralization assay.
antiserum at the 1:10 and 1:40 dilutions respectively. This result confirmed that the 
534/1/1 antiserum was able to delay the infection of H9 cells with SIVmac251.
6.4 DISCUSSION
Hybrid Ty-VLPs have been produced that cany the putative V3 region from the SIV 
isolate mac251. Western blot analysis demonstrated that OGS534 VLPs reacted 
positively with serum from a macaque experimentally infected with SIVmac251f 
therefore confirming that the sequence contained in the SIV:Ty-VLPs is immunogenic. 
However, the antibody response elicited by OGS534 VLPs, as determined by ELISA 
against a V3 peptide or SIV-infected cell lysate, has suggested that this region may only 
be weakly immunogenic. Even when immunizations were carried out in Freund’s 
adjuvant only low levels antibodies were detected. The results presented in section
6.3.1 therefore suggest that the SIV V3 sequence is weakly immunogenic, in contrast 
to the HIV V3 loop that is highly immunogenic.
It is possible that the lack of potency of anti-OGS534 sera against the V3 20-mer 
peptide, SIV-infected lysate or infectious virus was due to differences between the 
amino acids in the V3 sequence carried by the SIV:Ty-VLPs and the V3 sequence 
present in the test antigens and infectious virus. The effect of this difference will remain 
unclear without sequencing the envelope genes of the infectious virus stock or virus 
derived antigen. Alternatively, a second VLP construction could be evaluated that 
contained the 1991 Los Alamos database sequence.
In order to determine whether the V3 loop carried by OGS534 VLPs elicited the 
production of neutralizing antibodies, a two stage SIV neutralization assay has been 
developed. Difficulties were encountered in both the cell culture and antigen detection 
stages of the assay. The development of a routine assay is critically dependent on the
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availability of reproducible virus stocks. Such stocks were not always available, often 
resulting in insufficient virus being added to initiate a productive infection within the 27 
day period. Productive infection, and possible neutralization, was monitored by 
measuring the levels of p27 antigen in the cell culture medium. p27 antigen was 
detected by developing an antigen capture assay. Although optical density readings 
obtained using polyclonal sera as the capture and detecting antibodies were low, the 
assay was specific and reproducible. Furthermore, the assay gave results which were 
comparable with a commercially available assay. Ultimately the use of monoclonal 
antibodies may result in a more sensitive assay. To this end, anti-p27 monoclonal 
antibodies were evaluated as capture antibodies and one, 12G6, was shown to be the 
most effective. The direct labelling of a second antibody, recognising a different epitope 
to that recognised by 12G6, for p27 detection, would allow further refinement of the 
assay.
Anti-OGS534 antisera from five animals were tested for the presence of neutralizing 
antibodies. Only serum from one of the immunized animals was able to delay the time 
course of SIV infection in vitro. This result can only be regarded as preliminary due to 
the small numbers of assays carried out and the lack of optimization of the assay itself.
The results presented in this chapter indicate that it may be possible to elicit 
weakly-neutralizing antibodies against the V3 region of the SIV envelope glycoprotein. 
However, taken together with more recent data from other laboratories (discussed in 
chapter 8), it appears that this region is not the principal neutralization determinant and 




HYBRID HIV GAG VLPs
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7.0 INTRODUCTION
HIV infected individuals mount a strong humoral and cellular immune response to the 
gag encoded proteins, i.e., the core proteins of the virus. Studies of the immune 
response induced against gag encoded proteins suggest that these proteins should be 
included in a vaccine candidate against HIV. However, in general, HIV neutralizing 
antibodies have not been reported against the core proteins, probably because these 
proteins are internal and therefore anti-GAG antibodies do not block binding or entry of 
the virus to susceptible cells. It is likely that to achieve successful protection, an HTV 
vaccine candidate will have to include a component that elicits production of 
neutralizing antibodies. A preparation that combined the gag encoded proteins and the 
neutralizing epitope of the envelope glycoprotein gpl20, the V3 loop, may therefore be 
advantageous. Gheysen et al. (1989) have shown that when the GAG precursor 
polypeptide Pr55 is expressed using the baculovirus system, this protein has the ability 
to self assemble into virus-like particles. Furthermore, Adams et al. (1987a) have 
demonstrated that the gag gene of retroviruses is directly analogous to the TYA gene of 
Ty, i.e., the gene that encodes the pi carrier protein of the hybrid Ty-VLP system. 
Therefore, an attractive way forward may be to engineer GAG as a carrier protein for 
the V3 loop. A GAG:V3 hybrid particle would combine the neutralizing epitope of 
gpl20 with the T helper cell and CTL epitopes of GAG to make a potential HTV vaccine 
candidate.
Two expression systems have been used to investigate expression of GAG:V3 fusion 
proteins. The baculovirus system was chosen because, as mentioned above, expression 
of the GAG precursor polypeptide in insect cells resulted in the production of GAG 
particles (Gheysen et al.. 1989). Expression in yeast was also investigated because of 
the analogy between gag and TYA and also work with the Ty-VLP system had 
previously demonstrated that high levels of fusion proteins could be achieved using this
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expression configuration. In addition, using two expression systems gave the 
advantage of generating reagents from different cell backrounds for testing immune 
responses to the whole of GAG. For example, GAG particles produced in yeast could 
be used to assay the anti-GAG responses generated against hybrid GAG:V3 particles 
produced in insect cells.
The baculovirus system exploits the Autographica califomica nuclear polyhedrosis 
virus (AcNPV) (reviewed by Miller, 1988). Progeny virus is produced in two forms; 
extracellular virus particles and occluded virus particles. Following infection 
extracellular virus particles are produced, then later in the life cycle virus particles are 
occluded into a paracrystalline matrix composed of a 29kD protein called polyhedrin. In 
this form the virus can infect new hosts by horizontal transmission. As cell to cell 
infection is mediated by extracellular virus, the synthesis of polyhedrin is a 
non-essential function in cell culture. Therefore the gene coding for polyhedrin can be 
replaced by a foreign gene of interest. Expression of the foreign protein is driven by the 
polyhedrin promoter. The expression strategy is outlined in Figure 7.1. Production of a 
recombinant baculovirus is dependent on homologous recombination between 
sequences present in the expression vector and the Autographica califronica nuclear 
polyhedrosis virus (AcNPV) DNA. Recombination occurs at a frequency of about 1%. 
Following co-transfection of insect cells with AcNPV DNA and the transfer vector 
encoding the gene of interest, selection of a putative recombinant virus is by 
microscopic examination of viral plaques. A recombinant baculovirus does not express 
polyhedrin, therefore polyhedrin-negative plaques are picked. The putative recombinant 
baculoviruses then undergo several rounds of plaque purification and a virus is selected 
by analysis of expression of the foreign protein.
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Figure 7.1 Baculovirus expression system
The yeast expression system utilizes a modified galactose, PGK-based inducible 
promoter (Kingsman et al.. 1991). The promoter is similar to that of the yeast 
expression vector pOGS40 described in chapter 1, section 1.4, but is more tightly 
regulated in the presence of glucose. The expression vector containing this promoter 
was modified by Mr. David Krige to allow insertion of genes with BamHl sites at their 
5' and 3’ ends. The resulting expression vector was designated pOGS700.
A range of GAG and GAG: V3 proteins have been expressed and analysed for their 
ability to form particles in both systems. Characterization of the fusion proteins has 
been earned out by Western blot analysis, immunofluorescence and electron 
microscopy, and immunogenicity studies have been carried out in rats.
7.1 ANALYSIS OF EXPRESSION OF FULL LENGTH GAG AND 
GAG:V3 FUSION PROTEINS
7.1.1 Constructions
Figure 7.2 illustrates the constructions made to facilitate expression in yeast and in the 
baculovirus system. The GAG protein of HIV-1 (isolate BH10) is encoded by a 1.6 kb 
gene. The gag gene encodes a precursor protein, Pr55, which is subsequently cleaved 
to produce the core proteins p i7, p24 and pl5 which is further cleaved to p7 and p6. 
This gene was engineered to have BamHI restriction sites at its 5* and 3’ ends and 
cloned into pSP46 so that it could be easily inserted into the expression vectors. This 
tailored gag gene in pSP46 was constructed by Dr. Sally Adams and was designated 
pOGS 15. A gag:V3 fusion gene was made by inserting the HXB2 V3 loop gene 
(described in chapter 3, section 3.1) at a Bell! site located 300 base pairs from the 3’ 
end of the gag gene.The first stage of making the gag:V3 fusion gene was to insert 
synthetic oligomers in the Belli site to maintain the gag reading frame following 
insertion of the V3 loop. Insertion of the oligomers was confirmed by sequencing and
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Figure 7.2 Construction of the gene coding for the GAG:V3 fusion protein
the resulting plasmid was designated pOGS554. The V3 loop gene was then inserted 
into the Belli site to generate pOGS555. Cloning into this site positioned the V3 loop 
gene in the gag gene between the regions encoding the p7 and p6 proteins.
The gag and the gag:V3 fusion genes were excised from pOGSIS and pOGS555 as 
BamHl fragments and cloned into the yeast expression vector pOGS700 containing the 
galactose inducible promoter. The resulting plasmids were designated pOGS557 (gag) 
and OGS559 (gag:V3) respectively. The gag and the gag:V3 fusion genes were also 
cloned into the baculovirus transfer vector pAcYMl and the plasmids designated 
pOGS553 and pOGS556 respectively.
7.1.2 Expression in yeast
Yeast strain BJ2168 was transformed with plasmids pOGS557 (full length GAG) and 
pOGS559 (full length GAG:V3) and cultures grown as described for the production of 
hybrid Ty-VLPs (chapter 2, section 2.13). After induction by galactose, samples of 
cells were taken and disrupted by vortexing in the presence of glass beads. The 
resulting cell lysates were analysed by Western blot using a monoclonal antibody 
(DuPont, antibody 9283) that is reactive with the p24 core protein of HTV. The 
antibody was reactive with a band of 55kD in the lysate of cells transformed with 
pOGS557 that contained the gag gene encoding the GAG precursor protein Pr55. The 
antibody was also reactive with a band of 59kD in the lysate of cells transformed with 
pOGS559 which contained the gag:V3 fusion gene. The increase in the size of the 
GAG:V3 fusion protein was as expected as the V3 loop is approximately 4kD. The p24 
immunoreactive protein observed in the OGS559 cell lysate also reacted positively with 
the V3 loop monoclonal antibody 9284. These results confirmed that the 59kD protein 
contained both GAG and gpl20 components.
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Cells transformed with OGS557 and OGS559 were examined by transmission election 
microscopy to determine whether the expression of GAG and GAG:V3 fusion protein 
resulted in particle formation. Electron micrographs of a pOGS557 transformed cell 
(Figure 7.3a) showed that the GAG protein was associated with the cell membrane as 
an electron dense double banded layer around the membrane. This layer was not 
present in control BJ2168 cells. Large protrusions were also seen at the cell surface, 
suggesting that budding of the GAG protein had been prevented by the cell wall. Figure 
7.3b shows an electron micrograph of a yeast cell transformed with pOGS559. The 
GAG:V3 fusion protein accumulated as aggregated material in the nucleus of the cell. 
The nuclear localization of this GAG:V3 fusion protein is not easily explained but will 
be discussed in section 7.5.
The targeting of other retroviral gag encoded precursors at the cell membrane has been 
shown to be dependent on myristilation (Schultz and Oroszkin, 1983). Myristilation is 
a post-translational modification which involves removal of the N-terminal methionine 
and addition of a myristic acid moiety at the next amino acid which is always a glycine 
residue. The signal for myristilation therefore includes an M-G sequence at the 
N-terminus, although the presence of a serine residue at amino acid position six is also 
thought to be important. Studies with the HIV GAG precursor protein expressed using 
the baculovirus system have confirmed that myristilation is required for association 
with the cell membrane (Gheysen et al. 1989) and that removal of this sequence 
resulted in intracellular accumulation of the GAG protein in insect cells.
To test whether removal of the GAG myristilation signal would result in intracellular 
particle formation in yeast, a further construction was made, shown in Figure 7.4. The 
myristilation signal was removed by inserting synthetic oligomers at the BamHI site at 





Figure 7.3 Electron micrographs of yeast cells transformed with (a) pOGS557 
that expressed m yristilated GAG where the arrows indicate the large membrane 
protrusions and (b) pOGS559 that expressed myristilated GAG:V3 where the 
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Figure 7.4 Construction of the gene coding for non-myristilated GAG
myristilation signal downstream of the a re-created BamHI site. The resulting plasmid 
was designated pOGS564. The 5' end of the gag gene in pOGS 15 was replaced with a 
Pstl-Bgll fragment from pOGS564. The resulting plasmid pOGS565 therefore 
contained a BamHI cassette coding for full-length non-myristilated GAG. The BamHI 
fragment was excised from pOGS565 and inserted into the yeast expression vector 
pOGS700 to generate pOGS566. A gene encoding a non-myristilated GAG:V3 fusion 
protein was also made by a Pstl-Bgll replacement of the 5’ end of the gag gene in 
pOGS555 with that in pOGS564 and the resulting plasmid designated pOGS568. The 
BamHI fragment from pOGS568 was inserted into pOGS700 to generate pOGS569.
Figure 7.5 shows an electron micrograph of a yeast cell transformed with pOGS566 
encoding the non-myristilated GAG protein. Although the protein that accumulated in 
the cytoplasm was particulate, the majority was found to be aggregated rather than 
present as discrete particles. However, this observation confirmed that the myristilation 
signal on GAG was essential for cell membrane taigeting. The non-myristilated 
GAG: V3 fusion protein was also expressed and was found to accumulate in the nucleus 
in the same way as the myristilated GAG: V3 fusion protein. This observation indicated 
that the myristilation signal responsible for the cell membrane targeting of GAG was in 
some way overidden when the protein was expressed as a GAG:V3 fusion.
These data demonsrated that expression of full length GAG and GAG:V3 fusion 
proteins in yeast, either myristilated or non-myristilated, did not result in the fomation 
of discrete particles.
7.1.3 Expression using the baculovirus system
The myristilated, full length GAG and GAG:V3 proteins were expressed in insect cells 
using the baculovirus system. Recombinant baculoviruses expressing these proteins
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Figure 7.5 Electron micrograph of a yeast cell transformed with pOGS566 
that expressed non-myristilated GAG. The arrow indicates the particulate 
aggregated material in the cytoplasm.
were made by Dr. Katy Gearing at British Biotechnology and infected insea cells were 
examined by electron microscopy by Dr. Keith Gull at Manchester University. The 
results are shown here to provide background information. Figure 7.6a shows an insect 
cell infected with the recombinant baculovirus expressing GAG and confirmed the 
work of Gheysen et al. (1989) where virus-like particles of approximately lOOnm 
diameter budded from the cell membrane. Figure 7.6b shows an insect cell infected 
with the recombinant baculovirus expressing the GAG: V3 fusion protein. As seen in 
yeast cells (Figure 7.3b), an aggregated mass of the protein was found in the nucleus. 
This indicated that the nuclear localization observed in yeast was not simply a cell 
type/expression system phenomenon.
Taken with the results described in section 7.1.2 these data demonstrated that hybrid 
GAG:V3 particles did not assemble when full length GAG:V3 fusion proteins, which 
contained the V3 loop within GAG, were expressed using either the yeast or the 
baculovirus systems. Alternative constructions were therefore examined in order to 
re-establish particle formation and budding.
13. ANALYSIS OF EXPRESSION OF TRUNCATED GAG
As mentioned previously the GAG precursor Pr55 is proteolytically cleaved to yield 
pl7, p24, p7 and p6. pl7 is the matrix protein, p24 is the major core protein and p7 is 
involved in nucleic acid binding. However, the role of p6 in infectious virions is as yet 
unclear. Particle formation by a truncated form of GAG that had p6 removed from the 
C-terminus was therefore analysed as a step towards producing a GAG:V3 C-terminal 
fusion protein where the V3 loop effectively replaced p6.
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Figure 7.6 Electron m icrographs of insect cells infected with recom binant 
baculoviruses that (a) expressed GAG where the arrow indicates budded 
particles and (b) expressed GAG:V3 fusion protein where the arrow indicates 
the nuclear aggregated material.
7.2.1 Constructions
To construct a gene coding for a p6-deleted GAG protein, the gag gene was truncated 
to 1.3kb by insertion of oligomers coding for a stop codon at the Belli site in 
pOGS554 (Figure 7.7). The oligomers also contained a BamHI site that enabled 
excision of the truncated gag gene as a 1.3kb BamHI fragment for insertion into the 
expression vectors. The plasmid containing this cassette coding for truncated GAG was 
designated pOGS562. The 1.3kb BamHI fragment from pOGS562 encoding 
myristilated p6-deleted GAG was cloned into the baculovirus transfer vector pAcYMl 
and the resulting plasmid designated pOGS572.
A gene coding for non-myristilated truncated GAG was also constructed by replacing 
the Tend of the gag gene in pOGS564 with a Pstl-Bgll fragment from pOGS562 to 
generate pOGS571.The BamHI fragment from pOGS571 was inserted into the yeast 
expression vector pOGS700 to yield pOGS575.
7.2.2 Expression in yeast
Yeast cells were transformed with pOGS575 (non-myristilated truncated GAG) and 
cultures grown as described for production of hybrid Ty-VLPs (chapter 2, section 
2.13). Initial evaluation of the expression of the truncated GAG protein was by 
Western blot and sucrose gradient analysis. A 4ml packed-cell volume was 
resuspended in 4ml TEN buffer and cells were broken by vortexing with glass beads. 
The resulting cell lysate was analysed by Western blot. A band corresponding to the 
predicted size of 47kD reacted positively with the anti-p24 MAb 9283. Cellular debris 
was removed from the lysate by centrifugation at 3krpm for Five minutes (Beckman 
RT6000B centrifuge) and 1ml of the resulting supernatant was loaded onto each of two 
10ml 10 to 60% sucrose/TEN gradients. The gradients were spun at 40krpm (Beckman 
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re 7.7 Construction of myristilated and non-myristilated truncated gag gene
minutes. The gradients were fractionated to 1ml fractions. Figure 7.8 shows Western 
blot analysis of the gradient fractions of the two different spin times. After 45 minutes 
some of the 47kD GAG protein still remained at the top of the gradient After longer 
centrifugation all of the 47kD GAG protein had moved into the gradient, suggesting 
that the protein was particulate in nature. The spread of GAG protein through the 
gradient indicated that the particles were heterogeneous. A lower molecular weight 
protein was also observed that remained at the top of the gradient which indicated that 
some of the GAG protein had been proteolytically cleaved and that this cleaved protein 
did not form particles.
Yeast cells transformed with OGS575 were examined by electron microscopy (Figure 
7.9). In this case GAG particles were observed in the cytoplasm and were 
approximately lOOnm in diameter. Removal of the myristilation signal and p6 therefore 
established particle formation by the GAG protein in yeast cells.
7.2.3 Expression using the baculovirus system
To produce a recombinant baculovirus expressing a myristilated truncated GAG 
protein, insect cells were cotransfected with AcNPV viral DNA and the transfer vector 
pOGS572 (myristilated, truncated GAG) using the method described in chapter 2, 
section 2.25. Recombinant baculovirus formation was screened in a Brown-Faulkner 
plaque assay (chapter 2, section 2.26) and ten polyhedrin negative plaques were 
selected. The putative recombinant baculoviruses underwent three further rounds of 
plaque purification. Expression of the truncated GAG protein was analysed by Western 
blot analysis of cell lysates infected with the recombinant baculoviruses using the 
anti-p24 MAb 9283. A single recombinant baculovirus was then selected and 
designated AcOGS572. Virus stocks of AcOGS572 were prepared as described in 
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Figure 7.8 W estern blots o f sucrose gradient analysis o f truncated GAG. 
The gradient shown in (a) as spun for 45 minutes and the gradient in 
(b) was spun for 2 hours 45 minutes.
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Figure 7.9 Electron micrograph of a yeast cell transformed 
with pOGS575 that expressed non-myristilated truncated GAG
Insect cells infected with the recombinant baculovirus AcOGS572 were examined by 
electron microscopy (Figure 7.10). Myristilated, truncated GAG protein assembled into 
particles that budded from the cell membrane. This observation indicated that p6 was 
not required for the formation and release of GAG particles in the baculovirus system. 
The truncated GAG particles were a similar size to those produced from the full length 
GAG protein (approximately lOOnm in diameter) but were perhaps more regular in 
appearance.
The results presented in section 7.2 therefore demonstrated that particles were produced 
by expression of non-myristilated, truncated GAG in yeast and myristilated, truncated 
GAG in insect cells.
73  ANALYSIS OF EXPRESSION OF TRUNCATED GAG:V3 
FUSION PROTEINS
Having demonstrated that removal of p6 did not prevent particle assembly, the next step 
was to determine whether expression of a truncated GAG:V3 protein, with the V3 loop 
fiised at the C terminus, could produce hybrid GAG:V3 particles.
7.3.1 Constructions
For expression in yeast the HXB2 V3 loop gene was cloned into the Belli site of the 
expression vector pOGS575 to generate pOGS579. Plasmid pOGS575 was described 
in section 7.2.1 and contains a gene encoding non-myristilated, truncated GAG. 
Plasmid pOGS579 therefore contained a non-myristilated gag: V3 fusion gene (Figure 
7.11).
The V3 loop gene was also cloned into the baculovirus vector pOGS572 at the Bglll site 
located at the 3' end of the myristilated truncated gag gene. Plasmid pOGS573
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Figure 7.10 Electron micrograph of an insect cell infected with 









Insert 2 V3 






Figure 7.11 Construction of vectors for expression of GAG:V3 fusion protein 
in (a) yeast and (b) insect cells
contained two copies of the V3 loop gene whereas plasmid pOGS574 contained a 
single copy (Figure 7.11). Expression of both the gae:V3 and the gag:V3:V3 fusion 
genes in insea cells was investigated.
73,2  Expression in yeast
Yeast cells transformed with pOGS579 (non-myristilated truncated GAG:V3) were 
analysed by Western blot and sucrose gradients as described in section 7.2.2. Western 
blots of cell lysates confirmed that a protein was expressed of the expeaed molecular 
weight of 51kD. This protein reacted positively with both the anti-p24 MAb 9283 and 
the anti-V3 loop MAb 9284. Sucrose gradient analysis revealed a similar profile as that 
seen with truncated GAG particles (see Figure 7.8). Although the GAG:V3 fusion 
protein moved into the gradient, it was spread throughout the fractions. This suggested 
that the particulate material was heterogeneous. Non-particulate low molecular weight 
degradation products were also observed.
The electron micrograph in Figure 7.12 shows particles present in the nucleus of 
OGS579 transformed yeast cells. These data demonstrate that hybrid GAG:V3 particles 
can self-assemble in yeast cells. The nuclear location of this non-myristilated, truncated 
GAG: V3 fusion protein was consistent with that of the other GAG: V3 fusion proteins 
described above.
7.3.3 Expression using the baculovirus system
Recombinant baculoviruses were produced that expressed the GAG:V3 and the 
GAG:V3:V3 fusion proteins as described in section 7.2.3. The baculoviruses were 
designated AcOGS574 (GAG: V3) and AcOGS573 (GAG: V3: V3) respectively. 
Infected insect cell lysates were examined by Western blot analysis. The blot shown in 
Figure 7.13a was probed with the anti-p24 MAb9283 and demonstrated the increase in
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Figure 7.12 Electron micrograph of a yeast cell transformed 














































Figure 7.13 W estern blot analysis of infected insect cell lysates. 
The blot in (a) was probed with an anti-p24 MAb and the blot 
in (b) was probed with an anti-V3 MAb.
size of the GAG:V3 and the GAG:V3:V3 fusion proteins as compared to GAG alone. 
The blot seen in Figure 7.13b showed a positive reaction of the anti-V3 loop MAb9284 
to both the GAG:V3 and the GAG:V3:V3 fusion proteins. As expected, the anti-V3 
loop MAb9284 did not react with GAG.
The presence of both GAG and V3 components in the infected insect cells was analysed 
by fixed cell fluorescence described in chapter 2, section 2.17. Figure 7.14a shows the 
negative control of AcNPV infected cells incubated with the anti-p24 MAb9283 where 
no staining was observed. Figure 7.14b shows anti-p24 staining of insect cells infected 
with the recombinant baculovirus AcOGS572 (truncated GAG). The staining pattern 
around the edge of the cells suggested that the GAG protein was on the surface of the 
cells. In contrast anti-p24 staining of insect cells infected with recombinant baculovirus 
AcOGS574 (truncated GAG:V3) suggested that the protein was present both on the 
surface and the interior of the cells as indicated by the punctate pattern, with some cells 
showing brightness at the edges. (Figure 7.14c). Cells infected with the recombinant 
baculovirus AcOGS573 (truncated GAG:V3:V3) and stained with the anti-p24 MAb 
indicated that the majority of the protein was inside the cells (Figure 7.14d).
Immunofluoresence of the infected insect cells was also carried out with the anti-V3 
loop MAb9284. Cells infected with the recombinant baculovirus AcOGS572 (truncated 
GAG) did not stain with MAb9284 (Figure 7.15a). Figure 7.15b and c shows that both 
the AcOGS574 (GAG:V3) and AcOGS573 (GAG:V3:V3) infected cells were 
specifically stained with the MAb9284, but that the intensity of staining was lower than 
with the anti^)24 antibody. This could indicate that the anti-V3 loop monoclonal 
antibody had a lower affinity than the anti-p24 monoclonal antibody, or that the V3 





Figure 7.14 Immunofluorescence of baculovirus infected insect cells. The cells were stained with 
an anti-p24 MAb. The cells in (a) were infected with AcNPV. The cells in (b) were infected with 
AcOGS572 that expressed truncated GAG. The cells in (c) were infected with AcOGS574 that 




Figure 7.15 Immunofluorescence of (a) OGS572, (b) OGS574 and
(c) OGS573 infected cells. The cells were stained with anti-V3 MAb9284.
The results obtained by immunofluorescence were confirmed by examining AcOGS574 
(GAG:V3) and AcOGS573 (GAG:V3:V3) infected cells by electron microscopy.
Figure 7.16 shows an electron micrograph of an insect cell infected with AcOGS574 
and indicates that the myristilated truncated fusion protein had retained the ability to 
assemble into panicles. Approximately half the particles were budding from the cell, 
whereas the remainder were located in the nucleus. Furthermore the electron 
micrograph of an AcOGS573 infected cell (Figure 7.17) showed that the GAG:V3:V3 
fusion protein formed particles that were all located in the nucleus. Again, this result 
suggested that nuclear localization of the fusion protein was influenced by the V3 loop 
sequence.
In summary, hybrid GAG:V3 panicles were produced following expression of a 
non-myristilated, truncated GAG:V3 fusion protein in yeast and after expression of 
myristilated truncated GAG:V3 and GAG:V3:V3 fusion proteins in insect cells. An 
unexpected change in the location of the hybrid GAG: V3 particles as compared to the 
location of GAG particles was observed.
7.3.4 Purification of GAG:V3 and GAG:V3:V3 particles from the 
nuclei of insect cells
To produce particles for immunization studies, a purification strategy for the hybrid 
OGS574 (GAG:V3) and the OGS573 (GAG:V3:V3) particles from insect cells was 
developed. These particles were selected for evaluation so that a comparison could be 
made of the immune responses induced by the single and double V3 components.
Initially, the optimum parameters of infection for expression were determined. Cultures 
were infected at different multiplicities of infection (m.o.i) and expression examined 
over time by Western blot. Optimum expression of both GAG:V3 and GAG:V3:V3
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Figure 7.16 Electron micrograph of an insect cell infected with recom binant 
baculovirus AcOGS574 that expressed m yristilated truncated GAG:V3
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Figure 7.17 Electron micrograph of an insect cell infected with recombinant 
baculovirus AcOGS573 that expressed myristilated truncated GAG:V3:V3. 
The arrows indicate the nuclear particles.
fusion proteins occurred after infection with two plaque forming units (pfu)/cell and 48 
hours incubation.
The presence of both the GAG:V3 and the GAG:V3:V3 particles in the nuclei of 
infected cells was exploited as part of the purification process. Various methods and 
conditions were investigated to prepare nuclei (detergent treatment, centrifugation), to 
release the particles from purified nuclei (DNAse treatment, sonication) and to purify 
further the released particles (centrifugation parameters). The purification procedure 
developed and an example of OGS574 GAG:V3 particle preparation is described 
below.
A 400ml insect cell culture at lxlO^cells/ml was infected with the recombinant 
baculovirus AcOGS574 at 2pfu/cell. The 400mls of culture was split into 2x200ml 
aliquots in 500ml spinner flasks. The cultures were incubated at 27°C for 48 hours. 
Cells were harvested into 12 tubes by centrifugation at 3krpm for five minutes 
(Beckman RT6000B centrifuge). Each tube was resuspended in 4ml of TEN buffer 
containing 0.5%NP40 and incubated on ice for 10 minutes. The nuclear and 
cytoplasmic fractions were separated by centrifugation at 3krpm for 5 minutes 
(Beckman RT6000B centrifuge). The nuclear pellets were washed three times in PBS 
buffer and resuspended in a total of 36mls of PBS. The nuclei were sonicated for 6 
cycles, 15 seconds on, 10 seconds off (MSE Soniprep 150), and the sonicate was then 
loaded onto a step gradient. The gradients were prepared in SW41 tubes (Beckman) by 
pipetting 1ml 60% sucrose/TEN followed by 3ml 30% sucrose/TEN. The sonicate 
(6ml) was loaded onto each gradient and the gradients were centrifuged at lOkrpm for 
10 minutes (Beckman L8-70 ultracentrifuge, SW41 rotor). The gradients were 
harvested into 1ml fractions and aliquots were analysed by SDS-PAGE (Figure 7.18a). 
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Figure 7.18 Purification of OGS574 GAG:V3 particles
The SDS-PAGE gel in (a) shows a fractionated sucrose gradient
The SDS-PAGE gel in (b) shows 2.5, 5 and 10 |ig  of the final material
also included some contaminating proteins. The 60% sucrose cushions were pooled 
and dialysed against 500ml of TEN buffer overnight at 4°C. The protein concentration 
of the dialysate was estimated by Biorad assay and adjusted to lmg/ml. The 
SDS-PAGE gel in figure 7.18b shows loadings of 2.5,5 and lO îg of the final 
material. This preparation yielded 17mg of OGS574 GAG:V3 particles.
The rapid pelleting of the GAG:V3 particles suggested that the material was aggregated 
to some extent This possibility was further examined by negative stain electron 
microscopy of the particle preparation as described in chapter 2, section 2.16. The 
electron micrograph in Figure 7.19a shows that the OGS574 GAG:V3 particles were 
heterogenous in size. The particles appeared to be aggregated in filamentous material 
that may have been DNA. OGS573 GAG:V3:V3 particles appeared similar to OGS574 
GAG:V3 particles (Figure 7.19b).
7.4 IMMUNE RESPONSES GENERATED AGAINST HYBRID 
GAG:V3 PARTICLES
Rats were immunized in order to determine the immune responses generated against 
OGS574 GAG:V3 and OGS573 GAG:V3:V3 particles. Six groups of five rats received 
100}ig doses of each of the immunogens. Groups 573/1 and 574/1 received the priming 
immunization in complete Freund's adjuvant and boost immunizations in incomplete 
Freund's adjuvant. Groups 573/2 and 574/2 received the OGS573 and OGS574 
particles in conjunction with aluminium hydroxide and groups 573/3 and 573/4 were 
immunized with particles alone. The animals were given a priming immunization and 
two boosts at three weekly intervals. Following a ten week period after the second 
boost the animals received three further boosts at three weekly intervals. Serum 
samples were taken before and one week following each boost Seram antibody levels 





Figure 7.19 Negative stain electron m icroscopy of
(a) OGS574 GAG:V3 and (b) OGS573 GAG:V3:V3 particles
chapter 5. Sera were also tested for the presence of virus neutralizing antibodies in the 
syncytium inhibition assay described in chapter 2, section 2.22. To measure the 
anti-GAG response an ELISA was developed using GAG protein expressed in yeast 
cells (see section 7.4.1).
7.4.1 Development of an ELISA to measure the anti-GAG response 
As described in section 7.3.4, OGS573 and OGS574 particles were purified from the 
nuclei of baculovirus insect cells. In order to measure the GAG-specific responses 
induced by immunization with this material, the GAG antigen used in the assay needed 
to be derived from an alternative cell-type. Expression of GAG in yeast cells provided 
such material for the development of an ELISA assay.
The anti-GAG ELISA was developed using partially purified OGS575 
(non-myristilated truncated GAG) particles (see section 7.3.2). pOGS575 transformed 
yeast cells were disrupted in the presence of glass beads and cellular debris was 
removed by centrifugation at 3krpm for five minutes (Beckman RT6000B centrifuge). 
The concentration of the GAG component was estimated by SDS-PAGE and Biorad 
analysis and adjusted to approximately 1 mg/ml. A microtitre plate was coated at 
concentrations of lpg, 5jig,10fig and 20jig/ml. The ability of OGS575 particles to 
detect anti-GAG responses was determined by titration of the anti-p24 monoclonal 
antibody 9283 and an anti-pl7 monoclonal antibody 9282 (DuPont). The anti-V3 loop 
monoclonal antibody 9284 was included as a negative control. The three monoclonal 
antibodies were also tested against an untransformed yeast lysate. No reactivity was 
observed against this lysate for any of the antibodies. Figure 7.20 shows the titration 
curves obtained at the different GAG coating concentrations. As expected, no reactivity 
was seen with the anti-V3 antibody. At a coating concentration of l|ig/ml lower 
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Figure 7.20 Monoclonal antibody titration by GAG ELISA
anti-pl7 and anti-p24 monoclonal antibodies were 1:400 and 1:4000 respectively. The 
differences in titre were probably due to either a difference in binding affinity of the 
antibodies or in accessibilty of the recognised epitopes. The anti-p24 mid-point titre 
was comparable with the titre obtained for the 9283 antibody in a DuPont anti-p24 
assay (Mr. John Senior, personal communication) and therefore demonstrated that the 
GAG ELISA was effective at detecting anti-GAG responses. In subsequent tests, 
OGS575 particles were used at a coating concentration of 5|ig/ml and the assay was 
carried out as described in chapter 2, section 2.18.
7.4.2 Antibody titres of animals immunized with hybrid GAG:V3 
particles
7.4.2.1 Anti-GAG responses
Anti-GAG serum antibody titres were determined using the assay described above and 
are detailed in Table 7. In group 573/1 animals received the OGS573 (GAG:V3:V3) 
particles in conjunction with Freund’s adjuvant and all elicited high titre anti-GAG 
antibodies. Four of the animals had maximum responses after the second boost, with 
titres ranging from 1:6000 to 1:15000. Animal 573/1/4 had a maximum response of 
1:12000 after the first boost. Sera taken 10 weeks following the second boost 
(pre-boost three) showed that the anti-GAG response had declined then increased again 
following the third boost Titres remained high throughout the rest of the immunization 
regime. Similar anti-GAG responses were observed in group 574/1, in which rats 
received OGS574 (GAG:V3) particles in conjunction with Freund’s adjuvant High 
titres were induced after the first and second boosts in all animals. Animals 574/1/3,4 
and 5 had maximum titres of 1:13000,1:13000 and 1:8000 respectively after the 
second boost Animals 574/1/1 and 574/1/2 had maximum responses post-boost four 
and three respectively.
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573/1/2 5000 7000 2000 NT 4000 3000
573/1/3 1200 9000 300 3500 4000 8000
573/1/4 12000 5000 1400 7500 NT NT
573/1/5 14000 15000 750 7000 11000 13000
574/1/1 8000 9000 2500 9000 11000 9000
574/1/2 8000 9000 600 11000 11000 9000
574/1/3 1000 13000 600 1500 2000 2500
574/1/4 1800 13000 3500 7000 11000 6000
574/1/5 5000 8000 1800 2500 4500 3500
Groups 573/1 and 574/1 received the immunizations in conjunction with Freund’s adjuvant.
Table 7 continued
Animal Post Post
boost 1 boost 2
Reciprocal mid-point titres
Pre Post Post Post *
boost 3 boost 3 boost 4 boost 5
573/2/1 7000 8000 1400 2000 6000 12000
573/2/2 1700 1000 100 2000 2000 4000
573/2/3 1800 1800 150 1500 1400 1400
573/2/4 2000 1800 100 3000 12000 15000
573/2/5 2800 4000 300 1800 NT 3500
574/2/1 9000 10000 1500 4000 5000 4000
574/2/2 3500 5500 600 2500 4500 4000
574/2/3 13000 15000 800 5000 3500 5500
574/2/4 8000 14000 1700 4000 14000 NT
574/2/5 2500 1800 700 1500 2000 2000
Groups 573/2 and 574/2 received the immunizations in conjunction with aluminium hydroxide.
Table 7 continued
Animal Post Post










573/3/1 <100 1400 1000 4000 3000 1300
573/3/2 <100 250 150 300 600 500
573/3/3 200 450 100 200 300 250
573/3/4 <100 750 <100 2500 3500 900
573/3/5 <100 350 <100 NT 250 250
574/3/1 800 1000 100 500 750 1000
574/3/2 <100 1000 100 300 500 650
574/3/3 900 600 <100 300 350 350
574/3/4 <100 5000 700 1500 2800 4500
574/3/5 600 NT 100 500 650 800
Groups 573/3 and 574/3 received the immunizations in the absence of adjuvant
High titre anti-GAG responses were also observed in the groups that received the 
particles in conjunction with aluminium hydroxide (573/2 and 574/2). All of the 
animals elicited a substantial response after the first boost. Maximum responses ranging 
from 1:5500 to 1:15000 were generated after the second boost in four of the animals in 
group 574/2. In group 573/2, animals 573/2/3 and 573/2/5 had maximum titres of 
1:1800 and 1:4000 post-boost two and the highest titres in the other three animals 
occurred post-boost five.
The responses elicited by OGS573 and OGS574 in the presence of adjuvants were 
comparable to the anti-GAG titres of human positive sera tested in the same assay (data 
not shown). Interestingly, the data shown in Table 7 demonstrate that the anti-GAG 
response was similar whether the immunizations were carried out in Freund's adjuvant 
or aluminium hydroxide. Furthermore, anti-GAG antibodies were also generated in the 
absence of adjuvant (groups 573/3 and 574/3; see Table 7). In particular, animals 
573/3/1,573/3/4 and 574/3/4 elicited comparable responses to those immunized with 
particles formulated with adjuvant. However, in the majority of the animals the overall 
response was lower in the absence of adjuvant
7.4.2.2 Mapping of linear epitopes of GAG recognised by 
anti-OGS573 and anti-OGS574 antisera
To further analyse the anti-GAG response elicited by the hybrid GAG particles, 
ELISA's were carried out to determine the reactivity of anti-OGS573 and OGS574 
antisera against a series of overlapping GAG peptides obtained from the MRC AIDS 
Directed Programme. The peptides used covered pl7 (amino acids 1-132), p24 amino 
acids 133-362) and p7 (amino acids 363-438). Peptides covering the pl7 and p7 
sequences were 15-mers overlapping by five and peptides covering p24 were 20-mers 
overlapping by ten. Microtitre plates were coated with the individual peptides at a
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concentration of 5|ig/ml and the anti-OGS573 and OGS574 antisera were tested at a 
dilution of 1:100. The assays were carried out as described in chapter 2, section 2.18.
Sera taken after each of the five boosts from one animal in each of the six groups were 
assayed. Figure 7.21a shows the peptide reactivity of antisera taken from animal 
573/1/5 that had received the immunizations in Freund's adjuvant. Antibodies 
recognised three sequences from p24 corresponding to amino acids 173-192,213-232 
and 343-362. Antisera from animal 574/1/2 (Figure 7.21b) also contained antibodies 
that recognised the amino acid sequence 343-362 and antibodies that recognised pl7 
and p7 peptides. Antisera from animal 573/2/1 (aluminium hydroxide) reacted against 
three peptides towards the C-terminus of p24 and one peptide sequence in p7 (Figure 
7.21c). Antisera from animal 574/2/2 gave a positive reaction against the N-terminus of 
p24, a sequence located towards the C-terminus of p24 and also contained antibodies 
that recognised the same peptide sequence in p7 as antisera from animal 573/2/1 (Figure 
7.2Id). Antisera from animal 573/3/1 that had received the OGS573 particles in the 
absence of adjuvant reacted against the N-terminus of p24 post-boosts one and two, 
although sera taken after subsequent boosts did not appear to react with this sequence. 
Antibodies were also present that reacted against a p7 peptide (Figure 7.2le). Little 
reaction was observed against any of the peptides with antisera taken from animal
574/3/4 (Figure 7.210.
Sera taken from all animals after the second boost were also assayed for antibodies that 
recognised the linear peptide sequences of GAG. The results are shown in Figure 7.22. 
Sera from the animals in group 573/1 (GAG:V3:V3; Freund’s) reacted with a 
C-terminal peptide of pl7, and several peptides within the p24 sequence. In group 
574/1 (GAG:V3; Freund’s) peptides at the N and C termini of pl7 were recognised, as 
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Figure 7.21 GAG linear epitope mapping
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Figure 7.22 GAG linear epitope mapping
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Figure 7.22 GAG linear epitope mapping
p 17=1 to 132, p24=133 to 362, p7=363 to 438
hydroxide) showed most reactivity with a C-terminal p24 peptide, with weaker 
reactions with other p24 regions. In group 574/2 (aluminium hydroxide), reactivity was 
again seen with the C-teiminal p24 region, with positive reactions throughout the rest 
of p24 and an N-terminal p7 peptide. The reactivities of the sera from groups 573/3 and 
574/3 (no adjuvant) were generally weaker, with reactions detected mainly in the p24 
peptides.
Antisera raised against the OGS573 (GAG:V3:V3) and OGS574 (GAG:V3) particles 
contained antibodies that recognised linear sequences throughout the GAG proteins. 
However, there was a tendency towards a greater number of reactivities toward the N- 
and C-terminal regions of the complete GAG sequence. In particular, most reactivity 
was observed at the C-terminus of p24.
7.4.23  Anti-V3 responses
Anti-OGS573 and OGS574 sera were assayed for the presence of anti-V3 antibodies 
against the HXB2 40-mer peptide. However, none of the sera taken after each boost 
had detectable anti-V3 antibodies in this assay. The sera were also tested for virus 
neutralizing antibodies using the syncytium inhibition assay. Sera taken post-boosts 
one and two failed to neutralize the virus. In contrast, sera taken post-boosts three, four 
and five from some of the animals reduced the number of syncytia present, but none 
gave rise to a 90% level of inhibition at any dilution. These data therefore suggested 
that the V3 loop was not presented in a suitable configuration on hybrid GAG:V3 
particles to induce virus neutralizing antibodies. Alternatively, the GAG epitopes may 
have been immunodominant over the V3 epitope, resulting in strong responses against 
GAG and only weak responses against V3.
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7.5 DISCUSSION
Expression of a number of GAG and GAG:V3 fusion proteins using both yeast and 
baculovirus systems have been investigated. The results are summarized in Figure 
7.23. As previously described by Gheysen et al. (1989), full-length myristilated GAG 
formed budded particles when expressed in the baculovirus system. In contrast, full 
length, myristilated GAG accumulated at the cell membrane in yeast In this case, 
budding of particles was probably prevented by the yeast cell wall It may be possible 
to produce budding GAG particles in yeast if expression was induced after removal of 
the cell wall to produce sphaeroplasts. Expression of non-myristilated full length GAG 
in yeast resulted in the formation of large inclusion bodies in the cytoplasm. This 
observation demonstrated that myristilation is essential for accumulation of the protein 
at the cell membrane and that modification of the GAG protein is required for 
intracellular particle formation in yeast
Initially, the V3 loop was inserted between the p7 and p6 domains of the GAG 
precursor protein, Pr55. This location was chosen because it was believed that insertion 
between these domains would be less disruptive than insertion within any of the GAG 
proteins and because a convenient restriction enzyme site was available. However, this 
insertion not only disrupted particle formation but also altered the cellular location of the 
GAG:V3 protein in both yeast and insect cells. As full length GAG alone did not 
accumulate in the nucleus in either yeast or insect cells this suggested that the V3 loop 
either directly or indirectly caused this change in cellular localization.
Expression of p6-deleted GAG has also been analysed. This approach was justified for 
two reasons. Firstly, the role of p6 in HIV has yet to be fully elucidated and similar 
proteins are not found in other retroviral GAG proteins. It is therefore possible that p6 
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Figure 7.23 Summary of GAG and GAG:V3 expression
formed by replacing p6 with a heterologous antigen. Secondly, previous studies with 
Ty (Dr. Sally Adams, personal communication) had demonstrated that truncation of the 
p i protein resulted in the formation of more stable particles.
Myristilated, truncated GAG formed budded particles that were similar to the particles 
produced from full length GAG when expressed in insect cells. This result showed that 
p6 was not required for particle assembly and release in this system. Furthermore, the 
particles appeared less heterogenous, perhaps supporting the idea that removal of p6 
might result in more stable or regular particle formation. The removal of p6 from 
non-myristilated GAG protein expressed in yeast resulted in the formation of 
cytoplasmic particles. In contrast, full length non-myristilated GAG did not form 
discrete particles in yeast These data suggest that, in yeast, the p6 sequence is 
deleterious to particle formation.
A non-myristilated truncated GAG:V3 C-terminal fusion protein produced hybrid 
GAG:V3 nuclear particles in yeast Similarly, a myristilated, GAG:V3 fusion protein 
also assembled into particles in insect cells. However, in this case both budded and 
nuclear particles were observed. A GAG:V3: V3 fusion protein produced only nuclear 
particles in insect cells. These data demonstrated that genetic modification of the gag 
gene of HTV can produce a carrier protein that can be used for the presentation of 
heterologous antigens. All of the constructions containing the V3 loop sequence, 
whether myristilated or non-myristilated, in either insect or yeast cells, resulted in 
nuclear localization of the fusion protein. The most obvious explanation for this 
phenomenon would be that V3 itself contains a nuclear localization signal. However, 
the V3 loop is not known to contain a conventional nuclear localization signal, although 
it does contain a series of basic residues as discussed below. The V3 loop forms part of 
the envelope protein of HIV that is believed to be stripped from the virion following
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infection. Even if the V3 loop contained a nuclear targeting signal it therefore seems 
unlikely that it would function as such in the infection cycle of the vims. A possible 
explanation for nuclear targeting of GAG: V3 particles is that the V3 loop in the 
GAG:V3 fusions causes a conformational change in GAG that reveals a previously 
hidden nuclear localization signal. In all of the constructions described above the V3 
loop was introduced at a viral protease cleavage site. In the systems used this site 
would not be cleaved as the viral protease was not present. It is however possible that 
the V3 loop sequence could itself be cleaved in these systems as it has previously been 
reported that the V3 loop contains a non-viral protease cleavage site. When the envelope 
glycoprotein gpl20 is expressed in mammalian cells, an unknown cellular protease 
specifically cleaves gpl20 within the V3 loop (Stephens et al.. 1990). It is not known 
whether this cleavage occurs when gpl20 is expressed in yeast or insect cells. 
However, if cleavage did occur, the V3 loop could be acting as a replacement cleavage 
site for that normally cleaved in GAG. Protease cleavage of GAG in the virus occurs 
post budding (Kohl et al.. 1988) and therefore the possible conformational change 
caused by cleavage would happen after the vims had left the cell. If the GAG:V3 
constructions were cleaved intracellularly the putative, cryptic nuclear localization signal 
could have been activated and the particles would then locate to the nucleus. A GAG 
fusion protein containing a sequence that is not cleaved by cellular proteases could be 
made in order to investigate this possibility.
Another possible explanation is that the combined GAG:V3 sequence itself creates a 
nuclear localization signal. A review by Dingwall and Laskey (1991) has suggested a 
nuclear targeting consensus sequence comprising a bipartite motif defined as two basic 
residues, a spacer region of any ten amino acids, followed by a second basic cluster in 
which at least three of the next five amino acids is basic. The HXB2 V3 loop contains 
the amino acid sequence RKRIR which could be the second basic cluster of the
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bipartite motif. Two basic amino acids, KK, are located in the p7 sequence of GAG. 
The spacing between these two basic clusters in the GAG:V3 fusion protein is 34 
amino acids. Bipartite signals have been described with spacer lengths other than ten. 
For example, Morin etal. (1989) showed that the spacing between the two basic 
clusters necessary for nuclear targeting of the adenovirus DNA-binding protein is 38 
amino acids. Therefore the two basic clusters present in the p7 sequence and the V3 
loop sequence could be responsible for the nuclear localization of the GAG:V3 fusion 
proteins.
A third possibility, and perhaps most likely, is that the V3 sequence alone is 
responsible for the nuclear targeting of the fusion proteins. A review by Roberts (1989) 
suggested a consensus sequence for a single basic cluster targeting signal. This 
consensus sequence is XXKKXK or XXKRXR. The sequence present in the V3 
loop described above conforms to this consensus. Also discussed in this review 
(Roberts 1989) was experimental evidence that efficiency of nuclear targeting is 
increased with increased copies of the signal sequence. This phenomenon was 
observed with the expression of the GAG:V3 and GAG:V3:V3 fusions in insect cells 
where the addition of two V3 loop sequences was required for the protein to locate 
entirely to the nucleus. The additional V3 loop sequence could also act to increase the 
efficiency of the putative bipartite motif discussed above.
The possibilties that the nuclear targeting of GAG:V3 particles is caused by either a 
bipartite motif or by the basic cluster in the V3 loop could be investigated by mutational 
analysis.
In order to produce hybrid GAG:V3 particles for analysis of the immune response a 
strategy has been developed for purifying OGS574 (GAG:V3) and OGS573
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(GAG:V3:V3) particles from the nuclei of insect cells. The nuclear location of the 
particles facilitated purification to some extent However, during the purification it 
became apparent that the hybrid particles were aggregating and, due to incoiporation of 
cellular components into the aggregates the final material was only approximately 80% 
pure. Negative stain electron microscopy revealed that discrete particles had been 
purified in a mesh of contaminating material derived from either nuclear proteins or 
DNA.
Immunogenicity studies of OGS574 and OGS573 panicles have been carried out in 
rats. The animals received the immunizations in conjunction with Freund’s adjuvant, 
aluminium hydroxide or without adjuvant All of the animals generated anti-GAG 
responses and, in particular, high titres were induced after one or two boosts in the 
animals that received the particles in an adjuvant formulation, litres were comparable 
between groups that had received the immunizations in conjunction with either 
Freund's adjuvant or aluminium hydroxide, demonstrating that the responses were not 
dependent on a powerful enhancer of the immune response and that they could be 
generated in a clinically relevant formulation. Anti-GAG titres obtained against the 
GAG hybrid particles were similar to anti-GAG titres of human HIV positive sera. 
Decline of anti-core protein antibodies has been correlated with the onset of disease 
(Schubach et al.. 1985; Lange et al.. 1986; Weber et al.. 1987). If hybrid GAG:V3 
particles induced a similar high litre response in humans they could therefore have a 
potential immunotherapeutic use.
Further analysis of the anti-GAG response induced by OGS574 and OGS573 hybrid 
particles has been carried out by evaluating the recognition of linear GAG sequences. 
There was some variation in the sequences reactive with the anti-OGS574 and OGS573 
antisera which has also been reported to be the case when examining linear sequences
140
recognised by HIV positive patients (Broliden et al.. 1989). However, in general, the 
majority of sequences that were recognised corresponded to the N and C-termini of the 
individual GAG proteins p i7, p24 and p7, and in particular the C-terminus of p24. As 
the termini are at the junctions of viral protease cleavage sites it may be expected that 
these sequences would be exposed on the surface of the GAG polyprotein and therefore 
more accessible for antibody recognition. However, the location of the viral protease 
within the virion remains to be determined. One of the p24 peptide sequences, amino 
acids 208 to 227, that was recognised by antisera from five of the OGS573 and 
OGS574 immunized animals, has also been shown to give a positive reaction with 
antibodies from 35% of a sample of 20 HIV positive patients (Broliden et al.. 1989). 
However, the peptide scan used in the OGS573/OGS574 study was not exhaustive due 
to the relatively large overlap between the peptides. Also this type of analysis does not 
identify conformational epitopes and is therefore limited in its usefulness in dissecting 
the anti-GAG immune response.
The anti-V3 response induced by OGS574 and OGS573 particles has also been 
analysed. In contrast to the anti-GAG response, the anti-V3 response was negligible, 
with only weak neutralizing antibodies being induced after a number of boosts. There 
was no difference in the response generated against one (OGS574) or two (OGS573) 
copies of the V3 loop which may suggest that the loop was not presented in a 
configuration that could induce neutralizing antibodies. An alternative explanation could 
be that a region of the GAG sequence is immunodominant over the V3 sequence. This 
would seem unlikely as V3 specific antibodies are present in human HTV positive sera 
(Goudsmit et al.. 1988; Goudsmit et al.. 1989). However, the sequence at the 
C-terminus of p24 identified as the most reactive region when tested against 
anti-OGS573 and OGS574 antisera has not been reported to be reactive with HIV 
positive sera. This may be due to the sequence being presented in a different
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configuration, i.e., as part of the GAG polypeptide rather than as a cleaved viral 
product. The C-terminal sequence of p24 may not be a "natural" viral epitope and in 
this alternative configuration it may show immunodominance over the V3 loop in 
eliciting antibody production when hybrid GAG:V3 particles are used as immunogens. 
A possible way of testing this would be to insert the V3 loop at the C-terminus of p24 
rather than at the C-terminus of p7. This could also be an effective way for improving 
the anti-V3 response without disrupting an important, clinically relevant epitope. It is 
possible that insertion of the C-terminus of p24 within GAG may disrupt particle 
formation. However, the sequence of p24 in this region contains the amino acid 
sequence GPGHKA. As Javerhian et al. (1989) have shown, virus neutralizing 
antibodies can be induced against the six amino acid sequence, GPGRAF, found at the 
tip of the V3 loop. Therefore, an alternative way forward may be to replace the next 
three amino acids C-terminal to the GPG sequence in p24 to create the GPGRAF 
sequence by site directed mutagenesis of the GPGHKA p24 sequence. Presentation of 
part of the V3 loop in this way may result in an effective conformation for the induction 
of neutralizing antibodies.
Although presentation of the V3 loop on OGS574 and OGS573 particles did not lead to 
the production of virus neutralizing antibodies, the particles have subsequently been 
shown to be highly effective at inducing V3-specific cytotoxic T-cell responses (CTL) 
(Mr. Stephen Harris, personal communication). Therefore, despite the lack of induction 
of neutralizing antibodies, the presence of high-titre GAG antibodies and V3-specific 
CTL may still make these particles attractive for immunotherapeutic treatment of 
HIV-positive individuals. In addition, with further modification of these hybrid 
particles, it may be possible to elicit virus neutralizing antibodies thereby producing a 
prophylactic vaccine candidate containing both humoral and cellular components 
believed to be required for protection against establishment of infection.
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The results presented in this chapter have described the production of a novel particulate 
antigen presentation system, using the HTV GAG polyprotein as a carrier for the 
heterologous antigen, the V3 loop. The particles have been found to be very effective at 







Hybrid Ty-VLPs have been constructed that cany the major neutralizing epitope of the
envelope protein gpl20 from different isolates of HIV-1. Analysis of antigen
presentation by hybrid HIV:Ty-VLPs concentrated on VLPs that cany the sequences
from clones BH10 and HXB2 of isolate BIB and also the sequence from the MN
isolate. VLPs carrying the BIB sequences gave a weak reaction with human positive
sera, whereas VLPs carrying the V3 loop from the MN isolate gave a very strong
reaction. This observation supports reports that the most commonly occuring isolates
io
have sequence homology within this region to isolate MN (Devash et al.. 1990; LaRosa 
et al.. 1990; Zwart et al.. 1991). Neutralizing antibodies to the V3 loop are 
type-specific whereas a potential vaccine candidate should elicit broad cross isolate 
neutralizing antibodies. Presentation of multiple V3 loop sequences has been 
investigated to determine whether a broad response could be generated.
The HTV V3:Ty-VLPs were used to immunize experimental animals and elicited 
anti-gpl20 and virus-neutralizing responses. However, the results showed that these 
responses were variable. Analysis of the responses generated against VLPs carrying V3 
loops from the clones of isolate BIB demonstrated that higher titre antibodies were 
generated against HXB2 V3:Ty-VLPs as compared to BH10 V3:Ty-VLPs. A similar 
observation has been reported by Neurath and Strick (1990) where rabbits immunized 
with HXB2 V3 peptide generated higher levels of BIB neutralizing antibodies than 
rabbits immunized with BH10 V3 peptide. These data further suggest that the 
differences in response are due to the immunogenicity of the sequence rather than to 
animal variation.
High titre neutralizing antibodies were generated against HXB2 V3:Ty-VLPs when the 
immunizations were carried out in either Freund's adjuvant or aluminium hydroxide.
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Aluminium hydroxide is currendy the only adjuvant approved for use in humans, and 
these results therefore demonstrate the efficacy of a hybrid VLP in a clinically relevant 
formulation. A memory response was also demonstrated. The HXB2 V3:Ty-VLPs 
therefore fulfilled two of the requirements of a potential vaccine candidate. However the 
immunogenicity of these VLPs was only tested in small groups of animals. Further 
experiments would be required, including dose responses and primate immunizations, 
before HXB2 V3:Ty-VLPs could be considered for evaluation in a clinical trial 
Preferably, a challenge experiment would be carried out in chimpanzees.
Although other HIV envelope immunogens that have been used in clinical trials (Zagury 
et al.. 1988; Cooney et al.. 1991) are derived from IIIB sequences, the clinical 
relevance of this isolate is questionable. Sequence analysis of virus isolates and 
serological analysis of infected individuals have shown that the IIIB isolate is rare, 
whereas MN-like isolates are common (Devash et al.. 1990b; LaRosa et al.. 1990; 
Zwart et al.. 1991). This suggests that potential vaccine candidates should include the 
MN sequence.
Immunogenicity studies of MN V3:Ty-VLPs showed that induction of high titre 
neutralizing antibodies was dependent on the presence of an immune response 
potentiator. High levels of MN neutralizing antibodies were generated when the VLPs 
were used to immunize animals with Freund's adjuvant, although peak titres were 
lower than the IIIB titres generated by the HXB2 V3:Ty-VLPs, whereas a poor 
response was generated when the particles were administered in aluminium hydroxide. 
As the anti-Ty titres were comparable in the groups that received HXB2 and MN 
V3:Ty-VLPs in aluminium hydroxide, these results suggest that the MN V3 loop 
presented on Ty-VLPs is less immunogenic than the HXB2 V3 loop, rather than 
differences being attributable to the VLP preparation. Although the amino acid
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sequences are similar at the C- and N-termini and the GPGRAF tip of the loop 
sequence is the same, non-conservative changes occur in the amino acids immediately 
to the left and right of the tip. This could alter the antigenicity of the principal 
neutralizing determinant in the MN loop. Javerhian et al.. (1989) have mapped the 
principal neutralization determinant to eight amino acids at the tip of the loop and have 
also shown that the location of the neutralization epitope varies between virus isolates 
with respect to the GPG sequence. The Javerhian study mapped the type specific 
neutralization epitope of IIIB to include the amino acids to the left of the tip. 
Immediately to the left of the tip are two amino acids QR in the IIIB V3 loop that are 
absent in the MN V3 loop. As discussed in chapter 3, the amino acid arginine has 
properties that could influence structure and therefore antigenicity. However, the MN 
neutralization epitope has not been specifically mapped and amino acids to the right of 
the tip could also be influential. As MN like isolates are the most common, it could be 
speculated that the vims has evolved in such a way as to render this sequence less 
immunogenic with the result that neutralizing antibodies raised to this epitope are less 
effective.
Immunization with multiple V3 loop VLPs also generated variable responses. A 
cocktail of five single V3 loop:Ty-VLPs, including VLPs carrying the sequences from 
the HIB isolate, resulted in a delayed response in the generation of BIB neutralizing 
antibodies. The use of such a cocktail is not therefore the optimum way of presenting 
multiple V3 sequences for generating cross neutralizing antibodies. Immunizations with 
a Ty-VLP carrying V3 loops from three different isolates, HXB2, MN and RF, also 
failed to induce high titre cross-neutralizing antibodies. However, the majority of 
animals generated relatively high levels of serum antibodies to the V3 loops. This 
suggested that presentation of V3 loops in this way resulted in sub-optimal 
configuration of neutralization epitopes and favoured the presentation of epitopes to
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which antibodies with no neutralization activity were raised. Higher neutralization titres 
were generated against MN in this configuration compared to when the MN loop was 
presented as a single V3 loop immunogen whereas the converse was found for the 
HXB2 loop. Palker et al. (1989) reported a similar observation with immunizations of a 
cocktail of peptides coding for the IIIB, MN and RF loops. Low titre neutralizing 
antibodies were generated, but with higher titres against MN. Immunogenicity was 
improved and higher cross-neutralizing titres induced by coupling each of the V3 loop 
peptides to a peptide coding for an additional T-cell helper epitope of gpl20. One report 
in the literature shows that it is possible to raise high titre neutralizing antibodies by 
presentation of multiple V3 loop sequences. Wang et al. (1991) presented an octameric 
peptide of the BH10 V3 loop that was 30 to 50 times more potent than a single peptide 
conjugated to BSA. Presentation of a cocktail of octamer peptides from six different 
isolates generated significant cross-neutralization titres. Possible alternative V3:Ty-VLP 
constructions that may increase the potential to induce high titre cross-neutralizing 
antibodies are outlined below.
One route to improve the response might be to incorporate additional HIV epitopes in 
the hybrid V3:Ty-VLPs that could provide '’help" in the production of 
cross-neutralizing antibodies. As discussed above, Palker et al. (1989) demonstrated 
this principal by coupling an additional T-helper epitope, known as Tl, of gpl20 to the 
V3 sequence. The sequence encoding this epitope could be inserted between multiple 
V3 sequences on a hybrid VLP, for example a pi C-terminal fusion of 
T1:HXB2:T1:MN:T1:RF could be made. This may provide an additional advantage by 
spacing the V3 loop sequences which could enhance the virus-neutralizing capacity as 
fusing the V3 sequences directly together appears to be deleterious for presentation.
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Presentation of sequences coding for the relatively conserved tip of the V3 loop could 
also be investigated. Javerhian et al. (1990) induced cross-isolate neutralizing 
antibodies by presenting a peptide coding for three copies of the GPGRAF sequence. 
As a hybrid Ty-VLP contains approximately 300 copies of the fusion protein it may be 
possible to induce high-titre cross-isolate neutralizing antibodies using this sequence or 
multiples of it
Alternative sites could be explored in pi to improve the responses against a less 
immunogenic sequence. The protein pi has been found to a powerful immunogen and 
immunodominant sites are likely to be found on the exposed surface of the particle. 
Such a site could be identified by immunogold labelling of particles using a panel of 
monoclonal antibodies raised against pi. The immunoreactive sequence that had been 
surface labelled by a monclonal antibody could then be mapped by Western blot 
analysis of pi that had been cleaved by, for example, cyanogen bromide and 
subsequent N-terminal sequencing of the products. Attempts could then be made to 
replace this sequence with the V3 loop. This may result in more efficient presentation 
and would also have the advantage of reducing the immunogenicity of pi.
It is difficult to compare the neutralization titres obtained in this study with those 
reported in the literature as experiments are carried out in different animal species and 
many different assays are used. Analysis of immunogenicity has concentrated on 
immunogens which contain IIIB sequences, including synthetic peptides coding for the 
V3 loop and recombinant forms of gpl20 and gpl60.
The most direct comparison is probably with the data from Neurath and Strick (1990), 
where anti-V3 loop peptide antisera were tested for IIIB neutralizing antibodies. 
Rabbits were immunized with 200|ig/dose of peptide in Freund's adjuvant with a
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similar schedule to that used for the V3:Ty-VLP immunogenicity studies. Neutralization 
titres of 1:8 and 1:100 were recorded for anti-BHIO and anti-HXB2 peptide antisera 
respectively. A cocktail preparation of 21 V3 loop peptides, which included BH10 and 
HXB2 peptides, generated neutralization titres of 1:24. Goudsmit et al. (1988) 
immunized rabbits with a DIB (BH10) V3 loop peptide conjugated to keyhole limpet 
haemocyanin (KLH), although a shorter sequence coding for amino acids 305-321 was 
used. The immunizations were carried out in conjunction with Freund's adjuvant and 
generated neutralization titres of 1:10. Palker et al. (1988) immunized goats with 28mg 
of synthetic IIIB or RF V3 peptides coupled to tetanus toxoid in conjunction with 
Freund's adjuvant and reported maximum neutralization titres of 1:160 after five 
boosts. In the study outlined above, Javerhian et al. (1989) immunized goats and 
guinea pigs with peptides encoding the IIIB, MN and RF V3 loops coupled to KLH 
and reported fusion inhibition titles of 1:40,1:20 and 1:320 respectively. Using an 
assay based on reduction of reverse transcriptase activity higher titres of 1:1500,1:280 
and 1:2560 were recorded. This highlights the variations that are seen in the literature 
depending on the assay used. It is also interesting to note that lower titres were 
recorded against MN. In a further study Javerhian et al. (1990) reported maximum 
fusion inhibition titres of 1:240 and 1:80 in sera raised against IIIB and MN peptides 
respectively. These studies further suggest that the MN V3 sequence is intrinsically less 
immunogenic than the IIIB sequence.
Only limited data are available for the presentation of V3 loop sequences in conjunction 
with aluminium hydroxide. Hart et al. (1990) carried out immunogenicity studies with 
V3 loop peptides in rhesus monkeys using different adjuvant formulations. The 
monkeys were given a cocktail of peptides containing the sequences from three clones 
of the IIIB isolate, each coupled to a T cell epitope peptide (amino acids 428-443 of 
gpl20). Immunizations in conjunction with Freund’s incomplete adjuvant generated
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substantial neutralization titres after three injections as measured by reverse 
transcriptase assays and after five injections using syncytial inhibition assays.
However, in one of the animals immunized in conjunction with aluminium hydroxide 
low neutralization titres were detected using the reverse transcriptase assay after the 
fourth, fifth and sixth immunizations and no neutralizing activity was detected using the 
syncytia inhibition assay.
Other immunogens that have been tested in conjunction with aluminium hydroxide are 
recombinant preparations of gpl20 or gpl60. Barrett et al. (1989) reported that when a 
vaccinia-derived recombinant gpl60 was used as an immunogen in goats the response 
was very poor when the material was adjuvanted with aluminium hydroxide compared 
to a good response when it was administered in Freund’s adjuvant. In conclusion, 
where studies have been carried out with aluminium hydroxide, the titres achieved are 
generally of low titre. This is in contrast to the V3:Ty-VLP studies described here, 
where titres induced by HXB2 V3:Ty-VLPs were equivalent, irrespective of the 
adjuvant used.
An exception is the work of Berman et al. (1990) who have reported protection of 
chimpanzees against infection by HIV after immunization with recombinant IIIB gpl20 
in aluminium hydroxide. Protection of the animals was correlated with levels of 
antibodies generated against the V3 loop. The animals had neutralization titres of 
1:320-1:640. Emini et al. (1992) provided direct evidence that V3 antibodies protect 
against virus challenge where a chimpanzee was successfully protected by passive 
immunization with a V3 mouse-human chimaeric monoclonal antibody. The 
neutralization titre at the time of challenge was 1:320.
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It is difficult to compare these results with those obtained using hybrid VLPs carrying 
the HXB2 V3 loop as the experiments were carried out in different species. However, 
in rabbits immunized with hybrid HTV HXB2 V3:Ty-VLPs in conjunction with 
aluminium hydroxide, neutralizing antibodies were detected with titres in a similar 
range to that reported in the protected chimpanzees. It is therefore possible that 
immunization with hybrid V3:Ty-VLPs can elicit neutralizing antibody levels above a 
threshold titre needed for protection.
8.2 Hybrid SIV:Ty-VLPs
Hybrid Ty-VLPs have been produced that carry the putative V3 region from 
SIVmac251 to investigate whether such a hybrid SIV:Ty-VLP would have use as a 
model vaccine candidate that could be tested in a challenge experiment Western blot 
analysis of the SIV:Ty-VLPs with sera from an experimentally infected macaque 
demonstrated that this region is immunogenic. However, immunogenicity studies on 
the SIV:Ty-VLPs have suggested that this region is only weakly immunogenic as low 
levels of anti-SFV envelope antibodies were detected even when immunizations were 
carried out in Freund's adjuvant Preliminary data suggest that it may be possible to 
elicit weakly-neutralizing antibodies against the V3 region of the SIV envelope. 
However, taken together with data from other laboratories it appears that this region is 
not the principal neutralization epitope of SIV.
Putney et al. (1991) have shown that high titre neutralizing antibodies against SIV are 
generated using native gpl20, but not against non-native envelope or peptides. This 
study concluded that the V3 loop is not, at least independently, a neutralizing 
determinant because V3 synthetic peptides do not raise neutralizing antibodies. The 
conformationally dependent principal neutralizing determinant was mapped to the 
C-terminal third of gpl20 using a 45kD native fragment. Recent studies by Kent et al.
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(1991b) have shown that monoclonal antibodies raised against the V3 region do not 
neutralize in vitro. Moreover, these monoclonal antibody studies indicate that the V2 
region of the envelope glycoprotein gpl20 contains a neutralization epitope of SIV and 
confirmed that conformational epitopes exist
As outlined in chapter 1, with the exception of one study, protection of macaques from 
SIV challenge experiments has been by vaccination with inactivated SIV or infected cell 
preparations. Lack of correlation with high-titre neutralizing antibodies and protection 
has been a major concern in these experiments. However recent findings have shown 
that uninfected cell preparations can induce protection against SIV challenge and that 
protection of these animals, and the animals vaccinated with SIV preparations, appeared 
to correlate with anti-cell antibody titres (Stott, 1991). These studies have therefore not 
yet demonstrated the relevance of neutralizing antibodies in successful challenge 
experiments. However, the SIV challenge model will remain valid for testing vaccine 
preparations designed to elicit production of neutralizing antibodies directed towards 
conformational epitopes, although it would appear that the extrapolation of results with 
the V3 region of SIV to the HIV model and vice versa, is not applicable.
S3  Hybrid HIV:GAG VLPs
Investigations have been carried out to determine whether the GAG precursor protein of 
HIV could act as a carrier for the V3 loop. This approach was taken as Gheysen et al. 
(1989) demonstrated that GAG expressed in insect cells self-assembled into budded 
particles and Adams et al. (1987a) have shown that the gag gene of HIV is directly 
analogous to the TYA gene which encodes the pi carrier protein of the hybrid Ty-VLP 
system.
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Expression of a number of GAG and GAG:V3 fusions in yeast and insect cells has 
been investigated and has led to the production of hybrid GAG:V3 particles. In both 
systems this was achieved by replacing sequences coding for the p6 protein at the 
C-terminus of GAG with the V3 loop. Electron microscopic analysis revealed an 
unexpected change in the cellular location of the hybrid particles. Formation of GAG 
particles in yeast required removal of the membrane targeting signal, i.e., the 
myristilation signal from the N-terminus of GAG and the deletion of p6. These particles 
were located in the cytoplasm. Expression of a non-myristilated, p6-deleted GAG: V3 
fusion protein resulted in the formation of nuclear particles. In insect cells, a p6-deleted 
GAG protein formed budded particles similar to particles produced from full length 
GAG, whereas expression of a GAG:V3 fusion protein resulted in the production of 
both nuclear and budded particles. Expression of a fusion protein containing two V3 
loop sequences resulted in the formation of particles located entirely in the nucleus. 
Possible explanations for nuclear targeting of the GAG:V3 fusions has been discussed 
in detail in chapter 7 and it seems possible that a cluster of basic residues present in the 
V3 loop sequence is responsible for this localisation.
The development of hybrid GAG:V3 particles required modification of the GAG 
protein which in turn led to some interesting observations in both yeast and insect cells. 
Expression of GAG in yeast has confirmed the work of others where a protein of the 
correct molecular weight of 55kD, that was immunoreactive with a p24 antibody, was 
produced (Jacobs et al..!989: Vlasuk et al.. 1989). As in this study, Jacobs et al.
(1989) showed that myristilated GAG targeted to the plasma membrane and 
non-myristilated GAG was located in the cytoplasm. However, comparison of electron 
microscopic analysis of transformed cells revealed differences in the nature of the GAG 
protein produced. The large protusions seen at the cell membrane (Figure 7.3a) were 
not found by Jacobs et al. (1989) and cytoplasmic particulate aggregates of
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non-myristilated GAG (Figure 7.5) were not reported. This may be due to a difference 
in the promoters used for expression, where higher levels of GAG expression were 
probably achieved by using the PGK/GAL system, resulting in sufficient accumulation 
of the protein to form more obvious structures.
In contrast to expression of full-length non-myristilated GAG, the p6-deleted GAG 
protein formed discrete particles in yeast. This demonstrated that in yeast the presence 
of p6 appeared to be deleterious for discrete particle formation. However expression of 
non-myristilated, full-length GAG in insect cells resulted in production of intracellular 
particles that located in the cytoplasm and nucleus (Gheysen et al.. 1989; Rover et al.. 
1991). These observations suggest that different expression systems may have some 
influence on both the form and location of non-myristilated GAG because in yeast, 
GAG was only found in the cytoplasm. In insect cells nuclear localization of 
recombinant protein may be due to the baculovirus system used as baculovirus locates 
to the nucleus as part of the infection cycle.
Rover et al. (1991) have expressed a number of non-myristilated and myristilated GAG 
proteins in insect cells. Expression of myristilated and non-myristilated pl5-deleted 
GAG was investigated and it was reported that the non-myristilated form did not 
produce particles whereas the myristilated form produced budded particles. In contrast 
Gheysen et al. (1989) showed that myristilated pl5 deleted GAG did not form 
particles. Expression of a non-myristilated, p6-deleted GAG protein resulted in a 
reduction of the number of particles found in the nucleus as compared to the full-length, 
non-myristilated GAG protein and it was proposed that p6 is involved in nuclear 
localization of GAG (Rover et al.. 1991). Expression of myristilated, p6-deleted GAG 
resulted in budded particles as found in this project. Gottlinger et al. (1991) constructed 
and expressed mutated proviruses that had all or part of p6 deleted. Virus particles
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assembled at the cell membrane and, although budding of p6-deleted virus particles 
occurred, they did not appear to be released. The particles also had an immature 
morphology and it was proposed that p6 is involved in final assembly and release of 
viral particles.
The discrepancies discussed above regarding the expression of modified GAG proteins 
by different laboratories indicate that the conclusions drawn by the authors in relation to 
the possible functions of GAG proteins in the virus should be regarded with caution. In 
an extensive electron microscopic examination of mammalian cells that had been shown 
by biological assays to be actively producing HTV, it was extremely rare to encounter 
cells with many budding or budded particles (personal observations). It is, however, 
common to find cells expressing recombinant forms of GAG producing large amounts 
of particles. This suggests that, in comparison to viral GAG production, recombinant 
GAG proteins are often expressed at very high levels, due to the promoters used or 
because of the absence of other viral proteins that may influence the level of particle 
production. The discrepancies found between this and other studies expressing the 
same modified GAG proteins suggest that these different observations may be due to 
the differences in levels of expression from the different promoters used. In addition, 
involvement of host cell factors may influence the form and function of GAG proteins. 
Taken together, these observations highlight the need to test any suggested functions of 
GAG proteins arising from work on recombinant proteins in HIV infected cells.
Immunogenicity studies have been carried out using hybrid GAG:V3 and GAG:V3:V3 
particles purified from the nuclei of insect cells. High-titre anti-GAG antibodies were 
generated in conjunction with either Freund's adjuvant or aluminium hydroxide. These 
responses were comparable to the anti-GAG responses seen in sera from HIV infected 
individuals tested in the same assay. In contrast, a weak humoral response to the V3
156
component of the particles was observed and the data suggest that the V3 loop was not 
presented in a favourable configuration to induce the production of virus-neutralizing 
antibodies. However, work carried out by other members of the group has 
demonstrated that GAG:V3 particles are effective at inducing cytotoxic T-cell 
responses. Suggested ways to improve presentation of neutralization epitopes by GAG 
have been discussed in chapter 7. These include insertion of the V3 loop at an 
alternative identified site in GAG and modification of a sequence in p24 to create a 
GPGRAF sequence. This in effect would create a GAG:V3 tip hybrid by minimal 
disruption of the sequence.
Limited data are available in the literature for comparison with this immunogenicity 
study, although Haffar et al. (1991) have studied the immune responses generated 
against recombinant GAG-ENV particles produced from coinfection of mammalian 
cells with vaccinia viruses carrying gag and env genes. Positive anti-GAG responses 
were recorded by Western blot analysis and low titre virus-neutralizing antibodies were 
detected.
The production of hybrid GAG:V3 particles has demonstrated that a modified GAG 
protein can be used as a carrier for a heterologous antigen. Although only weakly 
neutralizing antibodies were induced following immunization, high titre anti-GAG 
antibodies and V3 specific cytotoxic T-cell responses were generated.
8.4 Summary
Analysis of antigen presentation of the V3 loop by two particulate carrier systems has 
been investigated. Hybrid particles have been produced using the system developed at 
British Bio-technology based on pi, a protein encoded by the yeast retrotransposon, 
Ty, and a novel particulate carrier system has been developed by exploiting the
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self-assembly properties of the GAG polypeptide precursor protein of the HTV core 
proteins.
Hybrid V3:Ty-VLPs carrying the V3 loop sequence from the HXB2 clone of isolate 
IIIB elicited the production of high titre neutralizing antibodies, and a memory 
response, in a clinically relevant formulation. The titres were comparable to those in 
two protection studies reported to date (Berman et al.. 1990; Emini et al.. 1992). 
However, the hybrid Ty-VLP system may offer advantages over the immunogens used 
in these studies. In the Berman study the protected chimpanzees had been immunized 
with recombinant gpl20 and in the Emini study protection was achieved by passive 
immunization with an anti-V3 loop neutralizing monoclonal antibody. Presentation of 
the V3 loop as a hybrid Ty-VLP rather than as part of gpl20 eliminates concerns of 
possible deleterious side effects of the gp 120 interaction with the T-cell receptor CD4. 
Priming of the immune system and subsequent memory response offers an advantage 
over passive immunization with antibody.
The results presented in this project demonstrate the potential of using hybrid Ty-VLPs 
to induce HIV neutralizing antibodies and provides a baseline on which to improve the 
system to induce high titre cross-isolate neutralizing antibodies that would be required 
of a potential vaccine candidate.
Hybrid GAG:V3 particles have been produced in yeast and insect cells using a modified 
GAG protein as the carrier protein. The results have shown that a strong humoral 
immune response is generated against the GAG component and, as decline in anti-GAG 
antibodies has been correlated with onset of disease in HIV infected individuals, the 
particles could have a potential immunotherapeutic use. Although the results have 
demonstrated that GAG can act as a particulate carrier system for a heterologous
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antigen, the V3 loop, only weak humoral responses were observed against this 
component If further modification of these hybrid particles can be carried out to elicit 
the production of virus neutralizing antibodies, they would represent an attractive HIV 
vaccine candidate containing both the core and envelope components that may be 
required for protection in humans.
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The localization of neutralization determinants within the envelope glycoproteins of human immunodefi­
ciency virus (HIV) has been largely achieved by immunizing small animals in conjunction with Freund’s 
adjuvant. However, for eventual use in humans, candidate HIV vaccine components must also be efficacious in 
a nontoxic form ulation. We describe here the production of hybrid Ty viruslike particles carrying the major 
neutralizing domain of HIV and demonstrate the induction of high-titer virus-neutralizing antibodies and an 
HIV-specific T-cell proliferative response after immunization in conjunction with aluminum hydroxide. As 
aluminum hydroxide and aluminum phosphate are the only adjuvants currently licensed for use in humans, 
these observations have im plications for the development of an effective vaccine against HIV.
' The humoral immune response can be an important com­
ponent of protective immunity against infectious agents, and 
one strategy for immunoprophylaxis against AIDS may be 
the administration of an immunogen designed to elicit virus- 
neutralizing antibodies. Although many laboratories have 
demonstrated that all or parts o f the human immunodefi­
ciency virus (HIV) envelope glycoproteins induce neutraliz­
ing antibodies when administered in Freund’s adjuvant (9, 
18, 22, 33, 34, 36), very few studies have been done using 
clinically approved adjuvants. Aluminum hydroxide has 
generally only been used in studies involving primates, and 
in most cases in which neutralization has been observed, the 
titers have been low (3, 4, 6, 33). However, significant 
progress toward the development of an HIV vaccine has 
been made recently with the demonstration that recombinant 
gpl20 formulated in aluminum hydroxide can elicit protec­
tive immunity in chimpanzees against a homologous strain of 
HIV type 1 (HIV-1) (5). The protection was correlated with 
the induction of high-titer neutralizing antibodies and also 
with the presence of antibodies targeted against the principal 
neutralizing determinant of HIV (19) contained within the 
disulfide-cross-linked third variable domain (V3 loop) of 
gpl20. Although no adverse side effects were observed in the 
immunized chimpanzees, the immunosuppressive effects 
that may result from gpl20 binding to CD4 and inhibiting 
T-cell function in humans should still be taken into consid­
eration (10, 13, 24, 31). The use of immunogens containing 
neutralization determinants but deficient in CD4 binding may 
therefore be advantageous. Surprisingly, despite consider-
* C orresponding author.
able interest in the ability of V3 loop peptides to elicit 
neutralizing antibodies (19, 34, 35, 38) and the in vivo 
evidence that anti-V3 antibodies may prevent infection by 
HIV (5, 11), there have been no reports o f the efficacy of 
V3-based immunogens when administered in adjuvants ap­
proved for use in humans.
The approach that we took was to analyze the immuno- 
genicity of a V3 loop sequence presented as a particulate 
fusion protein. We have shown previously that a protein 
encoded by the Saccharom yces cerevisiae retrotransposon 
Ty can be used as a carrier for producing recombinant HIV 
antigens that induce both B-cell and T-cell responses in 
experimental animals (1, 30). The Ty particle itself can 
tolerate a wide range of additional protein sequence without 
disruption, allowing small peptide-sized fragments, protein 
domains, and full-length proteins to be accommodated (1, 
15, 30). In addition, any hybrid Ty viruslike particle (Ty- 
VLP) can be purified by using a generic protocol based on 
the physical properties o f the particle. To produce hybrid 
HIV V3-Ty-VLPs containing a V3 loop, synthetic oligomers 
encoding gpl20 amino acids 295 to 333 from isolate HXB2 
(14) were inserted into the BamWl site of plasmid pMA5620
(1) (Fig. la). The resulting plasmid (pOGS514) therefore
contained a Ty-HIV fusion gene under the control o f the 
efficient yeast phosphoglycerate kinase promoter (Fig. la). 
After transformation of plasmid pOGS514 into yeast cells, 
the fusion protein was expressed at high levels and assem ­
bled into 50-nm particles (Fig. lb ). These hybrid HIV
V3-Ty-VLPs were purified by a standard procedure that has 
been described previously (15), and the presence of the V3
sequence was confirmed by Western immunoblotting (data 
not shown). The location of the HIV component was ana­
lyzed by immunogold electron microscopy with a V3 loop- 
specific monoclonal antibody (MAb) (Fig. lc). When control




FIG. 1. C onstruction o f  H IV V 3-T y-V L Ps. (a) Structure o f  the 
expression  vector pM A5620 and the nucleic acid and predicted 
am ino acid sequence o f  oligom ers encoding the V3 loop o f HIV 
isolate H X B2. Plasmid pM A5620 has been described previously (1) 
and contains the first 381 cod on s o f  the TYA gene from the yeast 
retrotransposon T y l-1 5  (20) [TYA(d); shaded arrow], promoter 
sequences from the yeast PG K  gene (open arrow), a LEU2.2u. 
selection  and replication m odule (open box), a replication and 
ampicillin se lection  m odule from  pBR322 (thin line), and a PG K  
terminator fragment containing stop codons in all three reading 
frames and a transcriptional stop signal (black box). The codons of  
the synthesized  oligom ers w ere assigned according to yeast codon 
bias, using published tables o f  codon usage (16). Annealed oligomers 
were inserted into the BamHI site o f  pM A5620 to generate plasmid 
pOGS514. (b) E lectron micrograph o f  HIV V 3-T y-V L Ps, prepared 
for electron m icroscopy by procedures described previously (28). (c) 
Electron micrograph o f  H IV  V 3-T y-V L Ps probed with a gold- 
labeled anti-gpl20 M Ab. Im m unogold labeling was done by incubat­
ing HIV V 3-Ty-V L Ps with a gp l20-sp ecific  M Ab, 9284 (36) (Du 
Pont; raised against isolate IIIB). Bound antibody w as detected after 
incubation with anti-m ouse antibody conjugated to 5-nm gold parti­
c les (Sigma) and staining with 3% phosphotungstic acid.
N C T R P N N N T
GA TCT AAT TGC ACC CGT CCT AAC AAT AAC ACT
A TTA ACG TGG GCA GGA TTG TTA TTG TCA
R K R I R I Q R G P G
AGA AAG AGA ATT AGA ATC CAA AGA GGT CCA GGT
TCT TTC TCT TAA TCT TAG GTT ACA CCA GGT CCA
R A F V T I G K I G N
AGA GCT TTC GTT ACC ATT GGT AAA ATC GGT AAT
TCT CGA AAG CAA TGG TAA CCA TTT TAG CCA TTA
M R Q A H C N I S
ATG AGA CAA GCT CAC TGT AAC ATT TCT G




FIG. 1. Construction o f  HIV V3-Ty-VLPs. (a) Structure o f the 
expression vector pMA5620 and the nucleic acid and predicted 
amino acid sequence o f  oligomers encoding the V3 loop of HIV 
isolate HXB2. Plasmid pMA5620 has been described previously (1) 
and contains the first 381 codons o f the TYA gene from the yeast 
retrotransposon T yl-15 (20) [TYA(d); shaded arrow], promoter 
sequences from the yeast PGK  gene (open arrow), a LEU2.2p. 
selection and replication m odule (open box), a replication and 
ampicillin selection module from pBR322 (thin line), and a PGK 
terminator fragment containing stop codons in all three reading 
frames and a transcriptional stop signal (black box). The codons of  
the synthesized oligomers were assigned according to yeast codon 
bias, using published tables o f  codon usage (16). Annealed oligomers 
were inserted into the BamHI site o f  pMA5620 to generate plasmid 
pOGS514. (b) Electron micrograph o f  HIV V3-Ty-VLPs, s p a r e d  
for electron m icroscopy by procedures described previously (28). (c) 
Electron micrograph o f  HIV V3-Ty-VLPs probed with a gold- 
labeled anti-gpl20 MAb. Immunogold labeling was done by ia.ubat- 
ing HIV V3-Ty-VLPs with a gpl20-specific MAb, 9284 (36' (Du 
Pont; raised against isolate IIIB). Bound antibody was detected after 
incubation with anti-mouse antibody conjugated to 5-nm gold parti­
cles (Sigma) and staining with 3% phosphotungstic acid.
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452 NOTES J. V i r o l .
T A B L E  1. Serum antibody and neutralizing antibody titers o f  rabbits im munized with HIV V3-Ty-VLPs*
Adjuvant and 
animal no.
Reciprocal serum antibody midpoint titer of 
serum sample:
Reciprocal HIV neutralizing antibody titer of 
serum sample:
PI PB1 PB2 PB3 PB4 PB5 PI PB1 PB2 PB3 PB4 PB5
Freund’s adjuvant 
F I < 100 200 1,200 11,000 13,000 13,000 < 4 4 16 256 256 512
F2 < 100 200 2,000 8,000 9,000 2,000 < 4 8 32 32 256 128
F3 < 100 150 900 9,000 12,500 5,000 < 4 256 64 128 128 512
Aluminum hydroxide  
A l < 100 2,000 1,000 6,500 9,000 13,000 < 4 32 256 256 512 2,048
A2 < 100 900 400 500 2,000 5,000 < 4 64 128 32 128 512
A3 < 100 < 100 2,000 4,500 6,000 2,500 < 4 < 4 64 128 32 128
a Animals FI to F3 received a priming immunization in Freund’s complete adjuvant and were then boosted with HIV V3-Ty-VLPs in Freund’s incomplete 
adjuvant. Animals A1 to A3 received priming and booster immunizations of HIV V3-Ty-VLPs as an aluminum hydroxide precipitate. The levels of serum 
antibodies and virus-neutralizing antibodies were assessed in preimmune sera (PI) and in sera taken 7 days after each booster immunization (PB1 to PB5). Serum 
antibodies against gpl20 were measured by ELISA, and midpoint titers were calculated as the dilution of serum which gave rise to one-half the maximum optical 
density at 450 nm. Neutralizing antibody titers are expressed as the dilution of serum that resulted in 90% inhibition of syncytium formation. 90% inhibition of 
syncytium formation was defined as the degree of cytopathic effect observed in control wells infected with 50 TCID50 units of untreated virus. Six human immune 
sera (QC1 to QC6) from anonymous British HIV-positive blood donors (27) gave reciprocal neutralization titers of 80, 80 to 320,40,10,320, and 320, respectively, 
in this assay.
Ty-VLPs were probed with the same MAb, no specific 
labeling was observed. As the interior of the particles is 
unlikely to be accessible to the gold-antibody complexes, the 
specific labeling of the HIV V3-Ty-VLPs indicates that at 
least part o f the V3 loop region is exposed on the surface of 
the particles. ; ,
To establish that the V3 loop region was immunogenic 
when presented in this conformation, we initially used 
purified particles to immunize rabbits in conjunction with 
Freund’s adjuvant. Rabbits were immunized intramuscularly 
with 500 |xg o f purified HIV V3-Ty-VLPs at 2-week inter­
vals. A 500-|xg sample of HIV V3-Ty-VLPs contains 50 p,g of 
the HIV V3 loop component. The animals received a priming 
immunization in Freund’s complete adjuvant and were then 
boosted with HIV V3-Ty-VLPs in Freund’s incomplete 
adjuvant. Serum antibody titers were determined against 
recombinant gpl2Q (isolate IIIB [37]) secreted from Chinese 
hamster ovary (CHO) cells (Celltech Ltd.; obtained from the 
MRC AIDS Directed Programme) in an enzyme-linked im­
munosorbent assay (ELISA). Neutralization titers were 
measured by an infection inhibition assay based on the 
method described by Kinney-Thomas et al. (21). Briefly, 
heat-inactivated serum was incubated with 500 50% tissue 
culture infectious dose (TCID50) units o f HIV-1 isolate IIIB 
for 1 h at 37°C and then added to 105 C8166 cells. After 48 h 
at 37°C, the cultures were examined for the presence of 
syncytia. Titers were expressed as the dilution of serum that 
resulted in 90% inhibition of syncytium formation. Table 1 
(top) demonstrates that both serum antibodies and virus- 
neutralizing antibodies were detected after a single boost and 
increased to high titers after subsequent boosts. These data
therefore demonstrated that HIV V3-Ty-VLPs could be used 
to elicit significant levels o f anti-HIV neutralizing antibodies 
when administered with a potent adjuvant.
To evaluate the immunogenicity of the HIV V3-Ty-VLPs 
in a formulation that has been previously approved for use in 
humans, we administered the particles to rabbits as an 
aluminum hydroxide precipitate (Table 1, bottom). Surpris­
ingly, both the anti-gpl20 serum antibody titers and virus- 
neutralizing titers obtained against HIV isolate IIIB were at 
least equivalent to, and in some cases higher than, the 
responses obtained with Freund’s adjuvant. The specificity 
of the neutralization response was assessed with the diver­
gent HIV isolates RF (40) and MN (17). Sera taken from 
animals A l, A2, and A3 after the fifth booster immunization 
showed no significant neutralization of either o f these iso­
lates. The longevity of the anti-IIIB response was evaluated 
by analyzing sera taken from two of the immunized animals 
every 2 weeks after the final boost for a period o f 10 weeks 
(Table 2). The neutralizing antibody titers of animal A l  
remained constant at 1/512 for 8 weeks after the final boost 
and then dropped to 1/64, whereas the ability o f sera from 
animal A3 to neutralize HIV isolate IIIB declined gradually 
throughout the 10-week period, with a half-life o f 20 to 30 
days. However, in both animals, significant levels o f serum 
and neutralizing antibodies were still present 10 weeks after 
the last immunization.
Javaherian et al. (19) and Meloen et al. (29) have recently 
demonstrated that the major neutralizing epitope of HIV-1 
isolate IIIB is defined by eight amino acids (QRGPGRAF) at 
the tip of the V3 loop (Fig. 2A). We therefore investigated 
whether the antibodies raised against the HIV V3-Ty-VLPs
T A B L E  2. L ongevity o f  the antibody response in animals im m unized in conjunction with aluminum hydroxide*
Animal
no.
Reciprocal serum antibody midpoint Reciprocal HIV neutralizing antibody
titer at wk: titer at wk:
2 4 6 8 10 2 4 6 8 10
A l 1,000 4,000 800 1,100 300 512 512 512 512 64
A3 200 300 400 200 3,00U 64 64 32 16 16
a The levels of serum antibodies and neutralizing antibodies were assayed in sera'taken from animals at 2-week intervals after the final immunization with HIV 
V3-Ty-VLPs.
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FIG. 2. Binding o f rabbit serum and gpl20-specific MAbs to 
intact and cleaved recombinant gp l20. (A) Schematic representation 
of the epitopes recognized by V3 loop-specific MAbs 9284 (39) (Du 
Pont), 110.5 (23), and 0.5(3 (25). The loop sequence shown is from 
HIV-1 isolate IIIB. CHO-derived recombinant gpl20 (rgpl20; Cell- 
tech Ltd.; obtained from the MRC A IDS Directed Programme) can 
be specifically cleaved within the V3 loop by extended culture of the 
CHO cells before harvesting and purification o f the material (41). 
The cleavage site within the V3 loop is shown. (B) Binding profiles 
of rabbit serum A l and gpl20-specific M Abs to intact and cleaved 
rgpl20. Intact rgpl20 (solid lines) or 95%-cleaved rgpl20 (broken 
lines) at various concentrations was captured indirectly onto micro­
titer wells by a polyclonal sheep antibody raised against a C-terminal 
peptide o f gp l20 (D7324; Aalto BioReagents, Dublin, Eire) (32). The 
bound rgpl20 was then reacted with a fixed concentration of serum 
from rabbit A l taken 7 days after the fifth boost (1/3,000) (a), MAb 
110.5 (1/100,000 dilution o f  ascites fluid) (b), MAb 0.5(3 (1/100,000 
dilution of ascites fluid) (c), MAb 9284 (0.1 p,g/ml) (d). Bound 
antibody was detected after incubation with alkaline phosphatase- 
conjugated anti-species antibodies (Dakopatts, High Wycombe, 
United Kingdom and developm ent with the AM PAK ELISA ampli­
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